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Abstract 
 
Neuroinflammation and its role in seizure initiation and epilepsy disease development is 
being investigated, specifically the role of innate immune complement activation through 
the C5a receptor, C5ar1.  
 
C5ar1 expression was found to be significantly upregulated during epilepsy disease 
progression in several experimental mouse models, in addition to other complement 
components such as C3, the precursor to C5a. Building upon existing studies supporting 
the role of inflammation and other complement components in epilepsy, this finding 
indicates a contribution of C5a and complement activation in this disease. This lead to 
creation of the primary hypothesis of this thesis; inhibition of C5ar1 activation is potentially 
neuroprotective and anticonvulsant in epilepsy.  
 
To test this hypothesis a small peptide antagonist of C5ar1, PMX53, was used. It was 
shown to be anticonvulsant in two acute and two chronic seizure models. PMX53 
increased the seizure threshold significantly in both the 6Hz test and the corneal kindling 
model, as well as reduced EEG seizure power in the pilocarpine-induced SE model, 
indicating anticonvulsant actions. Studies using the chronic intrahippocampal kainate 
model combined with EEG, showed that PMX53 was acutely anticonvulsant after a single 
peripheral administration, significantly reducing total time in seizure by >50% as well as 
EEG seizure power. In addition, treatment of mice with PMX53 during pilocarpine-SE lead 
to a vast reduction in EEG seizure power highlighting further anticonvulsant effects. These 
results suggest inhibition of C5ar1 is beneficial in increasing seizure thresholds in several 
mouse models of epilepsy.  
 
Further studies using inert structural analogues of PMX53 and C5ar1-deficient mice in the 
6Hz model showed that PMX53’s anticonvulsant effect is C5ar1-dependent. This confirms 
my hypothesis that antagonism of C5ar1 is anticonvulsant. To determine if C5ar1-
mediated anticonvulsant effects lead to changes in subsequent cellular damage, neuronal 
cell death in the hippocampal formation was evaluated acutely after pilocarpine-induced 
SE. In both PMX53-treated animals and mice lacking the C5ar1 receptor, significant 
reductions in neuronal degeneration and loss were evident in key hippocampal areas 
including CA1 and CA3 pyramidal cell layers.  
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In addition, the explicit role of C5ar1 expression on microglial cells was investigated, given 
that consistent upregulation of the receptor was shown at varying stages post-epileptic 
insult in mice. Specifically microglial activation phenotypes were assessed, based on 
expression patterns of inflammatory and activation markers. M1 phenotype is considered 
to be more inflammatory in nature and is detected through expression of pro-inflammatory 
cytokines, i.e. IL-1β, TNFα, IL-6 and classical activation markers, i.e. CD16, CD86. M2 
phenotype is defined as being more reparative in nature, with markers such as Arginase1 
(Arg1) and Chitinase-like-3 (Ym1) being associated with this phenotype, all linked to 
different aspects of cell repair, as well as anti-inflammatory cytokines such as IL-4 and IL-
10.  
 
Different phenotypes were observed in two disease models; pilocarpine model and 
intrahippocampal kainate model. The inflammatory M1 phenotype was predominant in the 
late chronic stage of i.h. kainate model after prolonged and frequent seizure recurrence 
however was no microglial activation markers were upregulated in chronic pilocarpine SE 
mice suggesting high seizure frequency may be a factor mediating this activation. 
Immediately post epileptic insult (SE) differences were also present. A mixed M1/M2 
phenotype was seen in pilocarpine SE animals whereas only M1 markers were increased 
in i.h. kainate SE mice, suggesting that differences in SE may have affected these acute 
phenotypes, namely the contribution of peripheral inflammation in the pilocarpine model. It 
is clear from these findings that epilepsy disease progression, potentially dependent on 
spontaneous seizure frequency, drives a movement toward a recurrent microglial M1 
phenotype, showing significant increases in markers such as C3, TNFα and IL-1β. It is 
proposed that this shift in microglial activation state during epilepsy development drives a 
more “inflamed” CNS state, leading to a greater chance of hyperexcitability and hence is 
likely to contribute to further seizure occurrence in a cyclic manner.  
 
In addition, we have shown that C5ar1-deficiency during pilocarpine-SE promoted 
changes to cytokine expression in immune cells. Namely, C5ar1-deficiency led to ablation 
of increased TNFα expression in SE microglia acutely post-SE, as well as elevated IL-4 
expression on infiltrating immune cells. These changes coupled, suggest a more anti-
inflammatory CNS phenotype post-SE which may have putative disease-modifying 
potential.  
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The overall findings of this work suggest a role for C5ar1 in epilepsy development and 
seizure initiation supported by preclinical findings in several experimental epilepsy models 
showing that C5ar1 antagonism is anticonvulsant. This work also describes a potential 
new anticonvulsant drug target in C5ar1 which is novel in its mechanism compared to 
current antiepileptic drugs. In addition, this work has provided evidence that C5ar1 
expression on microglia may be linked to a driving shift in microglial activation phenotype 
throughout disease progression, which leads to a more inflamed and hyper-excitable CNS; 
a state which promotes seizure initiation and epilepsy disease progression. 
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1. Introduction 
 
1.1   Epilepsy  
 
Epilepsy is a debilitating neurodegenerative disease defined by the presence of 
spontaneous recurrent epileptic seizures which are caused by abnormal, excessive or 
synchronous neuronal activity in the brain (Fisher et al., 2005). The development of 
epilepsy, known as epileptogenesis, is a gradual degenerative process involving increased 
CNS hyperexcitability leading to neuronal damage and loss, reorganisation of cellular 
circuitry in key brain areas such as the hippocampus (De Lanerolle et al., 1989), and the 
potential development of psychiatric comorbid disorders such as depression and anxiety 
(Gaitatzis et al., 2004). The global prevalence of epilepsy is approximately 1% however 
this figure is higher in developing nations where access to healthcare and nutrition is poor 
(Sander, 2003, de Boer et al., 2008, Picot et al., 2008). A stigma is often associated with 
the disease driving many patients, especially in developing countries to hide their illness 
(Schneider and Conrad, 1980) which can further perpetuate psychiatric comorbidities such 
as depression.  
 
Approximately 60% of epilepsies are idiopathic, including genetically inherited cases, 
whilst the remaining 40% are secondary cases acquired as a result of CNS injury of some 
type. This could include, prenatal difficulties, stroke, brain tumour, CNS infections such as 
encephalitis or meningitis and traumatic brain injury typically from car accidents, falls or 
combat-associated head injuries (WHO, 2012).  
 
An initiating event leading to epilepsy development (epileptogenesis) is status epilepticus 
(SE) which can be induced in animal model and is defined as a continuous seizure period 
lasting > 5 minutes (Morimoto et al., 2004, Vezzani et al., 2009). In humans SE is triggered 
by insults such as stroke, CNS infection or head injury. This event drives changes in the 
hippocampus leading to acute neuronal death and hyper excitable hippocampal circuitry 
which triggers development of spontaneous recurrent chronic seizures. The development 
of anti-epileptogenic therapies, to prevent development of epilepsy following SE have not 
yet been discovered hence this is a key focus of future research in the area (Pitkänen and 
Lukasiuk, 2011).  
 
 
2 
 
1.1.1 Current state of anti-epileptic drugs and refractory populations 
 
Current antiepileptic drugs (AEDs) typically reduce seizures via two mechanisms; 
diminishing neuronal excitability via ion channel modulation (Na+, Ca2+, K+) or through 
enhancement of inhibitory signalling via γ-aminobutyric acid (GABA) receptors (Sirven et 
al., 2012). The current issues with these AEDs, other than serious adverse effects, are 
their lack of efficacy for a large proportion of epilepsy patients. It is for this reason, 
investigation into novel AED mechanisms are being sought.  
 
The prevalence of pharmacoresistance has been shown to be as high as 12.5% of total 
epilepsy patients in developed countries, with a global prevalence of approximately 35% of 
epilepsy patients, due to higher patient numbers in developing nations such as Africa 
(Picot et al., 2008, Boling et al., 2009, Kwan et al., 2011). Pharmacoresistant epilepsy is 
defined as failure of two appropriately chosen tolerated AEDs to achieve sustained seizure 
relief (Kwan et al., 2010). Surgery involving resection of the epileptic focus, typically a 
section of the temporal lobe, is an option in some cases however does carry high risk, 
although studies have suggested if surgery is appropriate for a patient it can lead to 
improved life expectancy and better quality of life (Choi et al., 2008).  
 
The high prevalence of refractory epilepsy, in addition to the debilitating adverse effects of 
current AEDs is what drives current research into alternative AED targets. The hope is this 
will lead to developing of new treatments with improved side effects and more widespread 
efficacy.  
 
1.1.2 Research models of epilepsy 
 
In order to gain a greater understanding of epilepsy and the mechanisms behind the 
disease a multitude of animal models have been developed which mimic different aspects 
of the disease. These models can be useful to determine underlying mechanisms relating 
to hyperexcitability and seizure generation as well as provide tools to allow development of 
new, more effective drug treatments. Rodent models (rat and mouse) in particular are 
most common in this field and have been shown to mimic pathophysiological features of 
the disease as well as undergo epileptogenesis, the process of epilepsy development. 
Selective models have also been shown to incorporate the development of common co-
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morbidities seen in human epilepsy patients including depression and anxiety (Jones et 
al., 2008, Sarkisova and van Luijtelaar, 2011).  
 
There are important distinctions to be made in regards to these models in terms of the 
clinical endpoint. Some models, such as the 6Hz, MEST, PTZ and flurothyl, only exhibit 
acute seizures which occur when induced by an electrical or chemical trigger. In this sense 
these models are only useful to test seizure thresholds. They are not models of epilepsy, 
because the animals are healthy and do not show any of the pathophysiological 
characteristics of epilepsy, however are effective as screening tools due to the fact that 
they are relatively simple to conduct and can be cost-effective.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Summary of the animal models utilized in AED research which mimic epilepsy disease 
pathophysiology and epileptic seizures. Predominantly rodents are used. As can be seen, excluding genetic 
models, chemoconvulsants and electrical shocks are used to induce seizures or epilepsy in animals. 
Outlined in red are the models utilised in this thesis which cover an array of acute-induced, chronic-induced 
and status epilepticus recurrent seizure models. Taken from (Löscher, 2011).  
 
On the other hand there are models which lead to development of pathophysiological 
features seen in human patients, such as neuronal cell death, circuitry re-arrangements 
and gliosis, and exhibit spontaneous recurrent seizures probably due to re-circuitry of brain 
connections in the hippocampus, thalamus, amygdala and piriform cortex (Toyoda et al., 
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2013). These models may be created through induction of SE by electrical or chemical 
means, including the use of pilocarpine and kainic acid, or kindling of central brain areas 
including the amygdala.  
Alternatively, they can be developed through manipulation of genes associated with 
hyperexcitability and neurotransmission, such as sodium channels (SCN2a), potassium 
channels (Kcnq2) and GABAA receptors (Gabbr1) to name a few (Kearney et al., 2001, 
Pitkänen et al., 2005), but also other genes not obviously associated with 
neurotransmission, e.g. Unverricht-Lundborg disease and tRNA mutations. Often these 
genes have been determined as targets based on clinical data showing inherited 
dysfunctions or absence of these gene variants in human epilepsy cases (Peters et al., 
1998). However, the proportion of patients with each of these specific genetic mutations is 
low (<1%). The specific genetic models are more likely likely to yield information that may 
be specific to that particular mutation. For this reason I have chosen to use models of 
acquired epilepsy, with no inherited genetic basis, including those acquired models that 
have been shown to be resistant to selected AEDs, therefore representing a “semi”-
pharmacoresistant population. An overview of the animal seizure and epilepsy models and 
their classifications are given in Figure 1.  
 
I have specifically chosen an array of these models to assess the role played by C5ar1 in 
epilepsy to ensure a variety of seizure induction mechanisms are at play, in addition to 
assessing models which display spontaneous seizures that most closely reflect the human 
condition. In this thesis I report results from acute electrically- (6Hz, MEST) and 
chemically-induced (PTZ; a GABAA receptor antagonist) seizure models, chronic 
electrically-induced seizures (corneal kindling) as well as models involving SE induction 
and spontaneous recurrent seizure development (pilocarpine; a cholinergic agonist & 
kainate; a specific ionotropic glutamate receptor agonist). Additionally, it has been 
suggested that the 6Hz and i.h. kainate models are resistant to certain AEDs, such as 
phenytoin and lamotrigine (Löscher, 2011, Wilcox et al., 2013). Thus, they are useful for 
evaluating treatments which may be effective for drug-resistant epilepsy populations, 
hence have been used as primary screening models in this thesis.  
 
Finally, mice have been used as the primary animal to model these epilepsies as they are 
less expensive than rats, are well characterised in the majority of the aforementioned 
models and less drug compound is needed based on their lower body weights.   
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1.1.3 Inflammation in epilepsy 
 
It is only in recent years that CNS inflammation has been considered as a potential 
contributor and even driver of epilepsy disease development and seizure generation 
(Vezzani et al., 2011).  
 
There are now many studies reporting the presence of inflammation in epilepsy animal 
models and human patient tissues (De Simoni et al., 2000, Vezzani and Granata, 2005). 
Perhaps of most interest are those that show inflammation actively contributing to disease 
development and in particular seizure induction. Of most relevance to this thesis are the 
pro-inflammatory cytokines TNFα, IL-1β and IL-6 as they are major players in inflammatory 
response and are known to have disease modifying potential in epilepsy models (Vezzani 
et al., 2002, Li et al., 2011).  
 
TNFα is key pro-inflammatory cytokine which is known to have pro-convulsant actions in 
the brain (Balosso et al., 2013). Specifically, expression of TNFα on microglial cells 
induced by peripheral systemic inflammation was reported to be proconvulsant, by 
significantly decreasing seizure thresholds of rats in the i.v. pentylenetetrazol seizure test 
(Riazi et al., 2008). There are many reported mechanisms by which TNFα can facilitate 
changes to brain excitability and promote seizure generation. TNFα is known to trigger 
endocytosis of inhibitory GABAA receptors (Stellwagen et al., 2005) as well as promote 
increased synaptic AMPA receptor availability (Beattle et al., 2002). Alterations to uptake 
and release of excitatory neurotransmitter glutamate have also been reported through a 
mechanism involving chemokine receptor CXCR4 signalling (Bezzi et al., 2001).  
 
In the majority of the brain disorder literature, IL-1β is thought to be pro-inflammatory, 
although some recent reports in microglial cultures (Giunti et al., 2012), spinal cord injury 
models (David and Kroner, 2011) and tumours (Mantovani et al., 2002) suggest that it can 
also be expressed by M2-type cells. IL-1β has been the focus of numerous studies in 
epilepsy models and has been mostly reported to be pro-inflammatory and proconvulsant 
in several seizure paradigms (Vezzani et al., 1999, Balosso et al., 2008). Inhibition of IL-1β 
actions either through direct antagonism of its receptor IL-1rα or through prevention of its 
biosynthesis via caspase-1 inhibition (the interleukin converting enzyme) was 
anticonvulsant in both kainic acid (Vezzani et al., 1999) and bicuculline (Vezzani et al., 
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2000) acute seizure tests in addition to preventing pilocarpine-induced seizures by 
delaying SE onset and associated damage (Marchi et al., 2009). Blockade of IL-1β was 
also anticonvulsant in several chronic epilepsy models including the refractory 
intrahippocampal kainate model (Balosso et al., 2008, Maroso et al., 2011), chronic 
kindling (Ravizza et al., 2008) and chronic spontaneous bicuculline induced seizures 
(Vezzani et al., 2000). IL-1β has also been shown to be a driver of enhanced neurotoxicity 
and subsequent neurodegeneration in an AMPA-induced seizure model (Patel et al., 
2006).  
 
The mechanisms by which IL-1β induces neurotoxicity and hyperexcitability are various. 
Direct effects of IL-1β on neuronal excitation are reported to be via activation of Src kinase 
which causes NMDA receptor activation and subsequent calcium flux into neurons causing 
excitotoxicity and generating seizure activity (Viviani et al., 2003, Balosso et al., 2008). 
Similarly, IL-1β is a known inducer of Nitric oxide (NO) which promotes neurotoxicity, a 
pathway that is also facilitated by NMDA receptors (Thornton et al., 2006) and has also 
been suggested to act synergistically with TNFα to promote further neurotoxicity (Chao et 
al., 1995). Additionally, IL-1β is thought to affect excitability through inhibition of glutamate 
uptake by astrocytes, similar to TNFα (Hu et al., 2000). 
 
IL-6 is another pro-inflammatory cytokine known to contribute to seizures in a 
proconvulsant manner promoting decreased seizure thresholds and severity in the PTZ 
model (Kalueff et al., 2004). Expression of IL-6 on astrocytes was also shown to enhance 
sensitivity of mice to glutamatergic (NMDA and kainate-induced) seizures as well as 
promote neurodegeneration (Samland et al., 2003).  
 
The involvement of inflammation, in particular pro-inflammatory cytokines, in seizures and 
epilepsy is clear. Anti-inflammatory approaches to block seizures are therefore suggested 
as a novel AED mechanism and have already shown to be effective in rodent seizure 
models (Vezzani and Granata, 2005, Maroso et al., 2011) as well as refractory paediatric 
epilepsy patients (Marchi et al., 2011). In addition, one of the primarily prescribed AEDs 
(sodium valproate) is known to inhibit TNFα and IL-6 production (Ichiyama et al., 2000) 
further advocating inflammation as a key pharmacological target to reduce seizures, 
neurodegeneration and potentially impede epileptogenic pathways. 
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1.2     Complement activation and C5ar1: their role in innate immunity 
 
1.2.1 The complement cascade; a facilitator of adaptive innate immune response 
 
The complement cascade is a key feature of the adaptive innate immune system host 
defence and is primarily responsible for identification and removal of pathogens from the 
body. There are 3 major activation pathways for the complement cascade; 1. Classical; 
mediated by binding of immune complexes and C1q; 2. Mannose-binding Lectin; mediated 
by lectin binding of mannose residues on pathogen surfaces; 3. Alternative; mediated by 
activities of C3 including pathogen binding and hydrolysis. Each activation pathway leads 
to production of central complement component C3 which is then further cleaved to 
produce key mediators including C3a, C5, C5a and the membrane attack complex (MAC) 
(Figure 2).  
 
Additional activation of the complement cascade by endogenous danger signals has also 
been reported in the absence of foreign instigating pathogens (Gallucci et al., 1999, Zhang 
and Mosser, 2008). Damage associated molecular patterns (DAMPs) or alarmins are 
endogenous danger signals which originate from stressed or injured cells to alert the body 
to “danger” which can in turn initiate an innate immune response, such as complement 
cascade activation. Recognition of these signals is facilitated by pattern recognition 
receptors (PRRs), the same group of receptors which recognise pathogenic associated 
molecular patterns (PAMPs) derived from exogenous bacterial or foreign pathogens.  One 
of the primary DAMPs known to associate with complement and C5a activation in 
particular is High-mobility-group-box-protein 1 (HMGB1). HMGB1 has a bimodal function 
in the body; intracellularly it is a nuclear DNA-binding protein which acts as a transcription 
factor, however can be excreted and act extracellularly as a pro-inflammatory cytokine 
(Müller et al., 2001, Scaffidi et al., 2002). C5a presence is reported to trigger secretion of 
HMGB1 and promote its cytokine persona facilitating a cyclic activation pathway between 
HMGB1 as an initiating DAMP activator of the complement cascade and HMBG1 as a 
cytokine facilitating inflammatory responses triggered by complement activation (Rittirsch 
et al., 2008).  
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Figure 2: The complement cascade including its major activation pathways; Classical, Mannose-binding 
lectin, Alternative and endogenous danger signal recognition. Each activation pathway converges to produce 
C3, the central complement component which is cleaved to activate the cascade Key components of interest 
are the anaphylatoxins C3a and C5a which both lead to inflammation and cytokine production. Cleavage of 
complement components is achieved via cascade derived convertases which are formed by cleavage 
fragments from upstream components. The site of action of PMX53, a selective C5a receptor 1 antagonist, is 
shown in this figure to highlight its role in preventing C5a-mediated inflammation as a result of cascade 
activation. The membrane attack complex (MAC) is the terminal protein of this pathway and is important for 
clearance of pathogenic cells which it achieves through formation of membrane pores leading to cell lysis. 
MBL – mannose-binding lectin; DAMP – danger associated molecular patterns; PRRs – pattern recognition 
receptors; IgG – immunoglobulin G; MASPs – Mannose-binding lectin associated serine proteases 
 
The complement system, once activated, has multi-faceted roles not only in the periphery 
but also the CNS (Woodruff et al., 2010) including recognition and opsonisation of 
pathogens, phagocytosis, leukocyte adhesion and chemotaxis, myeloid cell activation 
including microglial activation, induction of inflammation through creation of soluble 
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anaphylatoxins C3a and C5a and cell lysis through formation of the C5b-9 pore, also 
known as the membrane attack complex (MAC). Complement peptide C5a is a potent and 
instrumental pro-inflammatory anaphylatoxin formed via proteolytic cleavage from its 
precursor C5, typically via C5 convertases formed from C3 during activation of the 
complement cascade, or alternatively directly by blood and cell-derived proteases (Amara 
et al., 2010). C5a activation through binding of major receptor, C5ar1, leads to production 
of pro-inflammatory cytokines including TNFα and IL-1β. C5a also has an additional 
receptor, C5ar2; however the activity of this receptor is still largely unknown and remains 
controversial (Okinaga et al., 2003, Chen et al., 2007). It has been suggested to act as a 
‘mop’ for excess C5a, binding it during times of C5a abundance however eliciting no pro-
inflammatory actions as a result. C5ar1 activation is of key interest due to its direct actions 
on pro-inflammatory mediator production therefore the C5ar1 receptor is the focus of this 
work, and not C5ar2, as C5ar1 has direct potential implications on inflammation and 
subsequent CNS excitatory changes relevant to epilepsy.  
 
 
1.2.2 Complement activation in epilepsy 
 
Relatively little is known about complement activation and its direct relationship to epilepsy 
and seizures. Past studies have focused on examination of resected or post-mortem tissue 
of epilepsy patients to determine expression of complement factors as well as the 
localisation of their expression in specific brain regions. Recent evidence has linked 
complement factor expression and activation with epilepsy and seizure development. 
 
For example, gene expression studies from experimental rodent TLE models as well as 
resected surgical tissue from human TLE patients have shown increased presence of C1q, 
C3, C3ar and C4  (Becker et al., 2003, Gorter et al., 2006, Jamali et al., 2006, Aronica et 
al., 2007). In addition increased immunoreactivity of these same factors in addition to the 
C5b-9 complex (MAC), have been documented on astrocytes, activated microglial cells as 
well as selected neurons in brain tissue from both TLE patients and rodent models 
(Aronica et al., 2007, Kharatishvili et al., 2014). The presence of MAC in epileptic tissue 
indicates that complement cascade activation has occurred and therefore C5a formation 
also. Moreover, increased levels of C3 were measured in serum of untreated epilepsy 
patients compared to healthy and AED-treated epilepsy controls (Başaran et al., 1994) 
further supporting the involvement of complement in epileptic seizures.  
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There is additional functional evidence to also support the involvement of complement 
within the brain as a mediator of seizure generation. In rats, direct sequential infusion of 
individual complement proteins, C5b through C9, to the hippocampus resulted in MAC 
formation and subsequently induced seizures as well as hippocampal neurodegeneration 
(Xiong et al., 2003). Additionally, C1q-deficient mice were shown to have elevated 
excitatory potential and epileptiform activity compared to their wildtype counterparts (Chu 
et al., 2010) indicating C1q absence may therefore be deleterious to epilepsy outcomes. 
Finally, a human study of mesial TLE patients showed that the prevalence of specific 
genetic polymorphisms in the C3 promoter region was significantly greater in epilepsy 
compared to control patients. The presence of these polymorphisms also correlated with 
increased febrile seizure susceptibility (Jamali et al., 2010).   
 
Links between endogenous danger signal activation of the complement cascade and 
hyperexcitability have also been shown specifically associated with HMGB1. HMGB1 and 
C5a have been shown to interact during inflammatory conditions and C5a is suggested as 
a primary stimulator of HMGB1 secretion and subsequent adoption of a pro-inflammatory 
cytokine state (Rittirsch et al., 2008, Ward, 2009). Increased presence of HMGB1 is 
reported in epilepsy patients including those with febrile seizures (Choi et al., 2011) and 
drug resistant epilepsy (Walker et al., 2012). Additionally functional studies to block 
HMGB1 action have led to changes in hyperexcitability. In vitro slice recordings of induced 
epileptiform activity showed that HMGB1 presence lowered focal ictal thresholds indicating 
proconvulsant activity (Chiavegato et al., 2014), whilst in vivo antagonism of HMGB1 in 
mice decreased acute and chronic kainic-acid induced seizures (Maroso et al., 2010). 
These findings support a proposed link between HMGB1 mediated activation of the 
complement cascade following initial traumatic insult (i.e. head injury) and further possible 
association with downstream C5a promoting seizure onset and recurrence (Rittirsch et al., 
2008).  
 
The only studies to investigate C5a directly in an epilepsy paradigm were those conducted 
by the Pasinetti group (Osaka et al., 1999a, Osaka et al., 1999b, Mukherjee et al., 2008). 
They showed increased hippocampal and cortical expression of functional C5ar1 following 
excitatory lesioning using kainic acid in mouse brain (Osaka et al., 1999a). In addition they 
reported that co-infusion of recombinant C5a with kainic acid into the brain (i.c.v) reduced 
apoptotic neuronal death in key hippocampal areas (Osaka et al., 1999b) suggestibly by 
regulation of glutamate receptor subunit 2 (Mukherjee et al., 2008). The finding that C5ar1 
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agonism is neuroprotective, through administration of C5a to the brain, conflicts with my 
hypothesis and is not supported in general by other literature findings surrounding the 
inhibition of C5a/C5ar1 in other neurodegenerative diseases (Woodruff et al., 2006, 
Woodruff et al., 2008, Fonseca et al., 2009).  
 
1.2.3 C5ar1 expression in the brain and its associated activation pathways 
 
Studies of C5ar1 expression in the brain have been relatively limited in both humans and 
mice. Glial cells, including both astrocytes and microglia but not oligodendrocytes, are 
known to express this receptor on their membrane (Gasque et al., 1995, Gasque et al., 
1997, Osaka et al., 1999a) however expression on neurons is somewhat debated (Gasque 
et al., 1997, Osaka et al., 1999a, O’Barr et al., 2001) in rodent and human brain. 
Expression of C5ar1 on presynaptic terminals of mossy fibres in the CA3 region of the 
hippocampus has been shown in rat (Crane et al., 2009). This finding is of relevance to 
epilepsy given that mossy fibre sprouting is a hallmark of epileptogenesis and occurs in 
both of the chronic epilepsy models I have utilised for my studies. Upregulated expression 
of C5ar1 has however been reported in many inflammatory-related CNS conditions which 
are commonly associated with development of secondary epilepsy including traumatic 
brain injury (Stahel et al., 1997, Stahel et al., 2000) and  stroke (Van Beek et al., 2000). 
 
The signalling activation pathways of C5ar1 in the brain and periphery are complex. 
Signalling of C5ar1 though NFκB, JAK/STAT and MAPK pathways have all been reported 
making this receptor highly versatile and adaptable in its actions. Outlined below, are 
those that are related to production of specific pro-inflammatory cytokines, known 
mediators of seizures.   
 
Through NFκB signalling pathways C5ar1 is known to control expression of pro-
inflammatory mediators including IL-1β, TNFα, IL-6, IL-8 and COX-2 (Hsu et al., 1999, 
Lappas et al., 2012). All of which are important cytokines linked to changes in convulsive 
thresholds (Vezzani et al., 2008, Li et al., 2011). NFκB-mediated signalling of C5ar1 to 
cause apoptosis of cells has also been illustrated in a mouse lupus model where PMX53 
and specific NFκB inhibitors where shown to block caspase-3 activation leading to 
maintained BBB integrity and reduced cell death (Jacob et al., 2011).   
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JAK/STAT facilitated signalling and upregulated expression of C5ar1 is also known to lead 
to a pro-inflammatory response in human mesangial cells causing IL-6 production 
(Shushakova et al., 2005) which is a known proconvulsant mediator (Samland et al., 2003, 
Kalueff et al., 2004).  
 
MAPK signalling is thought to be a facilitator of C5a-mediated apoptosis of cells through 
caspase-3 activation (Duncan and Morgan, 2003). Specifically, signalling through the p38 
MAPK pathway was also shown to be associated with LPS-induced expression of IL-6 and 
TNFα on peripheral blood mononuclear cells and not ERK or JNK signalling (Schaeffer et 
al., 2007) again relating C5ar1 signalling activation with proconvulsant cytokine production. 
 
1.2.4 PMX53: a C5ar1 antagonist 
 
The key compound of interest in this thesis is the cyclic hexapeptide PMX53, a selective 
antagonist of the human C5ar1 receptor with a molecular weight of 896 Da, which was 
developed in 1998 by Promics Pty Ltd as a peripheral anti-inflammatory agent (Wong et 
al., 1998, Reid et al., 2003).  
 
The chemical structure of PMX53 is based upon a six-member cyclic synthetic peptide 
scaffold modelled from the C-terminus of the human C5a protein where the receptor 
activation domain is located (Finch et al., 1999, Zhang et al., 2008) (Figure 3A, B).  
Chemical synthesis of the compound, Ac-Phe-cyclo-[Orn-Pro-D-Cha-Trp-Arg] is described 
by (Reid et al., 2003). Studies to assess antagonist efficacy of PMX53 using mutations of 
selected C5ar1 residues showed that the compound retained antagonist potency despite 
changes to the receptor structure (Higginbottom et al., 2005) further supporting its 
potency. NMR and ligand docking studies reported that PMX53’s key binding site to C5ar1 
is through an extracellular Arginine (Arg206) residue located on helix 5 of the receptor 
(Higginbottom et al., 2005). The modelled interaction between PMX53 and C5ar1 is shown 
in Figure 3C. 
 
Structural analogues of this compound were also produced in order to improve efficacy 
and bio-stability (Finch et al., 1999, March et al., 2004, Woodruff et al., 2005). PMX203 is 
an inert structure analogue of PMX53 which has no binding affinity for C5ar1 due to 
replacement of D-cyclohexylalanine with a glycine (Finch et al., 1999). PMX203 is used as 
a negative control for C5ar1 binding in these studies (Figure 3D). PMX205 is an 
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alternative C5ar1 antagonist with comparative binding affinity for C5ar1 which differs in 
structure due to methyl replacement of the terminal acetyl group of PMX53 and has 
improved gut stability (Woodruff et al., 2005) (Figure 3E). This compound is more 
lipophilic however (Log P value is 3.8, compared to 3.3 for PMX53) potentially leading to 
greater plasma protein binding and therefore reduced CNS permeability, as well as greater 
chance of accumulation in peripheral fatty tissues. For example, the plasma 
concentrations of PMX205 when measured in parallel to PMX53 at the same dose are 
lower after administration in rat (Woodruff et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Chemical structure of PMX53 and its analogues including ligand binding models to its receptor, 
C5ar1. (A) Chemical structure of PMX53, (Ac-Phe-cyclo-[Orn-Pro-D-Cha-Trp-Arg]) showing its cyclic 
hexapeptide backbone. Chemical formula for the compound is C47H65N11O7. (B) Lowest energy 3-dimensional 
structure bond representation of PMX53 based upon NMR studies (Zhang et al., 2008). (C) Model of PMX53 
docking into C5ar1 receptor with key receptor binding pocket residues shown (Higginbottom et al., 2005). (D) 
PMX203 chemical structure Ac-Phe-cyclo-[Orn-Pro-Gly-Trp-Arg].  The dotted circle denotes the difference in 
structure from PMX53.  (E) PMX205 chemical structure Me-Phe-cyclo-[Orn-Pro-D-Cha-Trp-Arg]. The dotted 
circle denotes the difference in structure from PMX53.  
 
Bioavailability and pharmacokinetic studies also showed that PMX53 was rapidly absorbed 
across mucosal membranes in rat with peak concentrations found as early as 5 minutes 
C 
B D 
A E 
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post administration (Morgan et al., 2008) however poor oral bioavailability was reported 
therefore this route of administration was not used in these studies. Plasma elimination 
half-life for PMX53 was 70 minutes in rat (Strachan et al., 2001). No detailed 
pharmacokinetic studies with PMX53 had been completed in mouse, nor was the brain 
permeability of PMX53 established. Completion of this in mouse after acute dosing is one 
aim of this thesis. 
 
Multiple studies assessing binding specificity of PMX53 have reported that it is specific for 
C5ar1 and does not prevent C5a binding to the alternate C5a receptor, C5ar2 (C5L2) 
(Scola et al., 2007, van Lith et al., 2009). This is an important characteristic of the 
compound allowing isolated modulation of C5ar1 activity which parallels to the knockout 
mouse model of C5ar1-deficiency which retains C5ar2 expression (Hollmann et al., 2008). 
Binding assays to screen affinities of PMX53 for alternative off-target human receptors 
was completed during drug development by Promics®. The receptors which PMX53 had a 
<1µM binding affinity were tachykinin NK2 (200nM) and bombesin (400nM) (unpublished 
data).  
 
Functional evidence that PMX53 selectively inhibits C5ar1 activation is reported in 
competitive binding assays with C5a and C5adesArg (an alternative C5ar1 ligand). PMX53 is 
able to block activation of polymorphonuclear leukocytes (PMNs) via C5a/C5adesArg binding 
in a dose dependent manner, in parallel to PMX203 which lacked effect due to its absence 
of binding affinity for C5ar1 (Reis et al., 2012). Further assays using human PMNs showed 
that PMX53 could inhibit C5a-driven chemotaxis in a dose-dependent manner, as well as 
reduce C5a-induced cytokine production (TNFα and IL-1β) (Haynes et al., 2000). 
 
Pre-treatment with PMX53 of rats in a model of reverse passive Arthus reaction, which 
initiates peripheral immune complex activation, reduced vascular leakage and influx of 
PMNs as well as reduced pro-inflammatory cytokine release by macrophages, primarily 
TNFα and IL-6 (Strachan et al., 2001) in agreement with human in vitro findings. Similarly, 
PMX53 inhibited IL-6 and IL-8 release induced by C5a in human fetal and placental 
membranes through an NFκB-mediated signalling mechanism (Lappas et al., 2012) 
providing further evidence that PMX53 is functionally able to selectively inhibit C5ar1 both 
in vitro and in vivo.  A summary adapted from Holland et al. (2004) is given in Table 1 
which outlines the animal models in which PMX53 has been tested.  
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Table 1. Summary of published in vivo studies utilising PMX53. Adapted from Holland et al. (2004). 
 
Model Clinical 
relevance 
Species PMX53 Dose 
(mg/kg) 
Results References 
C5a- & endotoxin 
induced 
neutropenia 
Sepsis Rat 0.3-3  (i.v.) Inhibited LPS- and C5a-induced 
neutropenia 
(Short et al., 
1999, Strachan et 
al., 2000) 
Dermal Arthus 
reaction 
Dermal 
inflammation 
Rat 1.0 (i.v.) 
1-10 (p.o.) 
Inhibited immune complex driven 
vascular leakage and systemic 
cytokine production 
(Strachan et al., 
2000, Strachan et 
al., 2001) 
Peritoneal Arthus 
reaction 
Peritoneal 
inflammation 
Rat 1, 10 (p.o) Inhibited vascular leakage, PMN 
infiltration and IL-6/TNFα 
production 
(Strachan et al., 
2001) 
Intestinal I/R injury Intestinal I/R 
injury 
Rat 
Mouse 
1 (i.v.) 
10 (p.o.) 
1-25ug (i.v.) 
Limited injury, inhibited 
neutropenia and edema, reduced 
PMN infiltration, reduced TNFα 
plasma levels 
(Fleming et al., 
2003) 
Immune complex 
mediated 
monoarticular 
arthritis 
Immune-
mediated 
monoarticular 
arthritis 
Rat 1, 3 (p.o.) Reduction in joint swelling, gait 
dysfunction, histopathology and 
cytokine levels 
(Woodruff et al., 
2002) 
Hepatic I/R injury Hepatic I/R 
injury 
Rat 1 (i.v.) 
10 (p.o; s.c.) 
Reduced mortality, PMN 
infiltration, MPO activity decline 
and TNFα decrease 
(Arumugam et al., 
2004) 
Cecal 
ligation/puncture 
Sepsis Mouse 1, 3 (i.v.) Improved survival (HUBER-LANG et 
al., 2002) 
TNBS-induced 
colitis 
Ulcerative 
colitis 
Rat 10 (p.o.) plus 
0.3 (s.c.) 
daily 
Reduction in colon edema, 
mortality and reduced MPO and 
TNFα in colon 
(Woodruff et al., 
2003) 
Influenza virus 
challenge 
Influenza Mouse 1 (i.p) Reduced numbers of flu-specific 
CD8+ T cells 
(Kim et al., 2004) 
Traumatic brain 
cryoinjury 
Traumatic 
brain injury 
Mouse 1 (i.p.) Reduced neutrophil extravasation (Sewell et al., 
2004) 
3-Nitropropionic 
acid-induced 
Huntington’s model 
Huntington’s 
disease 
Rat 10 (p.o) Reduced behavioural and motor 
deficits. Reduced striatal lesion 
size, apoptosis, haemorrhage 
and neutrophil infiltration 
(Woodruff et al., 
2006) 
Cerebral ischemic/ 
reperfusion injury 
Ischemic 
Stroke 
Mouse 1 (i.p.) Decreased infarct volume and 
improved neurological function 
(Kim et al., 2008) 
Secondary injury 
after spinal cord 
injury 
Spinal cord 
injury 
Mouse 1 (i.p.) Decreased IL-1β and TNFα, 
reduced astrogliosis, reduced 
damage score, reduced microglial 
activation 
(Li et al., 2014) 
 
i.v. – intraventricular; p.o. – oral; i.p. intraperitoneal; i.t. – intratracheal; s.c. – subcutaneous; TNF – tumour necrosis 
factor; IL-1β – interleukin -1β; LPS – lipopolysaccharide; MPO- myeloperoxidase; PMN – polymorphonuclear leukocyte 
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Finally, further binding studies showed that PMX53 does not alter activity of closely-related 
inflammatory mediators including anaphylatoxin C3a, fMet-Leu-Phe, platelet-activating-
factor, leukotriene B4 or pro-inflammatory cytokine IL-8 (March et al., 2004) supporting the 
selective inhibition of C5ar1. No published work is available to determine if PMX53 has 
effects on ion channels or excitatory neurotransmitters.  
 
Additional compounds utilised in this thesis to modulate actions of C5ar1 not related to 
PMX53 in structure include the non-selective agonist EP54, which has been shown to also 
bind and activate C3ar, an anaphylatoxin receptor upstream in the complement cascade 
(Scully et al., 2010) and W-54011, an alternative non-peptide antagonist of C5a receptors 
(Sumichika et al., 2002).   
 
The lack of selectivity of EP54 is not ideal. However, currently there are no superior small 
molecule agonists of C5ar1 available and activation of C5ar1 via administration of 
recombinant C5a is challenging due to its molecular size and the fact that it will also bind 
other receptors, including C5ar2.  
 
W-54011 was chosen as an alternative C5ar1 antagonist to PMX53 with a non-peptide 
based structure to further investigate the actions of C5ar1 inhibition in vivo. However, cell-
based assays have reported that W-54011 is unable to block C5a-driven Ca2+ mobilisation 
in polymorphonuclear leukocytesof rodents and select other mammals therefore it is 
possible that in vivo efficacy of this compound is unlikely (Sumichika et al., 2002). W-
54011 is the only alternative small molecule C5ar1 antagonist commercially available 
therefore it was still deemed appropriate to test for in vivo efficacy to attempt to 
corroborate the in vitro results in a poorly understood in vivo disease situation.   
 
A summary of each compound to be utilised and their chemical features are given in Table 
2. 
 
 
 
 
 
 
 
17 
 
Table 2. Chemical characteristics and binding affinities for C5ar1-related compounds utilised in this thesis. 
 
Compound Chemical Structure Molecular 
Formula 
Molecular 
weight 
Human 
IC50/ 
EC50 
LogP Primary 
references 
PMX53 AcF[OPd-Cha-WR] C47H65N11O7 896.1 g/mol 26nM 3.3 (March et al., 
2004, 
Higginbottom 
et al., 2005) 
PMX205 HC[OPd-Cha-WR] C45H62N10O6 838.5 g/mol 31nM 3.8 (March et al., 
2004) 
PMX203 AcF[OPGWR] C40H53N11O7 800 g/mol >1mM  (Higginbottom 
et al., 2005) 
W-54011 
 
C30H37CIN2O2 493.1 g/mol 2.2nM 6.6 (Sumichika et 
al., 2002) 
EP54 
(agonist) 
YSFKPMPLaR - 1210 g/mol 220nM 
(EC50) 
- (Finch et al., 
1997) (Scully 
et al., 2010) 
 
 
Preclinically PMX53 has been utilised in a wide variety of inflammatory-related disorders 
(Table 1) including some CNS-related conditions. PMX53 treatment has shown beneficial 
effects in animal models of traumatic brain injury (Sewell et al., 2004), Huntington’s 
disease (Woodruff et al., 2006), ischemic stroke (Kim et al., 2008), amyotrophic lateral 
sclerosis (Woodruff et al., 2008) and spinal cord injury (Li et al., 2014). In each of these 
cases neuroprotection was observed in PMX53-treated animals as well as instances of 
delayed disease progression and onset, and improved behavioural (neurological) score.  
 
Clinically PMX53 has been placed in two human Phase II trials where safety and 
tolerability of the compound in healthy patients was shown. Firstly, in a phase Ib/IIa pilot 
study for use as a dermal cream in inflammatory psoriasis patients in which improved 
outcomes were reported (Koehl, 2006). Secondly, as an oral treatment for chronic 
rheumatoid arthritis in which a lack of efficacy was observed (Ji et al., 2002, Vergunst et 
al., 2007).  
 
1.3     Microglial activation in neurodegenerative diseases 
 
Microglial activation in neurodegenerative diseases which have a CNS inflammatory 
component is common (Hanisch and Kettenmann, 2007, Perry et al., 2010), given that 
microglia are the key immune regulatory cells of the CNS and are responsible for 
production of mediators of inflammation including cytokines and antigen presentation 
elements. They also facilitate phagocytosis and cell migration and proliferation. The role of 
A 
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microglia as mediators of inflammation in the brain has been shown in diseases such as 
stroke (Hu et al., 2012), spinal cord injury (Kigerl et al., 2009, David and Kroner, 2011), 
traumatic brain injury (Kumar et al., 2013) and also Alzheimer’s disease (Morgan et al., 
2005, Varnum and Ikezu, 2012).  
 
To facilitate performance of their diverse functions within the brain, microglia adopt an 
‘activated’ state removed from their surveying phenotype. Activation states have been 
considered to fall into two groups; M1, classically activated state which is largely pro-
inflammatory in nature or, M2, alternatively activated state which is more anti-inflammatory 
and reparative (David and Kroner, 2011, Boche et al., 2013, Cunningham, 2013). M1-
polarized cells are known to express pro-inflammatory cytokines including IL-1β, IL-6 and 
TNFα, as well as cell surface markers including FC receptor CD16 and CD86 (Colton, 
2009, Kobayashi et al., 2013). M2-polarized cells however are characterised using anti-
inflammatory markers including IL-10 and IL-4, of which IL-4 is known to induce an M2 
state (Lyons et al., 2007), as well as enzymes associated with cellular repair such as 
Arginase 1 (Arg1), involved in nitric oxide synthesis and chitinase-like-3 (Ym1) involved 
with cell membrane scaffold integrity. Mannose receptor CD206 is another key M2 
activation marker (Gordon and Martinez, 2010). It must be understood however that clear 
barriers between M1 and M2 activation states are not present and that a spectrum of 
microglial polarization occurs. For example, it has been shown that IL-1β is able to 
associate with M2 activation of microglia in addition to M1, therefore definition of these 
cytokines as markers of microglial activation is fluid and depends on the disease state and 
in some cases post injury timepoint (Mantovani et al., 2002, Giunti et al., 2012). This 
spectrum of activation is supported by the fact that simultaneous expression of both M1 
and M2 markers have been found on microglia (Mosser and Edwards, 2008). For this 
reason we can only speculate about the overall general activation state of the brain, i.e. 
inflammatory or anti-inflammatory, and suggest conclusions based on the 
balance/presence of select M1 and M2 markers throughout disease progression.  
 
1.3.1 Microglial activation in epilepsy 
 
The presence of microglial activation in epilepsy is known however the full spectrum of cell 
activities and phenotypes during phases of epileptogenic development is not. 
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The presence of activated microglia have been shown in animal models, predominantly in 
rats, as little as 8 hours after initial epileptic insult (Taniwaki et al., 1996). Localisation of 
these activated cells was typically within the hippocampal formation, specifically in CA1 
and CA3 regions (Borges et al., 2003, Avignone et al., 2008, Shapiro et al., 2008) which 
are known areas of reorganisation and neuronal cell loss in epilepsy that lead to 
hyperexcitability and subsequent seizure generation (Toyoda et al., 2013). However, the 
presence of activated microglia has also been reported in other areas such as the 
thalamus, amygdala and piriform cortex (Borges et al., 2003) indicating microglial 
activation is widespread in the epileptic brain and co-localises with areas of neuronal 
degeneration.   
 
Assessment of activated microglia presence in human brain tissues illustrates a similar 
picture. Immunostaining of HLA-DR and CD68 in resected brain tissues of epileptic 
patients indicated presence of activated microglia (Beach et al., 1995, Crespel et al., 
2002). Most commonly, drug-resistant patients typically diagnosed with TLE and 
hippocampal sclerosis showed microglial activation with high prevalence in the 
hippocampal formation also (Boer et al., 2006, Najjar et al., 2011). These findings suggest 
a correlation between activated microglia presence and drug-resistance in epilepsy 
highlighting that understanding the role played by these cells and the contribution of their 
actions to seizures if of key importance for development of effective new treatments for 
refractory patients.  
 
In addition to identification of activated microglia in epilepsy models and human tissues, 
functional data showing changes to microglial cells in epilepsy have also been reported. 
Following experimental status epilepticus upregulation of purinergic receptors was 
observed along with functional enhancement of purinergic signalling and cell process 
motility (Avignone et al., 2008). Additionally, upregulation of purinergic receptor P2X4R 
was found post SE which was primarily localised to activated microglia (Ulmann et al., 
2013). P2X4R-deficiency during SE hampered selected features of microglial activation 
and not others, such as cell recruitment abilities and increased expression of voltage gated 
K+ channels. Also, neuronal cell death in the CA1 of the hippocampal formation was 
reduced in P2X4R-deficient mice suggesting this purinergic receptor regulates aspects of 
microglial activation related to excitotoxic damage.  These findings suggest that functional 
changes to microglial activation phenotypes following SE may facilitate excitation leading 
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to seizure generation further cementing the potential deleterious role microglial activation 
plays in epilepsy.  
 
1.3.2 Relationship to C5ar1 
 
It is known that C5ar1 is expressed on activated microglia (Gasque et al., 1997) however 
relatively little is known about its actions on these cells. Presence of the receptor on 
microglia suggests that it is able to facilitate changes to expression of pro-inflammatory 
cytokines when complement cascade activation occurs in times of innate immune defence, 
i.e. after a CNS insult such as SE. It is known that C5ar1 can directly activate NFκB 
mediated expression of TNFα (Zhang et al., 2007), a key pro-inflammatory mediator, also 
known to be proconvulsant (Riazi et al., 2008). Signalling pathways such as this outline 
why actions of microglia throughout epilepsy disease phases are important to understand 
in relation to the actions of C5ar1.  
 
Recently, it was reported that C5ar1 expression on microglial cells is controlled by FosB, a 
regulatory protein driving activation of transcription factor AP-1 (Nomaru et al., 2014). 
Following excitotoxic insult from kainic acid (i.p.), FosB was shown to be a regulator of 
increased C5ar1 expression on microglia, as FosB-null mice lacked C5ar1 upregulation. 
Additionally, decreased mRNA expression of inflammatory cytokines IL-6 and TNFα, both 
associated with C5ar1 and complement activation, were observed providing further 
evidence that mediation of C5ar1 is associated with changes to inflammatory cytokine 
expression following brain excitoxicity.  
 
In addition to facilitating changes to cytokine expression C5ar1 is also known to be related 
to ion channel activation on microglia. C5ar1 activation due to application of C5a on 
cultured murine microglial cells triggered outward potassium channel currents (Ilschner et 
al., 1996). Based on this premise, C5ar1 may potentially be affecting membrane potentials 
causing hyperpolarization of these cells. The relevance of this in regards to seizures is due 
to the presence of neighbouring neurons in dense areas such as a hippocampus. Large 
releases of K+ ions into the extracellular space may trigger depolarisation of proximal 
neurons contributing to hyperexcitability and seizure generation. This theory supports a 
role of C5ar1 in seizure generation despite the fact that neuronal expression of this 
receptor in mice is unclear (Gasque et al., 1997) as microglial cells may be utilised as 
initiators of latent neuronal excitability.  
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2. Aims and Objectives 
 
Overall aim  
    
To determine the preclinical efficacy of PMX53, a C5ar1 antagonist, as a new 
anticonvulsant and neuroprotective compound utilising several mouse models of epilepsy 
and seizures, in addition to investigating the role of C5a/C5ar1 and inflammation in 
epilepsy.  
 
Specific objectives 
 
1.  To determine the anticonvulsant profile of C5ar1 antagonist, PMX53, in both acute 
seizure and chronic epilepsy models, as well as define its neuroprotective properties in 
such models. We employed the use of established seizure models, namely the 6Hz, 
maximal electroshock, pentylenetetrazol (PTZ), corneal kindling, pilocarpine and 
intrahippocampal kainic acid models in order to determine PMX53’s anticonvulsant profile. 
Ability to reduce SE-induced neuronal cell death via inhibition or absence of C5ar1 was 
assessed using the pilocarpine and kainate chronic models with PMX53 and in C5ar1-
deficient and wildtype mice.  
 
2.  To contribute to an understanding of the mechanism of anticonvulsant action of 
PMX53 in seizure models. We assessed to what extent PMX53’s anticonvulsant action is 
mediated by C5ar1 and the complement system.  
 
3.  Assess the effect of status epilepticus and chronic seizures on microglial activation 
phenotypes within the CNS over time and epilepsy disease progression. The association 
between C5ar1 activation on microglia was also assessed to determine the role it plays in 
microglial phenotype adoption including cytokine expression.  
 
4.  To investigate anticonvulsant mechanisms of action of PMX53 at a cellular level, 
with particular focus on C5a-induced outward K+ channels on microglia. It was 
hypothesized that PMX53 mediated inhibition of potassium currents may affect excitability 
within the CNS therefore affecting likelihood of seizure initiation or potentiation. 
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3. Materials and Methods 
 
3.1    Compounds 
 
All compounds were dissolved in a vehicle consisting of 3.75% EtOH in H2O, just prior to 
drug administration. PMX-compounds were synthesized as previously described (Wong et 
al., 1998, Finch et al., 1999). PMX53 (AcF-[OP(D-Cha)WR]) was provided by Cephalon 
(Australia). PMX205 (HC-[OP(D-Cha)WR]), PMX203 (AcF-[OPGWR]) and EP54 
(YSFKPMPLaR) were provided by collaborators (Woodruff, T, UQ). All other compounds 
used were sourced from Sigma Aldrich unless otherwise stated (West Ryde, Australia).W-
54011 (Sumichika et al., 2002) was obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). Experimenter(s) were blinded to the compound, dose and vehicle used. 
 
All mice were administered a 3mg/kg subcutaneous dose of PMX53 and its analogues 
unless otherwise stated. The initial dose range chosen and administration route (s.c.) was 
based upon previous work using the PMX molecules in mouse models of 
neurodegeneration and inflammation (Woodruff et al., 2006, Fonseca et al., 2009, 
Manthey et al., 2011) summarised in Table 1. Further studies using these dose ranges 
(0.1-10mg/kg) were conducted in our primary acute seizure test (6 Hz model) with varying 
pre-treatment times in order to determine the optimal dose and pre-treatment incubation 
time of PMX53. A 3mg/kg dose administered 30 minutes prior to seizure induction was 
found to give the greatest and most reproducible anticonvulsant response in the 6Hz test 
(data not shown). A 60 minute pre-treatment with PMX53 was shown in one experiment to 
give maximal anticonvulsant response however this was not repeatable unlike the 30 
minute pre-treatment which was consistently anticonvulsant in >15 independent tests.  
 
3.2    Animals 
 
Male CD1 Swiss mice (Animal resource centre, Western Australia) between 7-10 weeks of 
age (approximately 30-35g) were used for all experiments unless otherwise stated. 
Animals were singly housed and maintained on a 12h light/dark cycle and allowed food 
and water ad libitum. Typical sample sizes for all acute seizure tests were 15 mice per 
treatment group. The standard deviation is typically 1.5 and allows us to detect differences 
in 2 mA in seizure thresholds between groups with 95% power at 5% significance with an 
n=15. Each seizure test was repeated a minimum of two times to ensure reproducibility, 
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however in some instances the same model was replicated >2 times, i.e. 6Hz test, in order 
to asses for different parameters.  These included dosing and timing of compounds, 
administration routes, alternate formulations of compounds including vehicles and 
neuroprotective versus anticonvulsant effects. All experiments were approved by The 
University of Queensland Animal Ethics Committee and conducted in accordance with 
their guidelines. All efforts were made to minimise animal numbers and suffering of 
animals.  
Breeding of C5ar1-/- knockout colony into CD1 background: C5ar1-deficient C57Bl/6 mice 
provided by T. Woodruff (UQ) were bred into the Swiss CD1 background at Australian 
Institute for Bioengineering and Nanotechnology (Brisbane, Australia) using externally 
sourced CD1 Swiss mice (ARC, Perth, Australia). Initial generation of C5ar1-deficient 
C57Bl/6 colony described by Hollmann et al. (2008).The initial breeding pairs were male 
C57/BL6 C5ar1-/- mice with female CD1 Swiss mice (ARC) to produce C5ar1 heterozygote 
offspring. 5 generational crosses were carried out to ensure all animals were a minimum of 
94% CD1 background before they were used for seizure testing. All animals used in 
seizure experiments were genotyped prior to use by PCR to confirm their C5ar1 receptor 
background.  
 
3.3    Acute seizure models 
 
3.3.1 6Hz model 
Mice were pre-treated with (s.c.) PMX53, other derivatives or vehicle 30 minutes prior to 
stimulation along with application of 0.5% Tetracaine (Sigma Aldrich, Australia) in 0.9% 
NaCl solution, to both corneas of the mice. Corneal electroshocks were supplied using a 
rodent electroshock unit (Ugo Basile, Italy) with the following shock parameters: 6Hz 
frequency, 3 second shock duration, 0.2ms rectangular pulse width, starting with a 14mA 
current. The up down method (Kimball et al., 1957, Giardina and Gasior, 2009) was used 
in order to determine the CC50 (critical current at which 50% of the mice seize) of the 
individual treatment groups. Saline was applied to both the corneas and the electrode 
immediately prior to stimulation to allow for solid conduction of the current. The presence 
or absence of seizure behaviour was recorded directly following the shock as described in 
the up down method (Kimball et al., 1957). If any seizure behaviour was witnessed, 
including head bobbing, forelimb clonus, loss of balance or clonic convulsions, this was 
classified as a yes, and the current was altered by 2mA increments accordingly. Statistical 
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analysis was conducted to determine the CC50 +/- SEM using the method described by 
Kimball et al. (1957).  
 
3.3.2 MEST model 
Mice were administered PMX53 (3mg/kg s.c.) or vehicle 30 minutes prior to the application 
of corneal electroshocks, which were generated using a Hugo Sachs Type 211 rodent 
shocker (Harvard Apparatus, Germany). Stimulation parameters of 50-60Hz sine wave 
frequency, 0.2 second shock duration starting at an 11mA current was used (Giardina and 
Gasior, 2009). 1 mA increments were used to determine the seizure threshold CC50 value 
using the up down method (Kimball et al., 1957). A 0.5% Tetracaine (Sigma Aldrich, 
Australia) in 0.9% NaCl solution was applied to corneas 30 minutes prior to stimulation. 
Saline solution was also applied to corneas and electrodes immediately prior to stimulation 
to ensure solid conduction. Immediately following shock administration mouse seizure 
behaviour was observed. Severe clonic convulsions followed by tonic extension of both 
forelimbs were classified as a yes. Mice that did not show any signs of seizure behaviour, 
or did not undergo full tonic extension, i.e. only 1 hindlimb was extended, were classified 
as a no. All mice were sacrificed via cervical dislocation immediately following seizure 
observational time.  
 
3.3.3 Intravenous pentylenetetrazol (PTZ) model 
Mice were manually restrained and their tails placed in a water bath of 47°C to allow for tail 
vein dilation. 10mg/ml PTZ (Sigma Aldrich, Australia) was delivered via a 30G needle 
attached to 0.5 mm PE tubing and a 1ml syringe. The needle was placed into the tail vein, 
which was confirmed by the spontaneous retraction of blood into the tubing. The solution 
was then perfused intravenously through the tail vein using a syringe pump set to 150 
µL/min. The volume of PTZ given was recorded for three successive seizures; the first 
twitch, the first generalized seizure and tonic extension (endpoint). The dose of PTZ 
required to reach each point was calculated per body weight and was reported as PTZ 
seizure thresholds (Mandhane et al., 2007).  
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3.4   Chronic seizure and epilepsy models 
 
3.4.1 Corneal kindling model 
Electroshock parameters of 50Hz, 0.4ms pulse were used to determine the effect of 
PMX53 on fully kindled mice. Mice were administered two electroshocks per day with at 
least 3 hours between shocks for a period of 20 days using a rodent electroshock unit as 
in the 6Hz model (Ugo Basile, Italy). Mice were considered fully kindled when they 
displayed ≥3 stage 5 seizures. Seizures were scored on a scale of severity from 0 to 5 with 
0 being no seizure. This scoring system was previously established by (Racine, 1972) and 
then modified by (Klitgaard et al., 1998). 0 = no reaction or immobility; 1= jaw clonus; 2= 
myoclonic twitches in forelimbs, sometimes including head nodding; 3= clonic forelimb 
convulsions; 4= clonic forelimb convulsions with rearing or falling; 5= loss of balance 
(Willis et al., 2010). Mice were administered PMX53 on day 20 (stimulation 40) when the 
median seizure score was 5. Half were treated with vehicle (3.72% EtOH in H2O, s.c. 
30min) and the other half with PMX53 (3mg/kg s.c. 30min) with the experimenters being 
blinded. Resultant seizures were scored according to the Racine scale and results 
collated. Diazepam was used as a positive control drug for this model as its anticonvulsant 
action in this model is well documented (Morimoto et al., 2004).  
 
3.4.2 Pilocarpine-induced status epilepticus (SE) model 
Mice were administered methyl scopolamine in 1mg/ml saline solution (2.5mg/kg i.p.; 
Sigma Aldrich, Australia) 15 minutes prior to injection of 345mg/kg (s.c.) pilocarpine 
dissolved in saline (Sigma Aldrich) which induced status epilepticus in >60% of mice, 
about 30% mice had no SE and 10% died. For the 90 minute period following pilocarpine 
administration, mice were observed and their seizure behaviour scored (as described in 
3.4.1). At the termination point of 90 minutes post pilocarpine, mice were classified as SE 
or NoSE and given 30mg/kg (i.p.) phenobarbital (PB) to stop seizures. After this time mice 
were placed on a heat pad and given 1ml of 4% dextrose twice daily as well as handfed 
jam. Weight loss was monitored. If >20% weight loss was observed mice were euthanized. 
Spontaneous recurrent seizures were observed in the mice >1 week post-SE, confirmed 
by EEG. The seizures observed were infrequent (~1-2 per day) and generalized in nature 
involving whole body clonus and often loss of balance.  
 
To determine if PMX53 treatment was anticonvulsant in this model, animals were injected 
with 3mg/kg s.c. PMX53 30 minutes following pilocarpine injection. At this timepoint the 
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majority of animals have already begun to experience severe seizures characteristic of 
status epilepticus (SE). Similarly, another group of animals were administered PMX53 at 
this same 30 min timepoint and were sacrificed 3 days post SE to determine if 
administration of PMX53 mid-SE could improve survival of neurons in the hippocampus. 
Animals were perfused with 0.9%NaCl + 1%NaN02 to remove blood and fixed with a 4% 
paraformaldehyde solution. Brains were collected for all animals and processed for 
histology (see section 3.6.1). To determine if absence of C5ar1 during pilocarpine-induced 
SE was subsequently neuroprotective, CD1xC5ar1-/- and CD1xC5ar1+/+ mice were used 
and no administration of PMX53 took place. Animals were sacrificed and perfused, as 
indicated above, at the 3 day timepoint for histology.  
 
3.4.3 Intrahippocampal kainate epilepsy model 
The protocol was based on that of Gouder et al. (2003). Briefly, mice were deeply 
anesthetised with a mixture of 1.8% Isoflurane (Troylab, Glendenning, Australia) and 
oxygen and placed on a stereotaxic frame (Kopf, Tujunga, California). An 80nL volume of 
20mM kainic acid (~1.7 nmol; KA; Sigma Aldrich) was stereotaxically injected unilaterally 
into the CA1 pyramidal layer of the hippocampus (AP -1.94, ML -1.25, DV-1.5 from 
bregma, Figure 4) using a 0.1µl glass microsyringe (Hamilton, Reno, NV) attached to a 33 
gauge stainless steel injection cannula (C315I, Plastics One, Roanoke, VA) via PE20 
tubing (Plastics One) filled with H2O. An external 26 gauge guide cannula (C315GA, 
Plastics One) was used to ensure direct delivery to the CA1 site. Infusion and injection 
cannula removal was carried out over a 2 min period to ensure minimization of reflux. The 
incision was sutured with nylon and a topical anaesthetic cream was applied (Emla® 5%; 
2.5% lidocaine, 2.5% priocaine). Immediately upon awakening the mice underwent status 
epilepticus for a continuous period of >4 hours. SE was not terminated with PB as in the 
pilocarpine model. Frequent focal epileptiform activity was observed in the hippocampus of 
these mice along with less frequent generalized seizures by ≥ 3 weeks post-SE which was 
confirmed by video EEG. This behavioural phenotype was consistent with other reports 
characterising this model (Riban et al., 2002, Langlois et al., 2012). Anecdotally, seizures 
often involved behavioural arrest and/or partial motor spasms including forelimb clonus 
and head bobbing. Tonic-clonic seizures causing loss of balance were rare in these mice.  
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Figure 4. Representative images of stereotaxic kainic acid injection into the CA1 pyramidal cell layer of the 
hippocampus of mice. (A, B) Clear injection into CA1 cell layer of 2 individual mice is achieved using trypan 
blue dye to visualise the injection site. (C) Higher magnification of injection site of another mouse to show 
that dye (representative of KA) is selectively injected into the CA1 layer and not that of surrounding tissue.  
 
For the drug administration paradigm, mice were recorded for a baseline settle period of 
60min, followed by a 90min baseline recording period, before drug injection and a second 
90min drug recording period. Each mouse was administered both vehicle and PMX53 in a 
blinded fashion with a 1 week washout period between administration and recordings.  
 
 
3.5   EEG recording and analysis of SE and chronic seizures 
 
3.5.1 Electrode implantation surgery 
Pilocarpine mice were implanted with recording electrodes 1 week prior to induction of SE 
to allow for recording of the SE phase. Intrahippocampal kainate mice were implanted 1 
week following kainate administration to the CA1 site and not immediately following i.h. 
kainate injection to prevent disturbance of the SE period due to anaesthetic use during the 
surgery. The implantation surgery typically took 45 minutes to complete for each animal.  
 
The surgery procedure was similar to that of the i.h. kainate injection surgery (refer 3.4.3). 
Briefly, mice were anaesthetized using 1.8% Isoflurane (Troy lab, Glendenning, Australia) 
in oxygen and mounted on a stereotaxic frame (Kopf, Tujunga, CA). The skin above the 
skull was shaved and cleaned with Betadine solution (Sanofi, Paris, France) prior to a 2 
cm lengthwise incision being made over the skull. The skull plate was cleaned with 30% 
H2O2 to reveal the Bregma line. Coordinates were traced from this point to determine the 
CA1 injection site on the left hippocampal formation. A small 1-2mm hole was made 
through the skull bone using a Dremel handheld drill with a round 1.5 mm bit (Dremel, 
Mount Prospect, IL). The bipolar depth electrode (formed from two twisted enamel-coated 
A B C 
28 
 
insulated stainless steel 170µm diameter wires, 0.4mm tip separation, E363/3/SPC, 
Plastics One, Roanoke, VA) was inserted using the stereotaxic arm at bregma AP: -1.94, 
ML: -1.25, DV -1.5 and secured with a small amount of superglue. Three surface screw 
electrodes (1.2mm diameter, stainless steel, E363/20/1.6/SPC, Plastics One) were then 
implanted to just below the dura mater. Two were placed bilaterally 2.5mm posterior to 
lambda and one was placed over the contralateral (3mm from midline) frontal cortex 1mm 
posterior to bregma to act as ground and reference (including cortical) electrodes.  
 
All electrodes were then mapped to a multichannel electrode pedestal (MS363, 6-channel, 
Plastics One) which was fixed using self-curing acrylic dental cement (Vertex Dental, Zeist, 
Netherlands) to encase the electrodes and wires and fix the pedestal securely to the 
mouse’s head. Pedestal and electrode mapping are shown in Figure 5. The minimal 
amount of cement was used to minimize weight. Once the cement was touch dry (2 minute 
wait) animals were given topical anaesthetic cream (Emla® 5%: 2.5% lidocaine, 2.5% 
priocaine) and 1 ml of saline (s.c.) for hydration before being removed from the stereotaxic 
frame.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Example of electrode and pedestal layout for intrahippocampal and cortex EEG recordings in mice. 
(A) Implantation schematic for mouse brain with 3 surface screw electrodes (cortex, reference, ground) and 
one bipolar hippocampal depth electrode at Bregma AP-1.94, ML -1.25, DV -1.5. (B) Placement of 
electrodes in 6-channel electrode pedestal which is attached to the animal’s head for recording of brain 
activity.   
 
Mice were monitored in their cage on a head pad for 1 hour after surgery to ensure their 
recovery. Food hoppers were removed from the cages following surgery and food pellets 
were placed on the ground to prevent their pedestals from catching/bumping into the 
hopper. Mice were allowed to recover for 1 week prior to any EEG recording taking place.  
B A 
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3.5.2 Recording protocol 
 
Implanted mice were weighed prior to being attached to the commutator via a 6-channel 
cable through the 6-channel pedestal implanted on the head. 2 grams was taken into 
account for the pedestal weight. All animals were placed in the clear recording cages (30 x 
20 x 22cm; H x W x D) with attached water bottles along with a small amount of bedding 
material and food (if it was a 24 hr recording session). Examples of the recording cages 
are shown in Figure 6.  
 
 
Figure 6. EEG recording cage housing and setup. Mice were housed in clear plexiglass cages during EEG 
recording. Eight mice could be recorded simultaneously with each compartment measuring 30 x 20 x 22 cm 
(H x W x D). Commutators with 6-channel cables on a free rotating mount were connected to the top of each 
box to detect each animal’s individual EEG response.  
 
Pilocarpine model: For 24 hour recordings mice were given food, water and bedding and 
recordings took place between 12:00 and 12:00 to ensure consistency. Mice were checked 
on every 6 hours. For assessment of status epilepticus mice were allowed a 1 hour settle 
period prior to a 60 minute baseline recording after which pilocarpine was administered 15 
minutes post PMX53 or vehicle injections (Figure 7A).  
 
Kainate model: For shorter 4 hour recordings (i.h. kainate model) no food or water was 
supplied, only bedding material to ensure minimal distractions occurred for the 90 minute 
drug treatment windows. All recordings took place between 09:30 and 14:30 to ensure 
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consistency between recording sessions. Once recording began the room was exited until 
the injection time to reduce stress to the animals. After injection the room was exited again 
until the end of the designated recording period. Mice were recorded in the same cage for 
both vehicle and PMX53 recordings which were spaced 7 days apart to allow for washout 
of the drug. Mice were not unattached from the commutator during injection of the vehicle 
or drug to allow for continuous recording. The recording paradigm allowed for a 1 hour 
settle period prior to a 90 minute baseline recording period. At this time the injection was 
made. A 10 minute drug binding period was allowed prior to another 90 minute test 
recording period. In total animals were recorded for 4 hrs 10min, with only 3 hrs being 
analysed for seizures; 2x 90 min periods (Figure 7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. EEG Recording paradigm for both intrahippocampal kainate and pilocarpine experiments to 
monitor brain activity during chronic seizures or SE. (A) PMX53 (3mg/kg s.c.) was administered to naïve 
mice prior to pilocarpine injection after a 60 minute baseline recording  followed by a 15 minute drug binding 
period. Animals underwent a 90 minute SE period. Total recording time for this experiment was < 4hours. (B)  
Effects of PMX53 on chronic recurrent spontaneous seizures in intrahippocampal kainate mice were 
determined by two parallel recording sessions. Mice were administered kainic acid directly to the 
hippocampal CA1 region 4 weeks prior to EEG recording, by which time spontaneous recurrent seizures 
appeared in the mice. Mice were allowed to settle for 1 hour prior to a 90 minute baseline recording, blinded 
injection of vehicle or PMX53, 15 minute drug binding period, and then a final 90min drug baseline period. 
This was repeated for each mouse twice with a 1 week washout period in between recordings. This allowed 
for paired comparison of results with each mouse received both PMX53 and vehicle. Total recording time for 
this experiment was 4 hours 15min (x2).  
 
A 
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Upon termination of the recording period mice were unhooked from the commutator cable 
and returned to their home cage. In some instances the electrode pedestal came loose on 
the skull. Any mice in which this occurred were unhooked immediately and euthanized. 
Any recordings from animals in which the full recording periods were not completed were 
excluded from the study.  
 
 
3.5.3 Seizure detection and analysis 
Compumedics Profusion 4 EEG software was used for EEG trace recording. Continuous 
video recording was taken in parallel for all mice which was used to visually confirm 
seizure analysis results. All drug administration and EEG recording and analysis was 
conducted in a blinded manner to ensure no experimenter bias occurred. 
 
Initially, EEG traces were analysed using Profusion EEG 4 acquisition software 
(Compumedics) to identify, in parallel with continuous recorded video, and exclude 
sections where mice were scratching or non-seizure ictal spikes were seen. This took 
place in a later review session so not to disturb the mice during the recording period. Often 
scratching was associated with sharp high amplitude spikes seen in the EEG trace. These 
periods were excluded for all mice. 
 
Exported hippocampal bipolar trace values were subtracted from one another to obtain the 
difference between the two electrodes (Hip1-Hip2). Reference trace values were 
subtracted as background from this trace. These values were then imported as a text file 
into Labchart 8 analysis software (AD Instruments) with a custom seizure detection marco. 
EEG was recording with a 512 Hz sampling frequency. Six channel filters were applied 
automatically within the macro to detect seizure activity and were as such: Channel 1 – 
raw data signal input (µV); Channel 2 - Bandpass filter data between 6 and 12Hz; Channel 
3 - Do an RMS (root mean square) calculation on Ch2 with a window width of 3 secs to 
remove isolated ictal spike activity; Channel 4: Further smooth Ch3 with a 10 second 
moving triangular window; Channel 5 - Detects when Ch4 is above or below a value of 14 
(arbitrary value found by trial and error of seizure false positive and negatives); Channel 6 
- Derivative of Ch5 to show when seizure is starting (upward spike) or ending (downward 
spike). Total power is then determined for each seizure between the 6-12Hz band. 
Seizures detected using Labchart were then collated and analysed in Excel. Ictal spike 
periods lasting <10 sec in duration were defined as non-seizure events and were excluded 
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from the analysis. Seizure frequency is reported as the number of seizure events per 
minute; seizure power is reported in units of voltage squared (V2). 
 
I.h. kainate model: In total there were four analysis periods for each mouse: Baseline 1, 
Vehicle-treated, Baseline 2, PMX53-treated. All analysis was based upon normalization of 
results from each test period to its respective baseline period to ensure consistency 
between recording days.  
Exclusion criteria: Mice were excluded from the study if they exhibited distinctly different 
seizure baselines between the two recording sessions. A change greater than 50% of the 
total time in seizure between sessions was considered too dissimilar for a valid 
comparative paired analysis to be made. Animals were also excluded if Labchart software 
did not detect any seizure activity, which occurred in ~60% of the mice recorded. Only 
“epileptic” mice exhibiting frequent hippocampal seizures (>5 seizures per 90 min 
baseline) were analysed.  
 
Seizure measurement parameters: Four seizure parameters were determined and 
compared for both baseline and test periods for each mouse, including total values from 
24 hour recordings in pilocarpine SE mice. Average seizure length (s), average seizure 
power (Hz), proportion of total recording time spent in seizure (%) and the number of 
seizure events per min (#sz/min) was determined for each animal. Results were expressed 
as a fraction of the respective baseline.  
A paired student’s t-test was conducted for each parameter to determine its potential 
significance level using GraphPad Prism 7 software (GraphPad, La Jolla, CA).  
 
3.6   Test for neurotoxicity using the Rotarod (motor impairment) 
This test is commonly used to determine whether a compound causes neurotoxic effects in 
the form of motor impairment. Animals are placed on a rotating rod and are challenged to 
stay on the rod for a predetermined period of time. Should animals fall before this time 
they are considered to have motor impairment and hence are displaying neurotoxicity as a 
result of drug treatment, such as PMX53. Mice are first given time to ‘learn’ on the rotarod 
apparatus 1-2 days prior to testing and drug administration to familiarise them with the 
movement. 30 minutes post PMX53, PMX203 or vehicle administration the animals are 
trialled on the Rotarod (Ugo Basile, Italy). The rod parameters are set at constant 25 rpm 
acceleration for a 60 second trial period. Each mouse is trialled 3 times and the mean 
latency to fall for each animal is reported and the average of each treatment group 
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calculated. A decrease in fall latency (sec) indicates minimal motor impairment which 
correlates to neurotoxicity of the test compound. Protocol adapted from Capacio et al. 
(1992) and Woode et al. (2011). 
 
 
3.7   Determination of acute neuronal cell death in chronic epilepsy models 
 
3.7.1 Fluoro Jade B immunostaining 
Fluoro Jade B (FJB) was used as a marker of neuronal degeneration to analyse acute 
hippocampal damage in pilocarpine-induced SE animals 3 days post-SE insult. The 
staining protocol used was described by Schmued and Hopkins (2000). Briefly, 9 µM 
coronal paraffin-embedded brain slices mounted on Superfrost-plus microscope slides 
(Menzel-Glaser, Berlin, Germany) were dewaxed using a series of 1 minute rehydration 
washes (100% Xylene x 2; 100% Ethanol x 2; 90% Ethanol x 1; 70% Ethanol x 1; Distilled 
H2O x 1). Slides were then incubated at room temperature in 0.06% KMnO4 solution for 10 
minutes on a shaker, washed in dH2O, then in a 0.0004% FJB in 0.1% acetic acid solution 
(Merck Millipore, Billerica, MA) solution for 15 minutes in the dark. Slides were washed 
three times in dH2O before being dehydrated in Xylene and coverslipped with DPX 
(Sigma, St Louis, MO). Degenerating cells were visualized on an upright fluorescent 
microscope (Axio Imager, Zeiss, Jena, Germany) using a FITC filter and pictures were 
captured for each hippocampal formation of every animal. The presence and density of 
FJB-positive cells in each of the major hippocampal areas (CA1, CA3, Dentate gyrus, 
Hilus) and was then analysed from the pictures in a blinded fashion using Imaris (Bitplane, 
Belfast, UK) software.  
 
3.7.2 Quantification of neuronal cell death 
Imaris spot detection software (Bitplane, Belfast, UK) was used to determine the number 
of FJB-positive cells in specific areas of the hippocampal formation. Spots were 
automatically detected based upon cell size and shape and were verified for each slide by 
eye to ensure false-positives were not being detected. The total area of each region of the 
hippocampal formation was outlined in the program by hand and calculated in mm2. FJB-
density of cells was determined by dividing the total number of positive spots in the region 
by the total area to give FJB+ cells/mm2. NoSE animals were used at conditional controls 
for all experiments. 
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3.8   Measurement of inflammatory markers 
   
3.8.1 RNA extraction and Quantitative real time PCR  
Mice were trans-cardially perfused with 1% NaNO2 in saline and brains were removed. 
Forebrain or hippocampal formations and cerebral cortices were separated and 
immediately frozen on dry ice. RNA extraction was carried out using the Qiagen RNAeasy 
MiniPrep kit according to manufacturer’s instructions (Qiagen, Limburg, Netherlands). 
Dnase treatment was carried out using Promega DNase kit (Promega, Madison, WI) and 
mRNA concentrations were determined using NanoDrop. cDNA synthesis was performed 
using the Tetro kit (Bioline, London, UK).  All qPCR was completed using SYBR green 
reagents (Applied Biosciences) and run on Viia7 machine (Applied Biosystems, Foster 
City, CA). A comparative Ct analysis was completed using Tata Box Protein (TBP) and 
hydroxymethylbilane synthase (HMBS) as housekeeping reference genes, along with 
glyceraldehyde-3-phosphate hydrolase (GAPDH) to control for DNA contamination. All 
mRNA amounts are reported as levels relative to housekeeping gene expression.  
 
3.8.2 Flow cytometry for biomarker detection 
The brain extraction protocol of immune cells was based on that from (Gelderblom et al., 
2009). Initially mice were trans-cardially perfused with cold 1% NaNO2 0.9% NaCl solution 
before immediate removal of the forebrain and tissue disruption using a straight-edge 
blade. Tissue was chopped to a fine paste and digested at 37 ̊C for 40 minutes in a 5 ml 
solution containing 0.1% DNase, 0.5% Collagenase A in Dulbecco’s modified Eagle 
Medium (DMEM). After 10x trituration with a 10 ml serological pipette, tissue was then 
passed through a 40 µM cell strainer (BD Falcon) and washed with 40 ml of cold sterile 
Phosphate Buffered Saline (PBS). Centrifugation at 4 ̊C for 10 minutes at 310 g was 
performed and the supernatant discarded. The pellet was then resuspended in 5 ml of red 
blood cell lysis buffer containing 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA (pH7.4) 
for 7 minutes on ice. The tissue was then washed with PBS and centrifuged again using 
the same parameters. The pellet was then resuspended and a standard Percoll gradient 
was performed (A: 78% Percoll in Phosphate Buffered Saline (PBS), B: 30% Percoll in 
DMEM). Following removal of cells (1ml) from the gradient interface, this sample was then 
washed with FACS buffer containing 0.5% BSA, 0.02% NaN3 in PBS.  Centrifugation at 
4 ̊C for 10 minutes at 700 g was carried out. The resultant pellet was then washed twice 
more with FACS buffer with centrifugation at 310g prior to being placed into round bottom 
96 well plates for staining.  
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Extracellular staining for C5ar1 and cell sorting markers: A cocktail containing several 
marker antibodies was prepared in FACS buffer; anti-C5ar1 (Alexa 488, MCA2456, AbD 
Serotec), anti-CD45 (PE-Cyanine 7, 25-0451, eBioscience), anti-Ly-6G (V450, 560603, BD 
Biosciences) and FC receptor blocker (non-conjugated anti-CD16/32, 16-0161, 
eBioscience). This cocktail was used in all preparations to allow for cell differentiation 
between infiltrating cells, neutrophils and resident CNS microglia. C5ar1 was included to 
allow for identification of cells (infiltrating and resident) expressing this receptor of interest. 
Briefly, cells were incubated with cocktail for 20 min at 4˚C. Cells were then washed twice 
before 20 min of fixation at room temperature in fixation buffer (eBioscience). Cells were 
then resuspended in FACS buffer for analysis.  
 
Intracellular Arg1 and Ym1 staining: After cocktail incubation cells were placed  in 
permeabilisation buffer (eBioscience)  for 20 min prior to a 45 min room temperature 
incubation with Fluorescein conjugated anti-Arg1 (IC5868F, R&D Systems) or non-
conjugated anti-Ym1 (MAB2446, R&D Systems) followed by PE conjugated anti-rat IgG2a 
(12-4817, eBioscience).  
 
Intracellular cytokine staining: Cells were incubated at 37 C̊ with 5% CO2 for 3 hours with 
an inhibitor of intracellular protein transport Brefeldin A (1:1000, 00-4506, eBioscience), in 
RPMI-1640 with β-mercaptoethanol and 10% foetal bovine serum prior to cocktail 
incubation. Cells were then permeabilized as described above and stained with the 
following directly conjugated antibodies: IL-1β pro-form (APC, 17-7114, eBioscience), IL-4 
(PE, 562044, BD Pharmingen), IL-6 (PE, 12-7061, eBioscience), IL-10 (PE, 554467, BD 
Pharmingen), IL-12 (p40/p70 subunit, PE, 554479, BD Pharmingen) and TNFα (PE, 
554419, BD Pharmingen).  
 
A BD LSRII flow cytometer was used for all experiments (BD Biosciences, San Jose, CA). 
BD FACsDiva software was used for all results capture and analysis. FlowJo software was 
used for creation of final representative figures (FlowJo, Ashland, OR). CD45 intermediate 
cells were gated as microglia, whilst CD45 high cells were gated as infiltrating immune 
cells (non-microglial). C5ar1 and Ym1 staining showed clear positive and negative 
populations therefore percentages of positive and negative cells were measured for 
analysis. All other cytokines were measured using median fluorescence intensity (MFI) 
and this value was used for analysis. For MFI analysed populations, sample values were 
normalised to control values to make comparisons between independent replicate 
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experiments. Naïve control samples were included for all experiments in addition to NoSE 
controls.  
 
 
3.9   Pharmacokinetic measurement of PMX53 concentrations in plasma and CNS 
 
3.9.1 Extraction and matrix optimisation 
LC-MS analysis of brain tissue and plasma samples was conducted to assess the relative 
levels of PMX53 in the CNS and circulation given the dose and timepoints tested in the 
various seizure models, as previously described. Swiss male CD1 mice (AIBN) were used 
to measure the concentration of PMX53 in plasma and brain. Mice were sacrificed by 
lethal injection of 60 mg/ml pentobarbital solution (Ilium, Australia) following PMX53 pre-
treatment (3 mg/kg s.c.) at the appropriate timepoint. Blood samples were first taken from 
the inferior vena cava via dissection of the mouse to open the lower abdomen cavity. A 
heparinised 27G needle and syringe was inserted into the inferior vena cava and a 
minimum of 400 µl of blood was removed from each mouse.  
 
Sample preparation for both brain tissue and plasma was carried out based on the 
protocol described by (Strachan et al., 2001).  
Blood samples were centrifuged at 6000 g for 12 minutes at 4°C, and the plasma 
supernatant collected. Following blood sampling the animal was perfused through the left 
ventricle with 0.9% NaCl solution containing 1% NaNO2 to act as a vasodilator. The brain 
was removed immediately following complete perfusion.  
Plasma processing: Plasma samples were precipitated with HPLC grade Acetonitrile 1:3 
(w/v) by centrifugation at 11000g for 15 minutes at room temperature. The supernatant 
was collected and evaporated by centrifugation then reconstituted in an equivalent volume 
of acetonitrile. This sample preparation was then analysed using LC-MS/MS.  
Brain processing: Perfused brains were thawed and homogenized 1:2 (w/v) brain tissue: 
milli Q water using a polytron homogenizer. The sample was then centrifuged at 13,000 g 
for 15 minutes at room temperature. The supernatant was collected and precipitated 
further using acetonitrile 1:3 (w/v). The same procedure was followed as for plasma 
processing.  
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3.9.2 LC-MS/MS analysis 
HPLC Grade acetonitrile and formic acid (AR Grade) was purchased from RCI Labscan 
(Bangkok, Thailand) and Labscan (Gliwice, Poland) respectively.  Deionised water was 
generated via an Elga Purelab Classic water purification unit (Veolia Water Solutions and 
Technologies, Saint Maurice Cedex, France). 
 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) data were acquired on a 
Dionex UltiMate 3000 liquid chromatography system (Dionex, California, USA) coupled to 
an ABSciex 4000 QTRAP mass spectrometer (ABSciex, Concord, Canada). The liquid 
chromatography system was controlled by Chromeleon software (v6.80, Dionex), and 
chromatographic separation was achieved by injecting 10 μL onto a Gemini-NX C18 150 
mm × 2 mm I.D., 3 μm 110 Å particle column (Phenomenex, Aschaffenburg, Germany) 
equipped with a pre-column Security Guard Gemini-NX C18 4 mm x 2 mm I.D. cartridge. 
The column oven temperature was controlled and maintained at 60 °C throughout the 
acquisition. The mobile phase flow rate was maintained at 300 μL/min for 5 minutes and 
the mobile phase (isocratic) was 50:50 (v/v) purified water:acetonitrile plus 0.1% (v/v) 
formic acid. 
 
The mass spectrometer was controlled by Analyst software (v1.5.2, ABSciex) and was 
equipped with a TurboV electrospray source operated in positive ion mode.  The following 
optimized parameters were used to acquire Multiple Reaction Monitoring (MRM) data: 
ionspray voltage 5300 V, nebulizer (GS1), auxiliary (GS2), curtain (CUR) and collision 
(CAD) gases were 40, 80, 15 and high (arbitrary units), respectively, generated via a 
N300DR nitrogen generator (Peak Scientific, Massachusetts, USA). The auxiliary gas 
temperature was maintained at 420 °C.  The analyte-dependent parameters for the 
detection of PMX are given in Table 3. For all analytes the entrance potential (EP) was 10 
volts. 
 
The samples were run with sample- and analyte-relevant calibration standards and pooled 
QC samples (Sangster et al., 2006, Hodson et al., 2009) to control for reproducibility of 
data acquisition and to ensure data integrity. Analyte stock solutions were prepared in 
purified water (Veolia). Data were processed and analysed in Analyst 1.5.2 and MultiQuant 
2.1 (ABSciex). Calibration curve shown in Figure 8. 
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Table 3. Analyte-dependent parameters for the transitions used in Multiple Reaction Monitoring data 
acquisition. 
 
Analyte 
Q1 Mass 
(Daltons) 
Q3 Mass 
(Daltons) 
Dwell Time 
(milliseconds) 
DP 
(Volts) 
CE 
(Volts) 
CXP 
(Volts) 
PMX53 
(quantifier) 
896.2 69.9 50 151 129 2 
PMX53 
(qualifier 1) 
896.2 158.9 50 151 89 8 
PMX53 
(qualifier 2) 
 
896.2 223.4 50 151 87 12 
 
Key: Q – quadrupole; DP – declustering potential; CE – collision energy; CXP – collision cell exit potential 
 
 
 
 
 
Figure 8. LC-MS/MS calibration curve 
for PMX53 analysis. Actual [PMX53] is 
shown on the x-axis versus measured 
[PMX53] on the y-axis determined using 
the LC-MS/MS analysis and extraction 
protocol outlined above. A high 
efficiency correlation was found for the 
measurement method as indicated by 
the R2=0.9991. 
 
 
 
 
 
 
3.10 Microglial cell culture 
 
3.10.1 Glial cell culture protocol 
Cortices from E15-17 outbred CD1 mouse embryos were dissected out and the meninges 
were removed. An average of 12-16 embryos was collected from each CD1 pregnant 
female. Cortices were then digested in a 0.5 mg/ml trypsin solution for 5 min at 37 ̊C, 
followed by incubation with trypsin inhibitor for the same time frame. Tissue was then 
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washed with and resuspended in DMEM in a 50 ml falcon tube before 15x trituration using 
a 10 ml serological pipette. The culture was then checked to ensure cells were separated 
and not clumped. The debris was allowed to fall to the bottom and the supernatant was 
moved to a new tube. If necessary an additional 5-10 triturations were performed to further 
separate cells. The total cell number was then counted using a haemocytometer and cells 
were resuspended in prepared cell culture medium containing 10% FBS in DMEM:Ham’s 
F12 nutrient including Penicillin (25 U/ml) and Streptomycin (25 µg/ml). Cells were seeded 
at various densities ranging from 2.5 - 5x105 cells/ml in 75cm2 filter cap flasks. Cells were 
maintained in a 37 ̊ C, 5% CO2 environment for 2-3 weeks until confluence of astrocyte 
cells was achieved. Half of the medium was changed every 2-3 days as required. 
 
3.10.2 Separation of microglial and coverslipping 
8-10 mm diameter glass coverslips (Neuvitro, El Monte, CA) were sterilised by flaming and 
coated with Poly-D-lysine (PDL, Sigma Aldrich) 1-2 days prior to microglial separation. 
Coverslips were placed in a 12-well plate and incubated at room temperature with 50 
µg/ml PDL solution for 1 hour. Coverslips were washed twice with PBS and allowed to dry 
prior to use with cells.  
 
Microglial cells were separated from the mixed glial culture by shaking of the flask side to 
side vigorously for two 10 second periods, checking for any lifting of the astrocytic layer in 
between shaking. Once >80% of microglial cells were shaken loose the supernatant was 
collected and the cells isolated by centrifugation (10 min, 310 g, 4 ̊C). Microglial cells were 
then plated on PDL coated glass coverslips at a density of 1x105 cells/ml housed in a 12-
well plate. Cells were allowed to settle for 20 minutes; non adherent cells were then 
washed off with PBS. Coverslips were maintained in a medium containing 20% astrocyte-
conditioned medium (see NOTE) in macrophage serum free medium (Gibco, Carlsbad, 
CA). Coverslips were maintained for 2 days prior to being used in patch clamp 
experiments.  
NOTE: astrocyte conditioned medium was taken from mixed glial culture. Microglial cells 
were shaken off and removed and fresh medium was added to the astrocyte layer. This 
was maintained for 3 days prior to removal of the media and centrifugation at 800rpm. The 
supernatant was collected and stored at -80 ̊C prior to use.  
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Figure 9. Representative image of primary mouse 
microglia used for patch clamp experiments. Primary 
cultured murine microglia were isolated and matured 
for 5 weeks before separation from astrocyte mixed 
culture. Cells were amoeboid in shape and typically 
showed stunted processes indicating a transient 
activation state of these cells.  
 
 
 
As shown in Figure 9, the microglia are neither quiescent nor fully activated/ramified when 
used for patch clamping, rather they are at an intermediary state of activation. Typical 
activated (ramified) microglia morphology is described by a dense enlarged cell body with 
shortened processes, whilst surveying (quiescent) cells have fine elongated processes 
and comparatively small granular cell bodies. Several intermediary morphologies are 
observed between these activation states; globular with complete retraction of processes 
and an amoeboid cell body or pseudopodic with truncated drawn-in processes and an 
enlarged granular cell body. The cultures used had a mixture of all morphologies present 
however predominantly the cells were pseudopodic in nature.  
 
 
3.11 Patch clamping of cultured primary microglia to record K+ currents 
 
The procedure was modified from Ilschner et al. (1996). Coverslips were placed on the 
stage of an inverted microscope (CKX4ISF, Olympus Ltd, Japan) and whole cell 
recordings were made using the patch-clamp technique in the whole cell voltage clamp 
configuration using an Axon Multiclamp 700B (Molecular Devices LLC, Sunnyvale, CA). 
Patch pipettes were pulled from borosilicate glass (GC150F-7.5, Harvard apparatus, U.K) 
with a vertical micropipette puller (PC10, Narshige, Japan). The resistance of pipettes was 
4-5 MΩ. The series resistance was compensated by 40-50% prior to recordings. Voltage 
steps with 35 mV increments were applied for 100 ms from a holding potential of -70 mV in 
both depolarising and hyperpolarising directions. Currents were digitized at 10 kHz and 
filtered at 2 kHz. C5a (20 nM) and PMX53 (100 nM) were applied via a continuous gravity 
perfusion system. All analysis was completed using GraphPad Prism 6.0 (GraphPad, La 
Jolla, CA).   
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3.12 Statistical analysis methods 
 
All statistical analyses were completed with GraphPad Prism 7.0 software (GraphPad, La 
Jolla, CA). All figures show Mean +/- standard error of the mean (SEM) unless otherwise 
stated. Statistical significance was considered when P <0.05. Statistical tests used include 
unpaired and paired student’s t-tests and one and two way ANOVAs with Bonferroni post-
hoc multiple comparisons post-tests. The statistical test used for analysis of each data set 
is stated in all figure legends and individual manuscripts.   
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4. Summary of papers during candidature and additional 
unpublished results  
 
4.1    Paper I – see Appendix 8.1 
 
“A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine 
epilepsy models” 
 
Melissa J Benson, Nicola K Thomas, Sahil Talwar, Mark P Hodson, Joseph W Lynch, 
Trent M Woodruff & Karin Borges  
 
Accepted for publication in Neurobiology of Disease – Impact Factor 5.56 
 
Aims: To determine to which extent C5ar1 absence or inhibition, using the receptor 
antagonist PMX53, is anticonvulsant in acute and chronic seizure/epilepsy mouse models. 
The absence or inhibition of C5ar1 during status epilepticus will also be assessed to 
determine subsequent changes to neuronal cell death in the hippocampal formation.  
 
Methods: Several acute seizure (6Hz; MEST; i.v. PTZ), chronic seizure (corneal kindling) 
and chronic status epilepticus (pilocarpine; i.h. kainate) models were used to test for 
anticonvulsant activity of 3 mg/kg s.c. PMX53. For the chronic i.h. kainate and pilocarpine 
epilepsy models seizures were measured using hippocampal EEG. For each model 
vehicle-treated mice were comparative controls. LC-MS/MS analysis was also utilised to 
determine the concentrations of PMX53 reaching the CNS after single s.c. administration. 
To assess for subsequent neuroprotective effects following anticonvulsant actions, C5ar1-
deficient and PMX53-treated mice were sacrificed 3 days after pilocarpine-induced SE and 
neuronal damage in key areas of the hippocampal formation was measured using Fluoro 
Jade B (FJB) as a histological marker of damage. Flow cytometry analysis of microglia in 
C5ar1-defcient mice acutely following pilocarpine-SE was also completed to determine if 
C5ar1-deficiency affects microglial expression of pro-inflammatory cytokines which may 
contribute to seizures.  
 
Results: PMX53 was found to be anticonvulsant against seizures in the 6Hz, corneal 
kindling, pilocarpine-SE and chronic i.h. kainate models after a single acute injection. 
Additionally, it was confirmed using an inert structural analogue (PMX203) and C5ar1-
deficient mice, that the anticonvulsant effect in the 6Hz model was C5ar1-dependent. 
Absence or inhibition of C5ar1 during pilocarpine-induced SE was also shown to cause 
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significant reductions in subsequent neuronal cell death in the CA1 and CA3 regions of the 
hippocampal formation 3 days post-SE.  LC-MS/MS analysis confirmed that PMX53 can 
reach the CNS in concentrations approximately equivalent to the IC50 after a single 
subcutaneous injection. Brain levels were >IC50 by 30 minutes post injection supporting 
our optimal timepoint of drug action in the seizure models. Additionally, assessment of 
microglial expression of pro-inflammatory cytokines acutely post pilocarpine-SE showed 
that C5ar1-deficient mice lack increased TNFα expression unlike their wildtype 
counterparts however other cytokines (including IL-1β) were not affected by C5ar1-
deficiency. Finally, PMX53 was shown to inhibit C5a-induced outward K+ currents on 
cultured primary microglia potentially providing evidence to support its acute 
anticonvulsant effects in the 6Hz test.  
 
Outcomes: The results from this study support the hypothesis that C5ar1 is involved in 
seizure initiation as well as neurodegeneration following an epileptic insult such as SE and 
may be mediating some effects through a TNFα-related mechanism. Additionally, PMX53 
is suggested to potentially mediate acute anticonvulsant effects through inhibition of K+ 
channel activation on microglia however a defined acute MOA for PMX53 is still unclear.  
C5ar1 is therefore suggested to be a novel anticonvulsant and antiepileptic drug binding 
target and merits further investigation, specifically related to the direct mechanism which 
modulates seizures on a cellular level.  
 
 
4.2   Paper II – see Appendix 8.2 
 
“Complex alterations in microglial M1/M2 markers during the development of epilepsy in 
two mouse models” 
 
Melissa Benson, Silvia Manzanero & Karin Borges 
 
Accepted for publication in Epilepsia – Impact Factor 4.6 
 
Aims: To characterise the changes in microglial M1 and M2 marker expression during key 
phases of epilepsy development in two chronic models.  
 
Methods: Pro-inflammatory M1 and anti-inflammatory/reparative M2 markers were used 
to determine the overall activation state of microglia during epileptogenesis in two mouse 
models; the pilocarpine-SE model and the intrahippocampal kainate model. Three key 
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disease timepoints were defined to assess microglial marker expression; acute (3 days 
post-SE), early chronic (21 days post-SE) and late chronic epileptic (5-12 months post-
SE). Flow cytometry techniques were used to measure expression of these markers on 
microglia following pilocarpine-SE. Quantitative real-time PCR was used to measure 
mRNA levels of selected M1 and M2 markers. EEG recordings of seizures were conducted 
to correlate late chronic phase seizure frequency with M1/M2 marker expression in each 
model.  
 
Results: In the pilocarpine model microglia were of mixed M1 and M2 phenotype early 
after SE, while in the kainate model only M1 markers were upregulated. Ablation of most 
M1/M2 marker expression was observed in both models at the early chronic timepoint 
which was continued in the pilocarpine model through to the late chronic epileptic phase. 
Resurgence of M1 and M2 marked expression was however seen in the i.h. kainate 
model, which shows much more frequent spontaneous seizures than the pilocarpine 
model at this stage.  
 
Outcomes: Differences in M1/M2 marker phenotype observed between each model are 
potentially due to dissimilarities in the initial SE insult and later chronic seizure frequency. 
The differences in initial acute phenotype may be due to the contribution of peripheral 
inflammation to the SE insult only found after pilocarpine injection. Meanwhile, the findings 
from the late chronic stage of the i.h. kainate model indicate that microglia may respond to 
frequent chronic seizures and then may contribute to seizure generation.  This work 
indicates that the role of microglia in mediating inflammatory CNS response after seizure 
insults and during epileptogenesis is complex and varies in different models.  
 
4.3    Paper III – see Appendix 8.3 
 
“C5ar1 suppresses IL-4 upregulation in infiltrating cells following pilocarpine-induced 
status epilepticus” 
 
Melissa Benson, Silvia Manzanero & Karin Borges 
 
Submitted and under review in Journal of Neuroinflammation – Impact Factor 3.6 
 
Aims: To determine if C5ar1 is upregulated acutely following pilocarpine-induced SE and 
if so, to which extent it plays a role in controlling inflammatory mediator expression on 
infiltrating immune cells. 
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Methods: Firstly, measurement of C5ar1 expression at both the mRNA and protein levels 
was carried out on 3 day post-pilocarpine wildtype mice using quantitative RT-PCR and 
flow cytometry. Measurement of both pro- (IL-1β, TNFα, IL-6, IL-12) and anti-inflammatory 
cytokines (IL-4, IL-10) and reparative enzymes (Arg1, Ym1) on immune cells in C5ar1-
deficient and wildtype mice was also conducted using flow cytometry techniques. Mice 
were sacrificed 3 days after pilocarpine-induced SE with naïve and NoSE animals being 
used for comparative controls for each C5ar1 genotype.  
 
Results: Endogenous expression of C5ar1 was higher on infiltrating cells compared to 
microglia in the brain regardless of SE. C5ar1 expression was increased 3 days post-
pilocarpine in SE wildtype mice, by 18 fold in cerebral cortex mRNA extracts, and also 
significantly on microglial cells, but not infiltrating immune cells. Several cytokines and 
repair enzymes were increased on both microglia and infiltrating immune cells following 
SE, including IL-1β, Ym1 and Arg2 however others were only elevated on selected 
populations. TNFα for instance was significantly increased in all cell populations following 
SE, except on microglia in C5ar1-deficient mice suggesting this receptor is causing 
attenuation of TNFα expression post-SE. Interestingly IL-4 was not elevated in any cell 
populations except C5ar1-deficient infiltrating cells, again suggesting C5ar1 is blocking IL-
4 expression increase following pilocarpine-SE.  
 
Outcomes: This study shows that C5ar1 is increased following pilocarpine-SE and 
absence of this receptor causes changes the inflammatory response of both microglia and 
infiltrating immune cell expression phenotypes. C5ar1-deficiency post-SE lead to a more 
anti-inflammatory state overall, confirming my first paper, indicating that this receptor is an 
important regulator of CNS inflammatory immune response in epilepsy and targeting this 
receptor may be beneficial for disease outcomes.  
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4.4  Lack of anticonvulsant effect of PMX53 in MEST and i.v. PTZ acute seizure models 
 
As part of the anticonvulsant screening process PMX53 was tested in two acute seizure 
models in addition to the 6Hz test. PMX53 (3 mg/kg s.c.) had no significant effects against 
either maximal electroshock or i.v. PTZ induced seizures when administered 30 minute 
prior to seizure indication. No changes to either CC50 or PTZ threshold, respectively, for 
each model were observed indicating a lack of anticonvulsant effect (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. PMX53 had a lack of anticonvulsant effect in both the i.v. pentylenetetrazol (PTZ) and Maximal 
Electroshock Threshold (MEST) acute seizure tests. When administered 30 minutes prior to seizure 
induction, PMX53 (3mg/kg s.c.) had no effect on increasing seizure threshold measures in either seizure 
test. PTZ dose and CC50 (critical current at which 50% of the mice seize) are used as measures of seizure 
threshold in the PTZ and MEST tests respectively. MEST test was repeated to ensure reproducibility of data. 
Both experiments results are shown. p>0.05 for both tests; one way ANOVA with Bonferroni multiple 
comparisons test was used for both tests. Mean ± SEM is shown. n=15 mice per group. Shaded green bars 
indicate PMX53-treated mice compared to vehicle (Control) treated open bars. 
 
4.5  Lack of anticonvulsant effect of alternative C5ar1 inhibitors in the 6Hz model 
 
Two alternative C5ar1 inhibitors were tested in the 6Hz model to determine if C5ar1 
inhibition in general was anticonvulsant, or if the effect seen was specific to PMX53 
(Figure 11A). W-54011 (Sumichika et al., 2002) and an analogue of PMX53 with 
comparative antagonist C5ar1 binding affinity, PMX205 (Finch et al., 1999, Woodruff et al., 
2005) were tested at the same timepoint and dose as PMX53 which was accepted within 
the literature to be mid-range for these compounds. Neither compound had any effect in 
the 6Hz model (Figure 11B, C). An agonist of C5ar1, EP54 (Hegde et al., 2008) 
administered at the same timepoint at 1 mg/kg (s.c.) dose also showed a lack of effect in 
the 6Hz test (Figure 11D). No LC-MS/MS analysis was conducted to determine if these 
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compounds in fact reached the CNS after subcutaneous injection (Woodruff T, personal 
communication). Lack of effect of W-54011 is not completely unexpected due to in vitro 
reports showing that it has limited binding affinity for murine C5ar1 (Sumichika et al., 
2002). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Two alternative antagonists (PMX205, W-54011) and one agonist (EP54) for the C5a receptor 
(C5ar1) display no effects on seizure threshold in the 6Hz test. (A) PMX53 (3mg/kg s.c.) significantly 
elevated the CC50 from control (vehicle-treated) when administered 30 minutes prior to 6Hz seizure 
induction indicating anticonvulsant efficacy (p<0.001). (B) W-54011 (3mg/kg s.c.) and (C) PMX205 (3mg/kg 
s.c.) did not significantly alter CC50 values from control mice levels when administered at the same timepoint 
indicating a lack of anticonvulsant effect (p>0.05). (D) C5ar agonist EP54 (1mg/kg s.c.) also failed to alter the 
CC50 from control (p>0.05). Unpaired student’s t-tests used for all data sets. n=15 per group. Mean ± 
Standard Deviation shown for each group.  
 
 
4.6       PMX53 does not inhibit mouse C5ar1 through β-arrestin mediated GPCR signalling  
 
To assess potential G-Protein coupled receptor (GPCR) signalling pathways inhibited by 
PMX53, a cell-based assay was used where mouse C5ar1 was expressed in a CHO-K1 
cell line with β-galactosidase as a reporter enzyme for β-arrestin recruitment (DiscoveRX, 
Freemont, CA).  This experiment was conducted to determine if PMX53 was mediating 
inhibition of C5ar1, a GPCR, through a β-arrestin mediated signalling mechanism. This 
pilot study was to be part of a larger project investigating several GPCR signalling 
mechanisms to elucidate which were actively involved in PMX53’s mechanism of action. 
Further studies to investigate its signalling pathways in mice are planned however were 
not able to be completed during this thesis.  
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Mouse recombinant C5a stimulated high enzyme activity indicating β-arrestin mediated 
signalling of C5ar1. The EC50 of mC5a was found to be 1.4 nM indicating a highly potent 
signalling response (Figure 12A).  
 
For the antagonist study with PMX53, the EC80 of mC5a (3 nM) was used. PMX53 was 
applied at a range of concentrations (1 nM – 30 µM) however no inhibition of β-
galactosidase activity was observed indicating PMX53 does not inhibit C5a-induced β-
arrestin recruitment of C5ar1 in mice (Figure 12B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. PMX53 does not inhibit mouse C5a-induced β-arrestin mediated signalling of C5ar1 in vitro. (A) 
DiscoveRX enzymatic assay of mouse C5ar1 expressed on CHO-K1 cells. Recombinant mouse C5a 
induced β-arrestin recruitment (reflected by Beta-galactosidase activity) in a dose-response manner. EC50 for 
mC5a was 1.4 nM. (B) PMX53 did not inhibit mC5a-stimulated (3 nM; EC80) β-arrestin recruitment of C5ar1 
at any concentration (1 nM – 30 µM). Mean ± SEM shown, n=2 per data point.  
 
4.7     PMX53 does not cause acute neurotoxicity (Rotarod test) 
 
Neither PMX53 nor PMX203 showed significant differences in mean fall latency (sec) on 
the Rotarod test compared to vehicle treated mice. This shows there is a lack of motor 
deficit or impairment in PMX-treated animals inferring a lack of acute neurotoxicity of the 
compounds in mice at this dose (Figure 13). 
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Figure 13. PMX53 does not cause motor impairment in 
the Rotarod test. PMX53 and inert structural analogue 
PMX203 (both 3mg/kg s.c.) show no significant 
decreases in fall latency compared to vehicle in the 
rotarod test, indicating an absence of motor impairment 
30 min post drug administration. n=3 trials per mouse 
with 14 mice per group. Mean +/- SEM shown; One-
way ANOVA with Bonferroni multiple comparisons test; 
(p= 0.21).  
 
 
4.8    Expression patterns of C5ar1 and C3 mRNA throughout epilepsy disease models   
 
To determine whether consistent complement presence, particularly relating to C5a and its 
receptor C5ar1, occurs during epilepsy disease model progression measurement of 
hippocampal mRNA transcripts of C5ar1 and the precursor to C5a, C3, were measured. 
C5a itself was unable to be measured reliably using QPCR techniques therefore we can 
only speculate about its presence.  
 
Increased mRNA expression of C5ar1 and C3 was observed at various timepoints in both 
the pilocarpine and i.h. kainate models. Specifically, C5ar1 was significantly elevated in SE 
mice at the acute timepoint (3 days post-SE) in both models (Figure 14A, C) however only 
pilocarpine-SE lead to a persistent increase in the early chronic stage (21 days post-SE). 
C5ar1 mRNA levels were not changed from control by the late chronic stage, however in 
the kainate model it is clear that age drives increased expression of C5ar1 in the 
hippocampus, as NoSE control levels are equivalent to acute levels in SE mice showing a 
large induction of this gene at the late chronic stage independent of SE (>5 months post-
SE). C3 mRNA transcripts were significantly increased consistently across all 3 timepoints 
in i.h. kainate SE animals however were only elevated acutely post pilocarpine-SE (Figure 
14 B, D).  This may indicate a greater presence of C5a in the i.h. kainate model throughout 
disease progression. It should be noted that acute samples in the pilocarpine model were 
from forebrain and not just hippocampus.  
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Figure 14. RNA expression levels of C5ar1 and complement component 3 (C3) in forebrain and 
hippocampus from pilocarpine- and i.h. kainate-treated mice at three timepoints associated with disease 
model progression; acute post-SE (3 days), early chronic (21 days) and late chronic (≥5 months). (A) In 
pilocarpine-SE vs. NoSE mice mRNA levels of C5ar1 were increased in the forebrain acutely (****P<0.0001, 
n=9-11) and in hippocampus at the early chronic timepoint (**P=0.0051, n=13-20) and not at the late chronic 
stage (P>0.05, n=5-7). (B) C3 mRNA transcripts were increased in forebrain of SE mice compared to 
controls acutely (**P=0.0046, n=5-9), however not in hippocampus at either early (P=0.34, n=8-12) or late 
chronic (P=0.128, n=6-7) timepoints. Unpaired, independent student’s t-tests used for analysis of all 
pilocarpine data sets due to differences in brain sampling (forebrain vs. hippocampus). (C) In i.h. kainate 
treated vs. vehicle treated mice mRNA levels of C5ar1 were increased in hippocampus at acute (*P=0.0253, 
n=5-8) but not early chronic (P>0.05, n=6-14) or late chronic timepoints (P >0.05, n=5-6). (D) C3 mRNA 
levels were increased at acute (***P<0.001, n=5-9), early chronic (*P<0.044, n=6-14) and late chronic 
timepoints (****P<0.0001, n=6-8). Expression levels shown as relative to housekeeping genes, TBP and 
HMBS. 2-way ANOVA with Bonferroni multiple comparisons test used.  Data expressed as Mean ± SEM. 
TBP; Tata box protein. HMBS; hydroxymethylbilane synthase.  
 
 
 
 
0 .0
0 .2
0 .4
0 .6
0 .8
C
3
m
R
N
A
* *
  A c u te
p o s t-S E
  E a rly
c h ro n ic
  L a te
c h ro n ic
N o S E
S E
B 
0 .0 0 0
0 .0 0 2
0 .0 0 4
0 .0 4
0 .0 8
0 .4
0 .5
0 .6
0 .7
C
5
a
r
1
 m
R
N
A
* * * *
  A c u te
p o s t-S E
  E a rly
c h ro n ic
  L a te
c h ro n ic
N o S E
S E
* *
C
5
a
r
1
 m
R
N
A
0 .0 0 0 0
0 .0 0 0 2
0 .0 0 0 4
0 .0 0 0 6
0 .0 0 0 8
0 .0 0 1 0
*
  A c u te
p o s t-S E
  E a rly
c h ro n ic
  L a te
c h ro n ic
A 
C D 
C
3
 m
R
N
A
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5 V e h ic le
K a in a te
* * * *
* * * *
  A c u te
p o s t-S E
  E a rly
c h ro n ic
  L a te
c h ro n ic
51 
 
5. Discussion  
 
5.1  C5ar1 as a novel target for antiepileptic drug development 
 
Collectively the results found in this thesis reveal that C5ar1 may be a novel target for AED 
drug development, particularly for refractory patients given its efficacy in several 
pharmacoresistant seizure models (6Hz, i.h. kainate). The reduction in neuronal cell loss 
post-SE with C5ar1 absence and inhibition also suggest this target may have putative anti-
epileptogenic potential if chronically inhibited.  
 
The major question that arises from these studies however is related to the anticonvulsant 
mechanism of action of PMX53. It is proposed that several different mechanisms may be 
at play to explain PMX53’s anticonvulsant efficacy against both acute and chronic 
seizures. One of which is through C5ar1 signalling leading to a less inflammatory state 
therefore reducing chronic seizure thresholds (i.e. i.h. kainate model). However the 
mechanisms responsible for acutely reducing seizure thresholds in naïve mice (6Hz) are 
unclear and require future studies. 
 
5.1.1 Anticonvulsant profile of PMX3 
 
Given the dual efficacy of PMX53 as an anticonvulsant against both acute (6Hz and 
pilocarpine models) and chronic seizures (i.h. kainate, kindled mice), it is suggested that 
there may be several mechanisms of action by which PMX53 can exert its anticonvulsant 
effects.  
 
Primarily, inhibition of inflammation, i.e. pro-inflammatory cytokine induction, would explain 
actions against both chronic seizures (i.h. kainate and potentially kindled mice) and acute 
pilocarpine-induced neuronal death (refer 5.1.3), however acute anticonvulsant actions in 
healthy mice are difficult to explain assuming lack of inflammation in the naive brain (refer 
5.1.2).  
 
At present it is difficult to deduce a definitive mechanism of action from the anticonvulsant 
profile of a drug alone, due to the fact that AEDs with different mechanisms of action are 
effective in specific models. This indicates that each of these seizure models does not 
selectively suggest a single anticonvulsant mechanism of action, rather that numerous 
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anti-epileptic approaches can block seizures induced by a single excitatory stimulus. For 
example, in the PTZ model efficacy of AEDs causing GABAergic enhancement, calcium 
channel blockade and sodium channel blockade are all reported highlighting that various 
pathways contribute to PTZ-induced seizures.   
 
The anticonvulsant profile of PMX53 is similar to that of levetiracetam (Klitgaard et al., 
1998), which binds to the synaptic protein SV2a, but in addition is postulated to act via 
other mechanisms that are still undefined (Madeja et al., 2003, Surges et al., 2008). Lack 
of effect of PMX53 in the PTZ and MEST models suggest mechanisms of action 
independent from GABAA receptors and sodium channels. This is proposed as the AEDs 
effective in these models all modulate either one of these pathways (Table 4).  
 
The i.h. kainate model is resistant to major AEDs, which all act on voltage-gated sodium 
channels (Wilcox et al., 2013), including sodium valproate, phenytoin, lamotrigine and 
carbamazepine. Efficacy of PMX53 against electrographic seizures in this model indicates 
PMX53 is a potential anticonvulsant treatment for refractory seizure types.  
 
Efficacy or lack thereof of PMX53 in these particular seizure models advocates that C5ar1 
inhibition with PMX53 may be effective against refractory seizures, independent from 
sodium channel inactivation and GABAA receptor modulation. However, this profile does 
not allow for elucidation of the exact anticonvulsant mechanism of action but does suggest 
it is different from existing AEDs.    
 
Lack of efficacy in some seizure models and not in others is common with AEDs and is 
thought to be a predictor of clinical efficacy also. Based on the effects with PMX53 in the 
chosen seizure models it is proposed that PMX53 is effective for treatment of complex 
partial seizure types, which are commonly experienced in refractory cases (Pisani et al., 
1999). The known safety and tolerability of PMX53 in humans (refer 1.2.4) is an important 
consideration for future development as an epileptic therapy, suggesting that a clinical 
future for a C5ar1 antagonist as an anticonvulsant treatment is promising.  
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Table 4. Relationship between rodent seizure tests and clinical application of current antiepileptic drugs 
(AEDs) including their mechanisms of action. Compiled from (Leite et al., 2002, Klitgaard et al., 2003, Bialer 
and White, 2010, Löscher, 2011, Wilcox et al., 2013). 
 
  RODENT MODEL   
AED 
6Hz MES(T) PTZ Kindling 
 
Pilo 
SE/cell 
death 
i.h. 
Kainate 
AED 
mechanism of action 
Clinical Application 
 of AED 
Phenobarbital + + + + +/+ + 
GABA enhancer 
Ca2+ channel blocker 
3rd line (all sz) 
Status Epilepticus 
Valproate + + + - +/+ - 
Na+ channel blocker 
GABA enhancer  
Partial, generalized & 
absence sz 
Carbamazepine + + - + -/+ - 
Promotes Na+ channel 
inactivation 
Partial & generalized sz 
Phenytoin - + - + -/+ - 
Enhanced slow-activation 
of voltage-gated Na+ 
channels 
Partial & generalized sz 
Clonazepam + - + + +/+ ? GABA enhancer 
Absence & generalized sz 
Status Epilepticus 
Ethosuximide + - + - -/? ? 
T-type Ca2+ channel 
blocker 
Absence sz 
Levetiracetam + - - + +/+ + 
SV2A ligand Focal, generalized sz 
PMX53 + - - + +/+ + 
C5ar1 antagonist 
Microglial K+ channel 
inhibitor 
Models indicate action 
against complex partial sz 
 
 
5.1.2 PMX53 is anticonvulsant through a C5ar1-dependent mechanism 
 
Anticonvulsant efficacy of PMX53 in both acute and chronic seizure models raises 
questions regarding its mechanism of anticonvulsant action as discussed previously. 
Efficacy against chronic seizures in the i.h. kainate model, kindled mice and pilocarpine-
SE, may be explained by an anti-inflammatory hypothesis, whilst acute anticonvulsant 
effects in the 6Hz model may be due to modulation of ion channel activity mediated by 
C5ar1 binding. 
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In the chronic epileptic stage, when spontaneous seizures are frequent in i.h. kainate-SE 
mice, I have confirmed that inflammation is present in the hippocampus (Paper II). It is 
therefore proposed that PMX53 reduces seizures via modulation of inflammatory cytokine 
expression, potentially through the same mechanisms seen acutely following pilocarpine in 
C5ar1-deficient brain immune cells (Paper III). Specifically, C5ar1-driven expression of 
pro-inflammatory TNFα is attenuated (Paper I) and anti-inflammatory IL-4 production is 
induced (Paper III) promoting a less inflamed CNS state overall, which is known to 
increase seizure thresholds (Vezzani et al., 2009, Riazi et al., 2010, Ravizza et al., 2011). 
Neuromodulatory actions of cytokines have been reported also (Schneider et al., 1998, 
Vitkovic et al., 2000), including TNFα and IL-1β, suggesting that transcriptional inhibition of 
these proteins by PMX53 may modulate changes to neuronal excitability and increase 
seizure thresholds alternatively in this manner. Both of these proposed mechanisms 
require fast transcriptional changes immediately following PMX53 administration. Based 
on the knowledge that pilocarpine can induce significant IL-1β production within ~30 
minutes after administration, it is possible that PMX53 can alter transcription of 
inflammatory cytokines within a short time frame (Marchi et al., 2007). Increased presence 
of inflammatory mediators has also been reported in kindled rodents (Plata-Salamán et al., 
2000) however fold changes in these mediators are significantly lower than those reported 
in Paper II in chronic i.h. kainate animals suggesting that an additional and/or alternative  
mechanism, not directly related to decreased pro-inflammatory cytokine presence, may 
play a role in PMX53’s anticonvulsant mechanism of action. 
 
The mechanism of anticonvulsant efficacy of PMX53 against acute seizures is still unclear. 
The inert structural analogue PMX203 lacked efficacy in the 6Hz test suggesting C5ar1-
dependency of the acute effect, which was also confirmed in the 6Hz C5ar1-deficient 
experiment, as only C5ar1-wildtype mice displayed anticonvulsant actions of PMX53. 
Conversely, the seizure threshold of non-treated C5ar1-deficient mice was equivalent to 
wildtype animals in the 6Hz test suggesting C5ar1-absence alone is not anticonvulsant 
toward acute seizures. This potentially indicates PMX53 is driving anticonvulsant effects 
through a C5ar1-dependent pathway in adjuvant to a pathway unrelated to C5ar1 but 
specific to PMX53. Lack of effect of two alternative C5ar1 antagonists (PMX205 and W-
54011) support the suggestion that inhibition of C5ar1 is not solely mediating the acute 
anticonvulsant effect, but rather it is specific to PMX53 itself which may be driving changes 
to seizure thresholds through non-C5ar1 mediated signalling possibly related to structural 
homology of other effector ligands. Finally C5ar1 pharmacological agonism using EP54 
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also failed to alter seizure thresholds in the 6Hz test further indicating that C5ar1 agonism 
is not always proconvulsant. The known affinity of PMX53 for alternate receptors 
(bombesin and tachykinin, T Woodruff personal communication) in human cells suggests 
these may be potential off-target binding sites however the concentrations of PMX53 
reaching the CNS are <10 fold lower than the IC50 for these receptors, therefore this is 
also unlikely.  
 
Caveats of these tests are present however and do not rule out C5ar1-mediated efficacy. 
No LC-MS/MS was completed for any alternative C5ar1 antagonists or agonists therefore 
it is not known whether they reached the brain prior to seizure induction. PMX205 is also 
more lipophilic therefore has reduced CNS entry potential (refer 1.2.4). PMX205 after 
systemic dosing in rats resulted in lower plasma concentrations compared to PMX53 after 
the same dose was administered supporting the statement that reduced comparative CNS 
levels are likely (Woodruff et al., 2005). Also, full dose-response and timepoint studies 
were not performed for W-54011 or EP54, therefore lack of effect may be due to non-
optimal administration. The non-specific nature of EP54 (also binds C3ar) casts doubt on 
the usefulness of this compound to test effects of C5ar1 on seizure thresholds. Also, lack 
of effect of W-54011 is not completely unexpected due to its low binding affinity for rodent 
C5ar1 isotypes (Sumichika et al., 2002). Finally, as with all knockout animals, 
developmental compensations may occur in C5ar1-deficient mice that explain the lack of 
altered seizure thresholds in the 6Hz test, particularly as C5a/C5ar1 is known to be 
involved in early brain development (Stephan et al., 2012). In summary, administration of 
recombinant C5a would be most effective to determine this. According to Dr. Milan Basta 
(personal communication) delivery to C5a to the brain increased the susceptibility to 
seizures. 
 
Additionally it is important to note that PMX205 nor other C5ar-related compounds were 
assessed in other seizure tests, only the 6Hz model. Therefore it is feasible that PMX205 
in particular may show effects similar to that of PMX53 in terms of reducing subsequent 
SE neuronal cell death and cytokine release through C5ar1-mediated mechanisms.  
 
To determine whether a C5ar1-mediated acute mechanism of action for PMX53 is 
conceivable C5a-induced K+ outward currents on microglia were investigated (Ilschner et 
al., 1996). As presented in Paper I, PMX53 inhibited K+ outflow induced by C5a 
application in cultured microglial cells. Direct modulation of channel opening is a fast 
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process therefore it is plausible that immediate release of C5a stores at the onset of 6Hz 
stimulation may drive K+ release from microglia which could in turn promote excitation of 
nearby neurons potentiating a seizure induced by the electroshock. Prior inhibition of these 
channels by PMX53 may reduce the likelihood of seizure potentiation and therefore 
increase the seizure thresholds of PMX53-treated mice. This mechanism is conceivably 
not robust enough to explain large changes in seizure threshold however, therefore other 
unknown mechanisms may contribute to this acute effect.  
 
Efficacy of PMX53 in the corneal kindled, i.h. kainate and pilocarpine-treated mice against 
acute seizures suggests a combination of both suggested mechanisms may be at play.  
 
5.1.3 C5ar1 antagonism or absence during SE insult leads to subsequent reduction 
in neuronal cell death in the hippocampus 
 
The mechanism by which PMX53 or C5ar1 absence can reduce neuronal loss in the 
hippocampus is suggested to be through an inflammatory mechanism. It was previously 
reported that inhibiting peripheral inflammation prior to SE using an IL-1 receptor 
antagonist reduced SE severity (Marchi et al., 2009), which was confirmed in my work 
when pilocarpine-SE seizure power was reduced by ~70% in PMX53-treated mice (Paper 
I). It is proposed that C5ar1 inhibition in the periphery prior to/during SE onset analogously 
reduces inflammation and hence SE severity causing a reduction in subsequent 
hippocampal neuron damage (Paper I).  
 
Protective effects of C5ar1 inhibition (including via use of PMX53) have been reported for 
models of several other neurodegenerative diseases including Alzheimer’s (Fonseca et al., 
2009) and Huntington’s disease (Woodruff et al., 2006), amyotrophic lateral sclerosis 
(Woodruff et al., 2008) and stroke  (Kim et al., 2008), several of which share common 
neurodegenerative pathways with epilepsy. 
 
Contradictory to previous findings that C5ar1 agonism is neuroprotective against 
excitotoxic injury (Osaka et al., 1999b), PMX53-mediated inhibition of C5ar1, as well as 
receptor absence (C5ar1-/-) showed >40% improvement in neuron loss in the hippocampal 
CA1 and CA3 regions (Paper I). Potential reasons to explain the opposing findings of 
Osaka et al. (1999b) may be related to the nature of the excitotoxic insult. Pilocarpine 
mediates excitotoxicity primarily through muscarinic Ach receptors, in comparison to kainic 
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acid which is AMPA kainate and glutamate receptor mediated. Also, in the Osaka study 
SE was not induced by kainate infusion, only a lesion was created. The absence of SE 
induction suggests that damage to the hippocampus was milder in their study compared to 
pilocarpine-induced SE and therefore comparable neuronal death was not achieved.  One 
flaw of the Osaka study was the choice of C5a used as the in vivo C5ar1 agonist. Human 
recombinant C5a was used in place of the mouse protein therefore leading to questions 
related to specificity of C5a binding. Also it was noted that the final CNS concentration of 
C5a after infusion was 4.8 µM which is >100 fold of measured C5a levels after an 
inflammatory insult (Krug et al., 2001), suggesting that physiological relevance is 
diminished and non-specific binding is plausible at this high concentration.  
 
This thesis did not assess the potential neuroprotective effects of PMX53 in the i.h. kainate 
model, which would be a direct comparative experiment to the Pasinetti group (Osaka et 
al., 1999b). This is a potential future direction of this work which would confirm the actions 
of C5ar1 in regulating neuronal damage following pilocarpine-induced SE. 
 
Further studies to determine if acute neuroprotection via C5ar1 inhibition/absence leads to 
changes in model outcomes i.e. reduced seizure occurrence or suppressed chronic 
inflammatory response, are needed in order to show that early C5ar1 inhibition can 
improve disease outcomes long term. This is highly relevant from a clinical standpoint and 
may provide evidence of anti-epileptogenic or disease-modifying effects of blocking C5ar1 
during epileptogenic insults.  
 
5.1.4 C5ar1 inhibition as a therapeutic target for drug development 
 
The development of novel therapeutics to target and inhibit C5ar1, such as PMX53, is 
currently a niche area of pharmaceutical drug development. The number of commercially 
available selective C5ar1 antagonists is limited and PMX53 is one of the most widely 
investigated pre-clinically within neurological disease models. There are obvious 
limitations to PMX53 in terms of it being developed for anticonvulsant purposes. The 
pharmacokinetics of the compound are undesirable for chronic treatment paradigms as it 
is rapidly absorbed by the intestinal mucosa and metabolised within <4 hours. A more 
metabolically stable formulation is needed, because consistent thresholds of drug 
concentration are needed within the CNS to repress seizure onset.  
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Advantages of targeting C5ar1 specifically within the complement cascade as opposed to 
others further up or downstream warrants discussion. When targeting an integral part of 
the body’s innate immune defence system it is imperative to ensure that overall the system 
is still able to function effectively and efficiently should there be an infection, injury or other 
traumatic event.  
 
There are several key advantages to selectively blocking activity at the C5ar1 level as 
opposed to other targets in the complement cascade.  
 
Firstly, blocking the activity of C5a (a terminal complement fragment) through inhibition of 
C5ar1 as opposed to the endogenous ligand (i.e. C5a antibody) prevents added inhibition 
of the alternative C5a receptor, C5ar2. The signalling mechanisms of this receptor are still 
not well defined however it has been shown to participate in cross-talk with C5ar1 in 
relation to inflammatory responses (Li et al., 2013) as well as have putative links to 
Alzheimer’s pathology (Fonseca et al., 2013). Based on the current limited understanding 
of C5ar2 it is preferable to avoid non-selective inhibition until more about its signalling 
mechanisms are understood and characterised.  
 
Secondly, modulation of upstream complement factor C5, either by direct inhibition (anti-
C5 antibody) or preventing its cleavage to C5a/C5b fragments will affect multiple pathways 
in the complement cascade. In addition to inhibiting both C5ar1 and C5ar2 activation, the 
formation of MAC (C5b-C9) will also be prevented which is a critical pathway required for 
clearance of pathogenic cells by causing formation of lysis pores in their membranes.  
 
Inhibition of upstream targets in the complement cascade have been studied primarily in 
relation to C3 and its cleavage product, C3a, an alternative anaphylatoxin. In terms of 
CNS-based studies C3a receptor antagonism has been shown to attenuate neurological 
damage following intracerebral haemorrhage (Rynkowski et al., 2009) and ischemic stroke 
(Ducruet et al., 2012) in mouse models showing that C3ar is a viable antagonist target to 
elicit anti-inflammatory responses. Similar to selective inhibition of C5ar1, selective 
inhibition of C3ar as opposed to the C3a ligand does not significantly inhibit normal 
function of the complement cascade nor affect further downstream pathways such as C5 
cleavage and MAC formation.  
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Currently there are no studies to show that selective inhibition of more upstream targets, 
such as C3 or C1q can affect CNS-related injuries or excitability therefore it is difficult to 
comment if this is an effective strategy. However inhibition of further upstream targets 
does lead to perturbation of a greater number of downstream signalling pathways 
increasing the risk of complement cascade dysfunction.  
 
My hypothesis is that by inhibiting a downstream terminal fragment (C5a) specifically 
through one of its receptors, C5ar1, the remainder of the complement system is able to 
function normally which is required for homeostatic control of innate immune responses to 
infection and damage. Additionally, C5a is known to be the most potent pro-inflammatory 
anaphylatoxin in the complement system therefore it is a logical target for pharmacological 
inhibition if maximal changes to inflammation are to be achieved.  
 
In terms of current molecule development there is a promising alternative compound, also 
with a peptide structure, shown to specifically inhibit C5ar1, currently being developed by 
Jerini Opthalamic (Ricklin and Lambris, 2007). JPE1375 has been reported to have 
greater efficacy than PMX53 in a peripheral immune murine disease model of reverse 
passive Arthus reaction (RPAR) (Schnatbaum et al., 2006). The ability of JPE1375 to 
inhibit neutrophil influx was >8 fold compared to PMX53 due to its 17 fold increased affinity 
for murine C5ar1, respective to PMX53. The affinity for human C5ar1 binding however was 
similar between the two compounds, therefore suggesting that for clinical translation 
PMX53 is just as relevant (especially given that it has passed Phase I clinical trials). 
However for murine based in vivo studies JPE1375 would be an excellent candidate to 
further assess the role played by C5ar1. One superior characteristic of JPE1375 is the 
improved intestinal stability of the compound which could indicate greater likelihood of 
clinical efficacy also.  
 
Currently there are no other specific small molecule antagonists of C5ar1 present in the 
literature. However there are several other approaches inhibiting complement activation in 
clinical trials, although none for neurological diseases (Sarma and Ward, 2012). These 
include antibody drugs, however administration of this type of therapeutic carries its own 
issues for CNS conditions as antibodies are unlikely to cross the BBB, therefore local 
administration would be required.  
 
60 
 
Another strategy is targeting of the upstream complement factor, C5, by using antibodies 
or small nucelotide aptamer RNA sequences which bind C5, preventing cleavage of the 
protein to C5a and C5b therefore also inhibiting MAC formation. As this approach involves 
several mechanisms the likelihood of increased off-target interactions may be greater as 
previously discussed (Reviewed by Sarma and Ward, 2012). However, currently 
Eculizumab, an anti-C5 antibody which inhibits the cleavage of C5 to terminal complement 
fragments C5a and C5b, is approved for a rare immunological condition, paroxysmal 
nocturnal hemoglobinuria (PNH) (Hillmen et al., 2006). The major adverse effect related to 
Eculizumab treatment is increased risk of infection from encapsulated organisms, 
specifically meningococcal bacteria, therefore vaccination is a pre-requisite to treatment.  
 
The major consideration for development of any complement-targeted therapeutics, 
including C5ar1 antagonists, is to ensure that innate immune defences are not 
compromised to the point that the body is unable to detect and respond appropriately to 
detrimental pathogenic insults. However, given the data from clinical trials, this does not 
appear to be the case, at least for selective C5ar1 antagonists.  
 
 
5.2  Microglia as a key regulator of inflammatory response in epilepsy disease 
development 
 
Microglia are the key immune-regulatory cells of the CNS and therefore are highly involved 
in controlling and triggering inflammatory response to injury or brain insult, such as a 
seizure. The presence of activated microglia has previously been reported in epileptic 
brain tissue (refer 1.3.1) however the role played by microglia during the epileptogenesis 
process is unknown. In this thesis I have shown that microglial activation, based on 
expression studies of M1 and M2 markers only, varies during epilepsy disease model 
progression and that C5ar1 plays a role in regulating microglial response to SE, including 
altering expression of cytokines known to affect seizure thresholds. 
 
5.2.1 Regulation of C5ar1 expression on microglia 
 
It was shown that C5ar1 is upregulated at both the mRNA and protein levels following 
either systemic pilocarpine or i.h. kainate excitotoxicity at a variety of timepoints extending 
to periods of chronic seizure (>5 months post-SE, Figure 14).  
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Increased expression of C5ar1 on microglial cells following an excitotoxic insult has been 
reported previously (Nomaru et al., 2014), however this study only showed changes in 
expression 24 hours post systemic kainate injection, which does not result in 
epileptogenesis or subsequent development of chronic seizures. This study may therefore 
be considered irrelevant to epileptogenic events involving C5ar1. Additionally, the 
timepoint assessed was extremely acute (24 hrs) and it is already known that upregulation 
of a large number of inflammatory systems and mediators peak at this timepoint (Acarin et 
al., 2000, De Simoni et al., 2000, Vezzani et al., 2002). This suggests complement 
upregulation may be present acutely post-SE but does not provide evidence for its 
continual presence throughout epilepsy progression. For this reason multiple later 
timepoints to observe C5ar1 expression correlating with neuronal death (3 days post-SE), 
reorganisation of the hippocampus during epileptogenesis (21 days post-SE) and the 
appearance of spontaneous seizures (>5 months post-SE) were chosen in this thesis to 
give a better understanding of the presence of C5ar1 in epilepsy models and its role in 
regulating excitoxicity.  
 
For example, the late chronic timepoint data presented in this thesis (Figure 14A, C) 
showed that C5ar1 mRNA levels were non-significantly changed between SE and NoSE 
animals in both pilocarpine and i.h. kainate models. A strong upregulation of C5ar1 with 
age was seen in the i.h. kainate model in the hippocampus that is potentially independent 
of seizures or may be masked by age. This finding highlights that C5ar1 is a more 
abundant in aged brain/hippocampus which could affect outcomes of C5ar1 inhibition in a 
variety of ways. Firstly, greater expression of C5ar1 could mean inhibition of the receptor 
has more potent effects than in younger brain, conversely it may also suggest that tight 
regulatory control of this receptor is altered with age and therefore efficacy of inhibiting the 
receptor may be altered.  
 
Complement factor 3 (C3) an upstream component from C5a, was elevated significantly at 
the majority of timepoints analysed. Specifically, increased C3 mRNA levels at the acute 
and late chronic timepoints were observed in both models, however C3 elevations were 
only observed in the early chronic stage in i.h. kainate-SE mice (Figure 14B, D). This 
constant elevation in C3 mRNA levels potentially implies that increased C5a is also 
present, suggesting greater likelihood of C5ar1 activation. 
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Another of the key considerations related to microglial specific expression of C5ar1 is its 
effects on ion channels, specifically K+ channels (Ilschner et al., 1996). As I have reported 
in this thesis (refer Paper I; 5.1.2), PMX53 is able to inhibit C5a-induced outward K+ 
currents on microglial cells which may otherwise stimulate neuronal excitability leading to 
decreases in seizure threshold. The increased expression of C5ar1 on microglia may 
directly augment this effect also, including the magnitude with which it contributes to 
altering seizure thresholds.   
 
Moreover, absence of C5ar1 expression on microglia and other immune infiltrating cells 
was shown to change cytokine expression patterns acutely post-pilocarpine SE (Paper I & 
III). C5ar1-deficient microglia lacked elevations in pro-inflammatory TNFα expression 
following SE whilst C5ar1-deficient infiltrating immune cells showed upregulated anti-
inflammatory IL-4 expression. Coupling of these changes demonstrates that C5ar1 
absence leads to a less inflamed immune cell phenotype overall following pilocarpine-SE 
and is therefore putatively beneficial to epilepsy outcomes. This may include those related 
to neurodegeneration as C5ar1 inhibition and absence were shown to be protective in the 
hippocampus following SE (Paper I). It is possible this neuroprotective effect is triggered 
by changes in immune cell cytokine expression such as reduced TNFα presence, which is 
known to be cause apoptosis of neurons when present (Talley et al., 1995). Similarly, IL-4 
has been shown to be protective of neuronal cells in a model of amyotrophic lateral 
sclerosis by reducing microglia-mediated neurotoxicity (Zhao et al., 2006) further 
supporting this theory.  
 
Expression of C5ar1 on other cells including astrocytes and neurons has previously been 
reported however is debated (Gasque et al., 1997, Osaka et al., 1999a, O’Barr et al., 
2001). Given the contribution of microglia as key regulators of inflammation in the brain it 
seems necessary to investigate their relationship of C5ar1 expression with functional 
changes to seizure thresholds and epileptogenesis, rather than placing the focus solely on 
neurons simply because they have direct excitotoxic mechanisms.  
 
5.2.2 M1/M2 phenotype shifts throughout disease development stages 
 
My experiments assessing the overall activation state of microglia throughout epilepsy 
disease model stages, by characterising the expression of M1- (IL-1β, TNFα, IL-6, IL-12, 
CD16, CD86) and M2- (IL-10, IL-4, Arg1, Ym1, FIZZ-1, CD206) associated markers, have 
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unveiled some interesting findings relating to epileptogenesis and the potential contribution 
of microglia to this process. Another key finding was that microglial response differs 
between epilepsy disease models, even in the chronic phase, which was not evident to the 
field previously.  
 
As reported in Paper II, shifts in expression of microglial markers (M1 and M2) were 
observed throughout the disease stages of the pilocarpine and i.h. kainate mouse models. 
Elevations of M1/M2 markers acutely post-SE (3 days) were partially confirmed by 
previous reported findings (de Bock et al., 1996, De Simoni et al., 2000, Ravizza, 2008). 
However, the lack of elevated expression in the ‘epileptogenic’ period (21 days post-SE) 
was formerly unknown except for IL-1β which similar to my findings was previously 
reported to be absent 21 days post i.h. kainate-SE (Pernot et al., 2011). Attenuation of 
expression in this period suggests that upregulation of M1 and M2 associated cytokines 
and enzymes are not meaningfully involved in the epileptogenic process in these mouse 
models. More specifically, it was shown that expression of inflammatory cytokines e.g. IL-
1β in this period in the pilocarpine model are not mediated by microglia as confirmed by 
flow cytometry experiments (Paper II).  
 
Others have shown selected M1/M2 markers to be increased between the acute (3 day) 
and early chronic (21 day) timepoints however, most commonly 7 days post-SE. TNFα 
was shown to be elevated in rat hippocampus at this timepoint following kainic acid-
induced SE (de Bock et al., 1996) and electrically-induced SE (Gorter et al., 2006). IL-1β 
and its receptor IL-1Ra were also shown to be elevated 7 days post-SE in electrically-
induced- SE rats (De Simoni et al., 2000, Vezzani et al., 2002, Gorter et al., 2006), 
pilocarpine-SE rats (Ravizza, 2008) and i.h. kainate mice (Pernot et al., 2011). These 
results conclude that the timepoints at which elevated expression of M1 and M2 markers 
ablate are varied and may be between the 7-21 day period following SE , i.e. for IL-1β and 
TNFα.  
 
Given that inflammation has been suggested as a contributor to epileptogenesis (Vezzani 
et al., 2009, Pitkänen and Lukasiuk, 2011) these results are confounding, however clearly 
show that relative to the acute post-SE (3 days) and late chronic periods (>5 months), 
minimal M1/M2 microglial expression is present at the early chronic stage (21 days post-
SE). For this reason it is suggested that targeting microglia to prevent expression of pro-
inflammatory (M1) mediators is not critical in the early chronic phase (21 days) and that 
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targeted treatment would be more efficacious once spontaneous recurrent seizures 
develop.  Suppression of M1-associated cytokines acutely post-SE may not lead to 
improved disease outcomes, unlike those proposed in the late chronic phase, due to the 
beneficial role of inflammation in removal of debris and invading pathogens. The presence 
of both M1 and M2 mediators acutely post-SE suggests a balance of microglial activation 
is present, which may be detrimentally affected should anti-inflammatory interventions be 
employed at this timepoint.  
 
In addition to this finding, significant differences in M1/M2 marker expression were seen 
between the pilocarpine and i.h. kainate epilepsy mouse models at each of the disease 
timepoints (Paper II). These differences are suggestibly due to differences in SE induction 
as well as chronic seizure frequency. Acutely post-SE i.h. kainate-SE mice showed only 
upregulation of M1 markers as opposed to pilocarpine-SE animals which had increased 
presence of M1 and M2 markers. The contribution of peripheral inflammation in the 
pilocarpine model is suggested as a source of differentiation between the models that may 
explain this disparity. Pilocarpine administration has been reported to induce upregulation 
of IL-1β in serum after systemic administration prior to SE onset (Marchi et al., 2007) 
predisposing mice to inflammation. Direct CNS administration of kainic acid does not 
induce such an inflammatory response and in turn may drive a solely M1 post-acute 
phenotype. In contrast, systemic inflammation in pilocarpine mice may drive additional 
elevations in M2 markers post-SE, potentially because of immediate peripheral and brain 
inflammatory pathway induction after pilocarpine injection, even preceding SE.  
 
In the late chronic phase differences between models are suggestibly correlative to seizure 
frequency. Minimal late chronic upregulation of M1/M2 markers are seen in pilocarpine 
mice possibly due to low seizure frequency (≤1 seizure per day) however i.h. kainate mice 
typically experience 10-30 seizures per hour and show recurrent elevations in both M1 and 
M2 markers in parallel (Paper II). Given that a reciprocal relationship between seizures 
and inflammation is proposed, resurgence of microglial activation and inflammatory 
markers in this late chronic phase are not unexpected due to high seizure prevalence. The 
significance of this conclusion may relate to human cases and potentially suggests that 
patients with high seizure frequency may benefit more from anti-inflammatory treatment 
paradigms than those experiencing infrequent seizures. Correlative studies to investigate 
the link between seizure frequency and inflammatory marker presence (including 
microglial activation) are currently lacking in both animal and human studies, however 
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would provide new insights into how inflammation contributes to epilepsy pathophysiology 
and seizure occurrence.  
 
5.3    Methodological considerations 
 
When using models of human disease (in vivo or in vitro) caution must be taken when 
interpreting results obtained in those models and transferring to the human condition. Here 
I have outlined considerations to the findings presented in this thesis on the basis of 
methodological limitations and restrictions.  
 
5.3.1 Animal models 
Epilepsy is a particularly difficult disease to mimic in animals due to the largely unknown 
mechanisms surrounding its development and progression (Galanopoulou et al., 2013). 
Each of the animal models utilised in this thesis initiates seizures or seizure insults such as 
SE using selective chemical compounds or directed electrical stimulations. This allows for 
induction of seizures, however the manner in which these seizures are initiated is primarily 
different from that of the human condition, (excepting spontaneous seizures in chronic 
epilepsy models) where multiple receptor subtypes contribute in driving seizure 
generation, not a selective homogenous subtype, for example muscarinic acetylcholine 
receptors which are stimulated with pilocarpine. This therefore highlights that the seizures 
generated in animal models of the disease are not truly representative of multifactorial 
seizure induction in human epilepsy patients. For this reason multiple epilepsy and seizure 
models must be utilised, each having different mechanisms responsible for initial seizure 
induction to determine if anticonvulsant treatments are specific to one seizure test/type or 
have a broader effectiveness.  
 
Therefore it is suggested that the results found in the intrahippocampal kainate model are 
most relevant to the human condition as this is the only model in which seizures are 
spontaneous and not due to the direct presence of electrical stimulus or 
chemoconvulsants in the CNS at the time of seizure onset.  
 
Another limitation of this study is related to PMX53 itself and its design. PMX53 was 
created to bind to the human C5ar1 receptor with high affinity and not the mouse receptor 
therefore the efficacy of PMX53 in blocking C5ar1-signalling in mice is somewhat 
unknown. I have shown from in vitro signalling assays that PMX53 does not inhibit β-
66 
 
arrestin mediated signalling of mouse C5ar1 (Figure 12B). However, there are alternative 
scaffold proteins that can be utilised by GPCR’s allowing pathway activation without β-
arrestin recruitment (Weston and Davis, 2002, Bouwmeester et al., 2004, Sun et al., 
2007). Therefore signalling of mouse C5ar1 through NFκB, JAK/STAT or ERK/MAPK 
mediated pathways may still be inhibited by PMX53. Comprehensive binding studies are 
limited in mice (Woodruff et al., 2001) therefore there is the potential, as with most drugs, 
that off-target binding occurs which may have biological effects. In this case, off-target 
binding of PMX53 in mice may provide an explanation of how PMX53 can alter seizure 
thresholds in naïve mice with no inflammation at a non-transcriptional level, i.e. 
anticonvulsant effects in the 6Hz model after 30 minutes. Further study to elucidate the 
specific binding targets of PMX53 in mice which specifically affect neuronal excitability is 
the next step in this research.  
 
5.3.2 Cell culture 
As with animal models, cell culture does not represent the ‘normal’ functioning state of 
isolated cell types in the brain therefore results garnered from this technique may not be 
fully representative of what may occur in the CNS during epilepsy. For example, in the 
cultures used there were no neuronal cells therefore the contribution of these cells to the 
actions of microglia and astrocytes in relation to activation state and expression patterns 
was absent. Also, the microglia were separated from astrocytes several days prior to patch 
clamp experiments potentially promoting a more activated phenotype which was visualised 
when observing the isolated cells just prior to use. A mostly pseudopodic morphology was 
observed indicating an intermediary state of activation (Figure 9).  This suggests that the 
results found with C5a on K+ currents may be related to the cells being in a semi-activated 
state, and may not be present in typical surveying microglia (such as those prior to 6Hz 
stimulation).  However, the microglial only cultures were supplemented with “astrocyte-
enriched” medium meaning they did have the growth factors produced by the astrocytes 
present which potentially assisted in keeping the cells as close to a ‘resting’ or surveying 
state as possible. In relation to epileptic animals, activation of microglia was shown with 
increased C5ar1 expression. Therefore the state of microglia used in these experiments is 
not completely removed from the in vivo condition.  
 
In terms of cultured microglial cells, approximately 50% did not respond to C5a stimulation 
suggesting they did not express C5ar1 therefore only those cells that did respond to 
stimulation were included in this study. In mice, I have shown microglial expression of 
67 
 
C5ar1 is increased 10 fold following SE (Paper III) however overall expression of C5ar1 on 
microglia still only accounted for 10% of total microglial cells (excluding non-microglial 
infiltrating immune cells). Therefore, the number of cells responding to C5a stimulation in 
vivo is potentially less than that in culture overall. However, if the small population of 
C5ar1-expressing microglia were located in key epileptic centres, such as the 
hippocampus, greater exaggeration of these C5ar1-mediated effects may occur.   
 
Ideally mixed cultures containing both adult glia and neurons would be optimal to 
determine the effect of PMX53 and C5a on excitatory currents however is was noted that 
even the presence of few astrocytes in the microglial cultures affected the strength of seal 
between the cell membrane and the patch pipette in a negative manner. This would 
suggest a mixed culture may lead to ‘leaky’ seals in patch clamp experiments preventing 
measurement of currents. Additionally, the growth factors in serum (supplemented in the 
culture medium) do not provide a physiological environment for cultured cells. Extracellular 
field potential recordings in ‘epileptic’ hippocampal slices are suggested as the next 
method in which to test PMX53 and its effects on cell excitability which may be closer to 
what is occurring in epileptic brain.  
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6. Concluding remarks 
 
In conclusion, this thesis has demonstrated a pathogenic role of complement C5ar1 
signalling in seizure initiation and severity including secondary associated effects on SE-
induced neuronal degeneration. From these studies the definitive mechanisms of 
anticonvulsant action for PMX53 are still unclear, particularly in relation to acute seizures. 
However, this work has outlined that inflammatory cytokine expression and modulation of 
microglial channel outputs are affected by C5ar1 absence or inhibition with PMX53 and 
appear to be parts of the mechanistic pathways involved. Specific studies with microglia 
revealed a complex pro- and anti-inflammatory response during epilepsy development. 
This response appears to be related to chronic seizure frequency as well as potentially the 
contribution of peripheral inflammation to initial SE onset. Our data advocate that inhibition 
of pro-inflammatory cytokines is most effective in the chronic epileptic phase, when 
spontaneous seizures are present and not prior based upon inflammatory gene expression 
patterns. C5ar1 was also shown to contribute to inflammatory response acutely following 
pilocarpine-SE with absence of the receptor leading to a less inflamed CNS state due to 
attenuated TNFα expression and upregulation of IL-4 mRNA levels. These findings 
therefore indicate a novel target for future AED development given the efficacy of PMX53 
in several seizure models, which may be effective for pharmacoresistant seizures. Lastly, 
C5ar1 inhibition may have beneficial disease-modifying outcomes after SE due to 
lessened neuronal death and the alteration of several immune pathways.  
 
Future directions of this work are needed to assess the anti-epileptogenic potential of 
C5ar1 inhibition and whether treatment with PMX53 during SE or acutely following can not 
only lead to reduced neuronal loss but also changes to disease outcomes. Chronic 
administration studies are also proposed to determine if persistent inhibition of C5ar1 
during epileptogenesis is beneficial to chronic seizure outcomes.  Another key aspect to 
uncover is the acute anticonvulsant mechanism of action of PMX53. Experiments using 
electrophysiological slice models are recommended to further elucidate how PMX53 is 
altering acute seizure thresholds, potentially independent from C5ar1-signalling.  
 
The significance of the discoveries made in this thesis apply to current refractory epilepsy 
patients and their need for seizure relief. At present >30% of patients have no effective 
treatment options with current AEDs, the majority of which modulate ion channels and 
GABAergic transmission (Bialer and White, 2010).  It is hoped that studies such as this 
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investigating novel, alternative mechanisms for seizure control and disease modification 
may one day lead to effective treatment for these refractory patients. It is proposed that 
future refractory AED development focus on pathways that may not be directly apparent to 
seizure generation, such as complement activation or the innate immune system, to 
broaden the scope of investigation and theoretically the likelihood of success.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
7. References 
 
Acarin L, González B, Castellano B (2000) Neuronal, astroglial and microglial cytokine expression 
after an excitotoxic lesion in the immature rat brain. European Journal of Neuroscience 
12:3505-3520. 
Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, 
Lambris JD (2010) Molecular intercommunication between the complement and 
coagulation systems. The Journal of Immunology 185:5628-5636. 
Aronica E, Boer K, van Vliet EA, Redeker S, Baayen JC, Spliet WG, van Rijen PC, Troost D, da 
Silva FH, Wadman WJ, Gorter JA (2007) Complement activation in experimental and 
human temporal lobe epilepsy. Neurobiology of disease 26:497-511. 
Arumugam TV, Woodruff TM, Stocks SZ, Proctor LM, Pollitt S, Shiels IA, Reid RC, Fairlie DP, 
Taylor SM (2004) Protective effect of a human C5a receptor antagonist against hepatic 
ischaemia-reperfusion injury in rats. Journal of hepatology 40:934-941. 
Avignone E, Ulmann L, Levavasseur F, Rassendren F, Audinat E (2008) Status epilepticus induces 
a particular microglial activation state characterized by enhanced purinergic signaling. The 
Journal of Neuroscience 28:9133-9144. 
Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, Vezzani A (2008) A 
novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. 
Brain : a journal of neurology 131:3256-3265. 
Balosso S, Ravizza T, Aronica E, Vezzani A (2013) The dual role of TNF-α and its receptors in 
seizures. Experimental neurology 247:267-271. 
Başaran N, Hincal F, Kansu E, Cidotǧer A (1994) Humoral and cellular immune parameters in 
untreated and phenytoin-or carbamazepine-treated epileptic patients. International journal 
of immunopharmacology 16:1071-1077. 
Beach T, Woodhurst W, MacDonald D, Jones M (1995) Reactive microglia in hippocampal 
sclerosis associated with human temporal lobe epilepsy. Neuroscience letters 191:27-30. 
Beattle EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Mark von Z, Beattie MS, Malenka 
RC (2002) Control of Synaptic Strength by Glial TNFα. Science 295:2282-2285. 
Becker AJ, Chen J, Zien A, Sochivko D, Normann S, Schramm J, Elger CE, Wiestler OD, Blumcke 
I (2003) Correlated stage- and subfield-associated hippocampal gene expression patterns 
in experimental and human temporal lobe epilepsy. The European journal of neuroscience 
18:2792-2802. 
Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, Vescovi A, Bagetta G, Kollias G, 
Meldolesi J (2001) CXCR4-activated astrocyte glutamate release via TNFα: amplification 
by microglia triggers neurotoxicity. Nature neuroscience 4:702-710. 
Bialer M, White HS (2010) Key factors in the discovery and development of new antiepileptic 
drugs. Nat Rev Drug Discov 9:68-82. 
Boche D, Perry V, Nicoll J (2013) Review: activation patterns of microglia and their identification in 
the human brain. Neuropathology and applied neurobiology 39:3-18. 
Boer K, Spliet W, Van Rijen P, Redeker S, Troost D, Aronica E (2006) Evidence of activated 
microglia in focal cortical dysplasia. Journal of neuroimmunology 173:188-195. 
Boling W, Palade A, Wabulya A, Longoni N, Warf B, Nestor S, Alpitsis R, Bittar R, Howard C, 
Andermann F (2009) Surgery for pharmacoresistant epilepsy in the developing world: A 
pilot study. Epilepsia 50:1256-1261. 
Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH, Dingledine R (2003) 
Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine 
model. Experimental neurology 182:21-34. 
Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, Cruciat C, 
Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon A-M, Schirle M, 
Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin A-C, Jackson DB, 
Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G (2004) A physical and functional 
map of the human TNF-[alpha]/NF-[kappa]B signal transduction pathway. Nat Cell Biol 
6:97-105. 
71 
 
Capacio B, Harris L, Anderson D, Lennox W, Gales V, Dawson J (1992) Use of the Accelerating 
Rotarod for Assessment of Motor Performance Decrement Induced by Potential 
Anticonvulsant Compounds DM Nerve Agent Poisoning. Drug and chemical toxicology 
15:177-201. 
Chao CC, Hu S, Ehrlich L, Peterson PK (1995) Interleukin-1 and tumor necrosis factor-α 
synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-
aspartate receptors. Brain Behavior and Immunity 9:355-365. 
Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H, Yeh WC 
(2007) C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. 
Nature 446:203-207. 
Chiavegato A, Zurolo E, Losi G, Aronica E, Carmignoto G (2014) The inflammatory molecules IL-
1beta and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of 
temporal lobe epilepsy. Frontiers in cellular neuroscience 8:155. 
Choi H, Sell RL, Lenert L, Muennig P, Goodman RR, Gilliam FG, Wong JB (2008) Epilepsy surgery 
for pharmacoresistant temporal lobe epilepsy: a decision analysis. Jama 300:2497-2505. 
Choi J, Min HJ, Shin J-S (2011) Increased levels of HMGB1 and pro-inflammatory cytokines in 
children with febrile seizures. Journal of neuroinflammation 8:135-135. 
Chu Y, Jin X, Parada I, Pesic A, Stevens B, Barres B, Prince DA (2010) Enhanced synaptic 
connectivity and epilepsy in C1q knockout mice. Proceedings of the National Academy of 
Sciences of the United States of America 107:7975-7980. 
Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. 
Journal of Neuroimmune Pharmacology 4:399-418. 
Crane JW, Baiquni GP, Sullivan RK, Lee JD, Sah P, Taylor SM, Noakes PG, Woodruff TM (2009) 
The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of 
hippocampal mossy fibres. Journal of neuroinflammation 6:34. 
Crespel A, Coubes P, Rousset M-C, Brana C, Rougier A, Rondouin G, Bockaert J, Baldy-Moulinier 
M, Lerner-Natoli M (2002) Inflammatory reactions in human medial temporal lobe epilepsy 
with hippocampal sclerosis. Brain research 952:159-169. 
Cunningham C (2013) Microglia and neurodegeneration: the role of systemic inflammation. Glia 
61:71-90. 
David S, Kroner A (2011) Repertoire of microglial and macrophage responses after spinal cord 
injury. Nature Reviews Neuroscience 12:388-399. 
de Bock F, Dornand J, Rondouin G (1996) Release of TNF [alpha] in the rat hippocampus 
following epileptic seizures and excitotoxic neuronal damage. Neuroreport 7:1125-1129. 
de Boer HM, Mula M, Sander JW (2008) The global burden and stigma of epilepsy. Epilepsy & 
Behavior 12:540-546. 
De Lanerolle N, Kim J, Robbins R, Spencer D (1989) Hippocampal interneuron loss and plasticity 
in human temporal lobe epilepsy. Brain research 495:387-395. 
De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, De Luigi A, Garattini S, 
Vezzani A (2000) Inflammatory cytokines and related genes are induced in the rat 
hippocampus by limbic status epilepticus. European Journal of Neuroscience 12:2623-
2633. 
Ducruet AF, Zacharia BE, Sosunov SA, Gigante PR, Yeh ML, Gorski JW, Otten ML, Hwang RY, 
DeRosa PA, Hickman ZL (2012) Complement inhibition promotes endogenous 
neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. 
PloS one 7:e38664. 
Duncan S, Morgan BP (2003) Beyond lysis: how complement influences cell fate. Clinical science 
104:455-466. 
Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD (1997) Biologically 
active conformer of the effector region of human C5a and modulatory effects of N-terminal 
receptor binding determinants on activity. Journal of medicinal chemistry 40:877-884. 
Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM (1999) Low-
molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor 
C5a. Journal of medicinal chemistry 42:1965-1974. 
Fisher RS, Boas WvE, Blume W, Elger C, Genton P, Lee P, Engel J (2005) Epileptic seizures and 
epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the 
International Bureau for Epilepsy (IBE). Epilepsia 46:470-472. 
72 
 
Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC (2003) 
C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-
induced injury☆,☆☆. Clinical immunology 108:263-273. 
Fonseca MI, Ager RR, Chu S-H, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, 
Tenner AJ (2009) Treatment with a C5aR antagonist decreases pathology and enhances 
behavioral performance in murine models of Alzheimer’s disease. The Journal of 
Immunology 183:1375-1383. 
Fonseca MI, McGuire SO, Counts SE, Tenner AJ (2013) Complement activation fragment C5a 
receptors, CD88 and C5L2, are associated with neurofibrillary pathology. Journal of 
neuroinflammation 10:25. 
Gaitatzis A, Trimble M, Sander JW (2004) The psychiatric comorbidity of epilepsy. Acta 
Neurologica Scandinavica 110:207-220. 
Galanopoulou AS, Kokaia M, Loeb JA, Nehlig A, Pitkanen A, Rogawski MA, Staley KJ, Whittemore 
VH, Dudek FE (2013) Epilepsy therapy development: technical and methodologic issues in 
studies with animal models. Epilepsia 54 Suppl 4:13-23. 
Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic 
cells. Nature medicine 5:1249-1255. 
Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Götze O, Morgan BP (1995) Identification 
and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. 
The Journal of Immunology 155:4882-4889. 
Gasque P, Singhrao SK, Neal JW, Götze O, Morgan BP (1997) Expression of the receptor for 
complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial 
cells in the inflamed human central nervous system. The American journal of pathology 
150:31. 
Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C-U, Siler DA, Arumugam TV, Orthey E, 
Gerloff C, Tolosa E (2009) Temporal and spatial dynamics of cerebral immune cell 
accumulation in stroke. Stroke 40:1849-1857. 
Giardina WJ, Gasior M (2009) Acute seizure tests in epilepsy research: electroshock- and 
chemical-induced convulsions in the mouse. Current protocols in pharmacology / editorial 
board, SJ Enna Chapter 5:Unit 5 22. 
Giunti D, Parodi B, Usai C, Vergani L, Casazza S, Bruzzone S, Mancardi G, Uccelli A (2012) 
Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of 
CX3CL1. STEM CELLS 30:2044-2053. 
Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. 
Immunity 32:593-604. 
Gorter JA, van Vliet EA, Aronica E, Breit T, Rauwerda H, da Silva FHL, Wadman WJ (2006) 
Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for 
temporal lobe epilepsy. The Journal of neuroscience 26:11083-11110. 
Gouder N, Fritschy JM, Boison D (2003) Seizure suppression by adenosine A1 receptor activation 
in a mouse model of pharmacoresistant epilepsy. Epilepsia 44:877-885. 
Hanisch U-K, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the 
normal and pathologic brain. Nature neuroscience 10:1387-1394. 
Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP (2000) Inhibition of C5a-
induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a 
receptor antagonist. Biochemical pharmacology 60:729-733. 
Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD (2008) A conformationally-biased, response-
selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing 
and presentation activities of human dendritic cells. International immunopharmacology 
8:819-827. 
Higginbottom A, Cain SA, Woodruff TM, Proctor LM, Madala PK, Tyndall JD, Taylor SM, Fairlie 
DP, Monk PN (2005) Comparative agonist/antagonist responses in mutant human C5a 
receptors define the ligand binding site. The Journal of biological chemistry 280:17831-
17840. 
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, 
Nakamura R (2006) The complement inhibitor eculizumab in paroxysmal nocturnal 
hemoglobinuria. New England Journal of Medicine 355:1233-1243. 
73 
 
Hodson MP, Dear GJ, Griffin JL, Haselden JN (2009) An approach for the development and 
selection of chromatographic methods for high-throughput metabolomic screening of urine 
by ultra pressure LC-ESI-ToF-MS. Metabolomics 5:166-182. 
Holland MCH, Morikis D, Lambris JD (2004) Synthetic small-molecule complement inhibitors. 
Current Opinion in Investigational Drugs 5:1164-1173. 
Hollmann TJ, Mueller-Ortiz SL, Braun MC, Wetsel RA (2008) Disruption of the C5a receptor gene 
increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing 
roles of C3a and C5a. Molecular immunology 45:1907-1915. 
Hsu MH, Wang M, Browning DD, Mukaida N, Richard DY (1999) NF-κB activation is required for 
C5a-induced interleukin-8 gene expression in mononuclear cells. Blood 93:3241-3249. 
Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC (2000) Cytokine effects on glutamate uptake 
by human astrocytes. Neuroimmunomodulation 7:153-159. 
Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J (2012) Microglia/macrophage 
polarization dynamics reveal novel mechanism of injury expansion after focal cerebral 
ischemia. Stroke 43:3063-3070. 
HUBER-LANG MS, RIEDEMAN NC, Sarma JV, YOUNKIN EM, McGUIRE SR, LAUDES IJ, LU KT, 
GUO R-F, NEFF TA, PADGAONKAR VA (2002) Protection of innate immunity by C5aR 
antagonist in septic mice. The FASEB journal 16:1567-1574. 
Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S (2000) Sodium valproate 
inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain research 857:246-251. 
Ilschner S, Nolte C, Kettenmann H (1996) Complement factor C5a and epidermal growth factor 
trigger the activation of outward potassium currents in cultured murine microglia. 
Neuroscience 73:1109-1120. 
Jacob A, Hack B, Chen P, Quigg RJ, Alexander JJ (2011) C5a/CD88 signaling alters blood-brain 
barrier integrity in lupus through nuclear factor-kappaB. Journal of neurochemistry 
119:1041-1051. 
Jamali S, Bartolomei F, Robaglia-Schlupp A, Massacrier A, Peragut JC, Regis J, Dufour H, Ravid 
R, Roll P, Pereira S, Royer B, Roeckel-Trevisiol N, Fontaine M, Guye M, Boucraut J, 
Chauvel P, Cau P, Szepetowski P (2006) Large-scale expression study of human mesial 
temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and 
complement systems in the entorhinal cortex. Brain : a journal of neurology 129:625-641. 
Jamali S, Salzmann A, Perroud N, Ponsole-Lenfant M, Cillario J, Roll P, Roeckel-Trevisiol N, 
Crespel A, Balzar J, Schlachter K (2010) Functional variant in complement C3 gene 
promoter and genetic susceptibility to temporal lobe epilepsy and febrile seizures. PloS one 
5:e12740. 
Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis F, Boackle SA, Takahashi K, Holers VM, Walport 
M, Gerard C (2002) Arthritis critically dependent on innate immune system players. 
Immunity 16:157-168. 
Jones NC, Salzberg MR, Kumar G, Couper A, Morris MJ, O'Brien TJ (2008) Elevated anxiety and 
depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common 
causation. Experimental neurology 209:254-260. 
Kalueff AV, Lehtimaki KA, Ylinen A, Honkaniemi J, Peltola J (2004) Intranasal administration of 
human IL-6 increases the severity of chemically induced seizures in rats. Neuroscience 
letters 365:106-110. 
Kearney J, Plummer N, Smith M, Kapur J, Cummins T, Waxman S, Goldin A, Meisler M (2001) A 
gain-of-function mutation in the sodium channel gene Scn2a results in seizures and 
behavioral abnormalities. Neuroscience 102:307-317. 
Kharatishvili I, Shan ZY, She DT, Foong S, Kurniawan ND, Reutens DC (2014) MRI changes and 
complement activation correlate with epileptogenicity in a mouse model of temporal lobe 
epilepsy. Brain Structure and Function 219:683-706. 
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) Identification 
of two distinct macrophage subsets with divergent effects causing either neurotoxicity or 
regeneration in the injured mouse spinal cord. The Journal of Neuroscience 29:13435-
13444. 
Kim AH, Dimitriou ID, Holland MCH, Mastellos D, Mueller YM, Altman JD, Lambris JD, Katsikis PD 
(2004) Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T 
cell responses. The Journal of Immunology 173:2524-2529. 
74 
 
Kim GH, Mocco J, Hahn DK, Kellner CP, Komotar RJ, Ducruet AF, Mack WJ, Connolly Jr ES 
(2008) Protective effect of C5a receptor inhibition after murine reperfused stroke. 
Neurosurgery 63:122. 
Kimball AW, Burnett Jr W, Doherty DG (1957) Chemical protection against ionizing radiation: I. 
Sampling methods for screening compounds in radiation protection studies with mice. 
Radiation Research 7:1-12. 
Klitgaard H, Matagne A, Gobert J, Wülfert E (1998) Evidence for a unique profile of levetiracetam 
in rodent models of seizures and epilepsy. European journal of pharmacology 353:191-206. 
Klitgaard H, Matagne A, Grimee R, Vanneste-Goemaere J, Margineanu D-G (2003) 
Electrophysiological, neurochemical and regional effects of levetiracetam in the rat 
pilocarpine model of temporal lobe epilepsy. Seizure : the journal of the British Epilepsy 
Association 12:92-100. 
Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi 
H, Suzumura A, Ishiguro N (2013) Minocycline selectively inhibits M1 polarization of 
microglia. Cell death & disease 4:e525. 
Koehl J (2006) Drug evaluation: the C5a receptor antagonist PMX-53. Current opinion in molecular 
therapeutics 8:529-538. 
Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J (2001) Complement factors C3a and C5a 
are increased in bronchoalveolar lavage fluid after segmental allergen provocation in 
subjects with asthma. American journal of respiratory and critical care medicine 164:1841-
1843. 
Kumar A, Stoica BA, Sabirzhanov B, Burns MP, Faden AI, Loane DJ (2013) Traumatic brain injury 
in aged animals increases lesion size and chronically alters microglial/macrophage 
classical and alternative activation states. Neurobiology of aging 34:1397-1411. 
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, 
Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the 
ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069-
1077. 
Kwan P, Schachter SC, Brodie MJ (2011) Drug-resistant epilepsy. New England Journal of 
Medicine 365:919-926. 
Langlois M, Bouyssieres C, Duveau V, Dumont C, Roucard C (2012) Improving the development of 
promising drug candidates: preclinical 
solutions developed in chronic models of epilepsy. Annual Meeting of the American Epilepsy 
Society San Diego, CA. 
Lappas M, Woodruff TM, Taylor SM, Permezel M (2012) Complement C5a regulates prolabor 
mediators in human placenta. Biology of reproduction 86:190. 
Leite JP, Garcia-Cairasco N, Cavalheiro EA (2002) New insights from the use of pilocarpine and 
kainate models. Epilepsy research 50:93-103. 
Li G, Bauer S, Nowak M, Norwood B, Tackenberg B, Rosenow F, Knake S, Oertel WH, Hamer HM 
(2011) Cytokines and epilepsy. Seizure : the journal of the British Epilepsy Association 
20:249-256. 
Li L, Xiong Z-y, Qian ZM, Zhao T-z, Feng H, Hu S, Hu R, Ke Y, Lin J (2014) Complement C5a is 
detrimental to histological and functional locomotor recovery after spinal cord injury in mice. 
Neurobiology of disease 66:74-82. 
Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM (2013) C5L2: a controversial receptor of 
complement anaphylatoxin, C5a. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 27:855-864. 
Löscher W (2011) Critical review of current animal models of seizures and epilepsy used in the 
discovery and development of new antiepileptic drugs. Seizure - European Journal of 
Epilepsy 20:359-368. 
Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA (2007) CD200 ligand–receptor 
interaction modulates microglial activation in vivo and in vitro: a role for IL-4. The Journal of 
neuroscience 27:8309-8313. 
Madeja M, Georg Margineanu D, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann E-J (2003) 
Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic 
mechanism of action? Neuropharmacology 45:661-671. 
75 
 
Mandhane SN, Aavula K, Rajamannar T (2007) Timed pentylenetetrazol infusion test: a 
comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. 
Seizure : the journal of the British Epilepsy Association 16:636-644. 
Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, Taylor SM (2011) 
Complement C5a inhibition reduces atherosclerosis in ApoE−/− mice. The FASEB Journal 
25:2447-2455. 
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-
associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends 
in immunology 23:549-555. 
March DR, Proctor LM, Stoermer MJ, Sbaglia R, Abbenante G, Reid RC, Woodruff TM, Wadi K, 
Paczkowski N, Tyndall JD (2004) Potent cyclic antagonists of the complement C5a receptor 
on human polymorphonuclear leukocytes. Relationships between structures and activity. 
Molecular pharmacology 65:868-879. 
Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, Betto G, Batra A, Carlton E, Najm I, Granata T 
(2009) Antagonism of peripheral inflammation reduces the severity of status epilepticus. 
Neurobiology of disease 33:171-181. 
Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, Teng Q, Alexopolous A, Janigro D 
(2011) Efficacy of anti-inflammatory therapy in a model of acute seizures and in a 
population of pediatric drug resistant epileptics. PLoS One 6:e18200. 
Marchi N, Oby E, Batra A, Uva L, De Curtis M, Hernandez N, Boxel‐Dezaire V, Najm I, Janigro D 
(2007) In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia 
48:1934-1946. 
Maroso M, Balosso S, Ravizza T, Iori V, Wright CI, French J, Vezzani A (2011) Interleukin-1β 
biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in 
mice. Neurotherapeutics 8:304-315. 
Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, 
Manfredi AA, Bianchi ME, Vezzani A (2010) Toll-like receptor 4 and high-mobility group 
box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature medicine 
16:413-419. 
Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM (2005) Dynamic complexity of the microglial 
activation response in transgenic models of amyloid deposition: implications for Alzheimer 
therapeutics. Journal of Neuropathology & Experimental Neurology 64:743-753. 
Morgan M, Bulmer AC, Woodruff TM, Proctor LM, Williams HM, Stocks SZ, Pollitt S, Taylor SM, 
Shiels IA (2008) Pharmacokinetics of a C5a receptor antagonist in the rat after different 
sites of enteral administration. european journal of pharmaceutical sciences 33:390-398. 
Morimoto K, Fahnestock M, Racine RJ (2004) Kindling and status epilepticus models of epilepsy: 
rewiring the brain. Progress in neurobiology 73:1-60. 
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nature 
Reviews Immunology 8:958-969. 
Mukherjee P, Thomas S, Pasinetti GM (2008) Complement anaphylatoxin C5a neuroprotects 
through regulation of glutamate receptor subunit 2 in vitro and in vivo. Journal of 
neuroinflammation 5:5. 
Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME (2001) 
The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. 
The EMBO journal 20:4337-4340. 
Najjar S, Pearlman D, Miller DC, Devinsky O (2011) Refractory epilepsy associated with microglial 
activation. The neurologist 17:249-254. 
Nomaru H, Sakumi K, Katogi A, Ohnishi YN, Kajitani K, Tsuchimoto D, Nestler EJ, Nakabeppu Y 
(2014) Fosb gene products contribute to excitotoxic microglial activation by regulating the 
expression of complement C5a receptors in microglia. Glia. 
O’Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR (2001) Neuronal 
expression of a functional receptor for the C5a complement activation fragment. The 
Journal of Immunology 166:4154-4162. 
Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, Brodbeck RM, Krause 
JE, Choe H-R, Gerard NP (2003) C5L2, a nonsignaling C5A binding protein. Biochemistry 
42:9406-9415. 
76 
 
Osaka H, McGinty A, Hoepken U, Lu B, Gerard C, Pasinetti G (1999a) Expression of C5a receptor 
in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 88:1073-
1082. 
Osaka H, Mukherjee P, Aisen PS, Pasinetti GM (1999b) Complement‐derived anaphylatoxin C5a 
protects against glutamate‐mediated neurotoxicity. Journal of cellular biochemistry 73:303-
311. 
Patel HC, Ross FM, Heenan LE, Davies RE, Rothwell NJ, Allan SM (2006) Neurodegenerative 
actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. 
Journal of neuroscience research 83:385-391. 
Pernot F, Heinrich C, Barbier L, Peinnequin A, Carpentier P, Dhote F, Baille V, Beaup C, Depaulis 
A, Dorandeu F (2011) Inflammatory changes during epileptogenesis and spontaneous 
seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 52:2315-2325. 
Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nature Reviews 
Neurology 6:193-201. 
Peters HC, Kämmer G, Volz A, Kaupmann K, Ziegler A, Bettler B, Epplen JT, Sander T, Riess O 
(1998) Mapping, genomic structure, and polymorphisms of the human GABA B R1 receptor 
gene: evaluation of its involvement in idiopathic generalized epilepsy. Neurogenetics 2:47-
54. 
Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A (2008) The prevalence of epilepsy 
and pharmacoresistant epilepsy in adults: a population-based study in a Western European 
country. Epilepsia 49:1230-1238. 
Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A (1999) The Efficacy of Valproate-
Lamotrigine Comedication in Refractory Complex Partial Seizures: Evidence for a 
Pharmacodynamic Interaction. Epilepsia 40:1141-1146. 
Pitkänen A, Lukasiuk K (2011) Mechanisms of epileptogenesis and potential treatment targets. The 
Lancet Neurology 10:173-186. 
Pitkänen A, Schwartzkroin PA, Moshé SL (2005) Models of seizures and epilepsy: Academic 
Press. 
Plata-Salamán CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE, Kelly ME, Bureau Y, 
Anisman H, McIntyre DC (2000) Kindling modulates the IL-1β system, TNF-α, TGF-β1, and 
neuropeptide mRNAs in specific brain regions. Molecular brain research 75:248-258. 
Racine RJ (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. 
Electroencephalography and Clinical Neurophysiology 32:281-294. 
Ravizza T (2008) Innate and adaptive immunity during epileptogenesis and spontaneous seizures: 
Evidence from experimental models and human temporal lobe epilepsy. Neurobiology of 
disease 29:142-160. 
Ravizza T, Balosso S, Vezzani A (2011) Inflammation and prevention of epileptogenesis. 
Neuroscience letters 497:223-230. 
Ravizza T, Noé F, Zardoni D, Vaghi V, Sifringer M, Vezzani A (2008) Interleukin converting 
enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1β 
production. Neurobiology of disease 31:327-333. 
Reid RC, Abbenante G, Taylor SM, Fairlie DP (2003) A convergent solution-phase synthesis of the 
macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug. The 
Journal of organic chemistry 68:4464-4471. 
Reis ES, Chen H, Sfyroera G, Monk PN, Köhl J, Ricklin D, Lambris JD (2012) C5a receptor-
dependent cell activation by physiological concentrations of desarginated C5a: insights 
from a novel label-free cellular assay. The Journal of Immunology 189:4797-4805. 
Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ (2008) Microglial activation and 
TNFα production mediate altered CNS excitability following peripheral inflammation. 
Proceedings of the National Academy of Sciences 105:17151-17156. 
Riazi K, Galic MA, Pittman QJ (2010) Contributions of peripheral inflammation to seizure 
susceptibility: cytokines and brain excitability. Epilepsy research 89:34-42. 
Riban V, Bouilleret V, Pham-Le B, Fritschy J-M, Marescaux C, Depaulis A (2002) Evolution of 
hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse 
model of temporal lobe epilepsy. Neuroscience 112:101-111. 
Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nature biotechnology 25:1265-
1275. 
77 
 
Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, 
Cianflone K, Köhl J (2008) Functional roles for C5a receptors in sepsis. Nature medicine 
14:551-557. 
Rynkowski MA, Kim GH, Garrett MC, Zacharia BE, Otten ML, Sosunov SA, Komotar RJ, Hassid 
BG, Ducruet AF, Lambris JD (2009) C3a receptor antagonist attenuates brain injury after 
intracerebral hemorrhage. Journal of Cerebral Blood Flow & Metabolism 29:98-107. 
Samland H, Huitron‐Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL (2003) Profound 
increase in sensitivity to glutamatergic‐but not cholinergic agonist‐induced seizures in 
transgenic mice with astrocyte production of IL‐6. Journal of neuroscience research 73:176-
187. 
Sander JW (2003) The epidemiology of epilepsy revisited. Current opinion in neurology 16:165-
170. 
Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID (2006) A pragmatic and readily implemented 
quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 
131:1075-1078. 
Sarkisova K, van Luijtelaar G (2011) The WAG/Rij strain: a genetic animal model of absence 
epilepsy with comorbidity of depressiony. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry 35:854-876. 
Sarma JV, Ward PA (2012) New developments in C5a receptor signaling. Cell health and 
cytoskeleton 4:73. 
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells 
triggers inflammation. Nature 418:191-195. 
Schaeffer V, Cuschieri J, Garcia I, Knoll M, Billgren J, Jelacic S, Bulger E, Maier R (2007) The 
priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway. 
Shock 27:623-630. 
Schmued LC, Hopkins KJ (2000) Fluoro-Jade B: a high affinity fluorescent marker for the 
localization of neuronal degeneration. Brain research 874:123-130. 
Schnatbaum K, Locardi E, Scharn D, Richter U, Hawlisch H, Knolle J, Polakowski T (2006) 
Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: 
increased receptor specificity and in vivo activity. Bioorganic & medicinal chemistry letters 
16:5088-5092. 
Schneider H, Pitossi F, Balschun D, Wagner A, Del Rey A, Besedovsky H (1998) A 
neuromodulatory role of interleukin-1β in the hippocampus. Proceedings of the National 
Academy of Sciences 95:7778-7783. 
Schneider JW, Conrad P (1980) In the closet with illness: epilepsy, stigma potential and 
information control. Social Problems 32-44. 
Scola A-M, Higginbottom A, Partridge LJ, Reid RC, Woodruff T, Taylor SM, Fairlie DP, Monk PN 
(2007) The role of the N-terminal domain of the complement fragment receptor C5L2 in 
ligand binding. Journal of Biological Chemistry 282:3664-3671. 
Scully CC, Blakeney JS, Singh R, Hoang HN, Abbenante G, Reid RC, Fairlie DP (2010) Selective 
hexapeptide agonists and antagonists for human complement C3a receptor. Journal of 
medicinal chemistry 53:4938-4948. 
Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, Sandor M, Fabry Z (2004) 
Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on 
neutrophil extravasation by C5a receptor antagonist. Journal of neuroimmunology 155:55-
63. 
Shapiro LA, Wang L, Ribak CE (2008) Rapid astrocyte and microglial activation following 
pilocarpine‐induced seizures in rats. Epilepsia 49:33-41. 
Short A, Wong AK, Finch AM, Haaima G, Shiels IA, Fairlie DP, Taylor SM (1999) Effects of a new 
C5a receptor antagonist on C5a‐and endotoxin‐induced neutropenia in the rat. British 
journal of pharmacology 126:551-554. 
Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park J-K, Hashimoto K, Haller H, Dumler I 
(2005) Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-
inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a 
receptor. Journal of cell science 118:2743-2753. 
Sirven JI, Noe K, Hoerth M, Drazkowski J (2012) Antiepileptic drugs 2012: recent advances and 
trends. In: Mayo Clinic Proceedings, vol. 87, pp 879-889: Elsevier. 
78 
 
Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H-P, Trentz O, Kossmann T, Morganti-
Kossmann MC (2000) Intracerebral complement C5a receptor (CD88) expression is 
regulated by TNF and lymphotoxin-α following closed head injury in mice. Journal of 
Neuroimmunology 109:164-172. 
Stahel PF, Kossmann T, Morganti-Kossmann MC, Hans VH, Barnum SR (1997) Experimental 
diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats. 
Molecular brain research 50:205-212. 
Stellwagen D, Beattie EC, Seo JY, Malenka RC (2005) Differential regulation of AMPA receptor 
and GABA receptor trafficking by tumor necrosis factor-α. The Journal of neuroscience 
25:3219-3228. 
Stephan AH, Barres BA, Stevens B (2012) The complement system: an unexpected role in 
synaptic pruning during development and disease. Annual review of neuroscience 35:369-
389. 
Strachan AJ, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2001) Inhibition of immune‐complex 
mediated dermal inflammation in rats following either oral or topical administration of a 
small molecule C5a receptor antagonist. British journal of pharmacology 134:1778-1786. 
Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM (2000) A new small molecule C5a 
receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in 
rats. The Journal of Immunology 164:6560-6565. 
Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh 
K, Ohtsuka T, Ohbora T, Mishina T, Komatsu H, Naka Y (2002) Identification of a potent 
and orally active non-peptide C5a receptor antagonist. The Journal of biological chemistry 
277:49403-49407. 
Sun Y, McGarrigle D, Huang X-Y (2007) When a G protein-coupled receptor does not couple to a 
G protein. Molecular BioSystems 3:849-854. 
Surges R, Volynski KE, Walker MC (2008) Review: Is levetiracetam different from other 
antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy 
revisited. Therapeutic advances in neurological disorders 1:13-24. 
Talley AK, Dewhurst S, Perry SW, Dollard SC, Gummuluru S, Fine SM, New D, Epstein LG, 
Gendelman HE, Gelbard HA (1995) Tumor necrosis factor alpha-induced apoptosis in 
human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 
and crmA. Molecular and cellular biology 15:2359-2366. 
Taniwaki Y, Kato M, Araki T, Kobayashi T (1996) Microglial activation by epileptic activities through 
the propagation pathway of kainic acid-induced hippocampal seizures in the rat. 
Neuroscience letters 217:29-32. 
Thornton P, Pinteaux E, Gibson RM, Allan SM, Rothwell NJ (2006) Interleukin‐1‐induced 
neurotoxicity is mediated by glia and requires caspase activation and free radical release. 
Journal of neurochemistry 98:258-266. 
Toyoda I, Bower MR, Leyva F, Buckmaster PS (2013) Early activation of ventral hippocampus and 
subiculum during spontaneous seizures in a rat model of temporal lobe epilepsy. The 
Journal of Neuroscience 33:11100-11115. 
Ulmann L, Levavasseur F, Avignone E, Peyroutou R, Hirbec H, Audinat E, Rassendren F (2013) 
Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus. 
Glia 61:1306-1319. 
Van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, Fontaine M (2000) 
Expression of receptors for complement anaphylatoxins C3a and C5a following permanent 
focal cerebral ischemia in the mouse. Experimental neurology 161:373-382. 
van Lith LH, Oosterom J, Van Elsas A, Zaman GJ (2009) C5a-stimulated recruitment of β-arrestin2 
to the nonsignaling 7-transmembrane decoy receptor C5L2. Journal of biomolecular 
screening. 
Varnum MM, Ikezu T (2012) The classification of microglial activation phenotypes on 
neurodegeneration and regeneration in Alzheimer’s disease brain. Archivum immunologiae 
et therapiae experimentalis 60:251-266. 
Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, Sanders ME, Reedquist 
KA, Tak PP (2007) Blocking the receptor for C5a in patients with rheumatoid arthritis does 
not reduce synovial inflammation. Rheumatology 46:1773-1778. 
79 
 
Vezzani A, Balosso S, Aronica E, Ravizza T (2009) Basic mechanisms of status epilepticus due to 
infection and inflammation. Epilepsia 50 Suppl 12:56-57. 
Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, De Simoni MG (1999) 
Interleukin-1β immunoreactivity and microglia are enhanced in the rat hippocampus by 
focal kainate application: functional evidence for enhancement of electrographic seizures. 
The Journal of neuroscience 19:5054-5065. 
Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nature 
reviews Neurology 7:31-40. 
Vezzani A, Granata T (2005) Brain inflammation in epilepsy: experimental and clinical evidence. 
Epilepsia 46:1724-1743. 
Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni M, Sperk G, Andell-
Jonsson S, Lundkvist J (2000) Powerful anticonvulsant action of IL-1 receptor antagonist on 
intracerebral injection and astrocytic overexpression in mice. Proceedings of the National 
Academy of Sciences 97:11534-11539. 
Vezzani A, Moneta D, Richichi C, Aliprandi M, Burrows SJ, Ravizza T, Perego C, De Simoni MG 
(2002) Functional role of inflammatory cytokines and antiinflammatory molecules in 
seizures and epileptogenesis. Epilepsia 43:30-35. 
Vezzani A, Ravizza T, Balosso S, Aronica E (2008) Glia as a source of cytokines: implications for 
neuronal excitability and survival. Epilepsia 49:24-32. 
Vitkovic L, Bockaert J, Jacque C (2000) “Inflammatory” cytokines. Journal of neurochemistry 
74:457-471. 
Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens M, Bartfai T, Binaglia M, Corsini E, Di Luca 
M, Galli C (2003) Interleukin-1β enhances NMDA receptor-mediated intracellular calcium 
increase through activation of the Src family of kinases. The Journal of neuroscience 
23:8692-8700. 
Walker L, Tse K, Sills G, Antoine D, Thippeswamy T, Marson A, Pirmohamed M (2012) HMGB1: A 
novel mechanistic biomarker in epilepsy. In: British Pharmacological Society Annual winter 
meeting  London, UK. 
Ward PA (2009) Functions of C5a receptors. Journal of molecular medicine 87:375-378. 
Weston CR, Davis RJ (2002) The JNK signal transduction pathway. Current opinion in genetics & 
development 12:14-21. 
WHO (2012) Epilepsy. World Health Organisation Factsheet No. 999. 
Wilcox KS, Dixon-Salazar T, Sills GJ, Ben-Menachem E, Steve White H, Porter RJ, Dichter MA, 
Moshé SL, Noebels JL, Privitera MD, Rogawski MA (2013) Issues related to development 
of new antiseizure treatments. Epilepsia 54:24-34. 
Willis S, Stoll J, Sweetman L, Borges K (2010) Anticonvulsant effects of a triheptanoin diet in two 
mouse chronic seizure models. Neurobiology of disease 40:565-572. 
Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP (1998) Small molecular probes 
for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from 
the C terminus of the human plasma protein C5a. Journal of medicinal chemistry 41:3417-
3425. 
Woode E, Poku RA, Abotsi W (2011) Anticonvulsant effects of leaf extract of Ficus exasperata 
Vahl (Moraceae) in mice. Int J Pharmacol 7:405-409. 
Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM (2010) The role of the complement 
system and the activation fragment C5a in the central nervous system. Neuromolecular 
medicine 12:179-192. 
Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2003) A potent human 
C5a receptor antagonist protects against disease pathology in a rat model of inflammatory 
bowel disease. The Journal of Immunology 171:5514-5520. 
Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG (2008) The 
complement factor C5a contributes to pathology in a rat model of amyotrophic lateral 
sclerosis. The Journal of Immunology 181:8727-8734. 
Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, De Vos K, Pollitt S, Williams HM, Shiels 
IA, Monk PN (2006) Therapeutic activity of C5a receptor antagonists in a rat model of 
neurodegeneration. The FASEB journal 20:1407-1417. 
Woodruff TM, Pollitt S, Proctor LM, Stocks SZ, Manthey HD, Williams HM, Mahadevan IB, Shiels 
IA, Taylor SM (2005) Increased potency of a novel complement factor 5a receptor 
80 
 
antagonist in a rat model of inflammatory bowel disease. Journal of Pharmacology and 
Experimental Therapeutics 314:811-817. 
Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2002) 
Antiarthritic activity of an orally active C5a receptor antagonist against antigen‐induced 
monarticular arthritis in the rat. Arthritis & Rheumatism 46:2476-2485. 
Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP, Taylor SM (2001) 
Species dependence for binding of small molecule agonist and antagonists to the C5a 
receptor on polymorphonuclear leukocytes. Inflammation 25:171-177. 
Xiong ZQ, Qian W, Suzuki K, McNamara JO (2003) Formation of complement membrane attack 
complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 
23:955-960. 
Zhang L, Mallik B, Morikis D (2008) Structural study of Ac-Phe-[Orn-Pro-dCha-Trp-Arg], a potent 
C5a receptor antagonist, by NMR. Biopolymers 90:803-815. 
Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, Lambris JD, Wetsel RA, Miwa T, Song W-C 
(2007) Regulation of Toll-like receptor–mediated inflammatory response by complement in 
vivo. Blood 110:228-236. 
Zhang X, Mosser DM (2008) Macrophage activation by endogenous danger signals. The Journal of 
Pathology 214:161-178. 
Zhao W, Xie W, Xiao Q, Beers DR, Appel SH (2006) Protective effects of an anti‐inflammatory 
cytokine, interleukin‐4, on motoneuron toxicity induced by activated microglia. Journal of 
neurochemistry 99:1176-1187. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
8. Appendices 
 
Appendix 8.1 
 
Paper I - Neurobiology of Disease revised accepted manuscript 
 
Benson MJ, Thomas NK, Talwar S, Hodson MP, Lynch JW, Woodruff TM & Borges K. 
(2015) A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in 
murine epilepsy models. Neurobiology of Disease – Accepted 4/2/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurobiology of Disease 76 (2015) 87–97
Contents lists available at ScienceDirect
Neurobiology of Disease
j ourna l homepage: www.e lsev ie r .com/ locate /ynbd iA novel anticonvulsant mechanism via inhibition of complement
receptor C5ar1 in murine epilepsy modelsMelissa J. Benson a, Nicola K. Thomas a, Sahil Talwar b, Mark P. Hodson c, Joseph W. Lynch b,
Trent M. Woodruff a, Karin Borges a,⁎
a Department of Pharmacology, School of Biomedical Sciences, The University of Queensland, Skerman Building, St Lucia, Queensland 4072, Australia
b Queensland Brain Institute, The University of Queensland, St Lucia, Queensland 4072, Australia
c Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia⁎ Corresponding author at: Skerman Building, Schoo
University of Queensland, St Lucia Campus, Brisbane, Que
E-mail address: k.borges@uq.edu.au (K. Borges).
Available online on ScienceDirect (www.sciencedir
http://dx.doi.org/10.1016/j.nbd.2015.02.004
0969-9961/© 2015 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 October 2014
Revised 21 January 2015
Accepted 4 February 2015
Available online 11 February 2015
Keywords:
Anticonvulsant
Epilepsy
Seizure
Complement
C5a
C5ar1
PMX53
Status epilepticus
NeurodegenerationThe role of complement system-mediated inflammation is of key interest in seizure and epilepsy pathophysiol-
ogy, but its therapeutic potential has not yet been explored. We observed that the pro-inflammatory C5a
receptor, C5ar1, is upregulated in two mouse models after status epilepticus; the pilocarpine model and the
intrahippocampal kainate model. The C5ar1 antagonist, PMX53, was used to assess potential anticonvulsant ac-
tions of blocking this receptor pathway. PMX53was found to be anticonvulsant in several acutemodels (6Hz and
corneal kindling) and one chronic seizuremodel (intrahippocampal kainatemodel). The effects in the 6Hzmodel
were not found in C5ar1-deficient mice, or with an inactive PMX53 analogue suggesting that the anticonvulsant
effect of PMX53 is C5ar1-specific. In the pilocarpinemodel, inhibition or absence of C5ar1 during status epilepti-
cus lessened seizure power and protected hippocampal neurons from degeneration as well as halved SE-
associated mortality. C5ar1-deficiency during pilocarpine-induced status epilepticus also was accompanied
by attenuation of TNFα upregulation by microglia, suggesting that C5ar1 activation results in TNFα release
contributing to disease. Patch clamp studies showed that C5a-inducedmicroglial K+ outward currents were
also inhibitedwith PMX53 providing a potential mechanism to explain acute anticonvulsant effects. In conclusion,
our data indicate that C5ar1 activation plays a role in seizure initiation and severity, as well as neuronal degener-
ation following status epilepticus. Thewidespread anticonvulsant activity of PMX53 suggests that C5ar1 represents
a novel target for improved anti-epileptic drug development which may be beneficial for pharmaco-resistant
patients.
© 2015 Elsevier Inc. All rights reserved.Introduction
Epilepsy is a debilitating disease, especially if seizures cannot be
managed with medication. The global prevalence of treatment-
resistancewithin epileptic populations is approximately 35%, highlight-
ing the need for new anti-epileptic treatments effective for these
patients (Kwan et al., 2011).
A new approach different from existing anti-epileptic drug (AED)
mechanistic pathways is proposed, stemming from recent findings
relating inflammation with epilepsy (Vezzani et al., 2011). Anti-
inflammatory approaches to block seizures have already shown to be
effective, not only in rodent seizure models (Vezzani and Granata,l of Biomedical Sciences, The
ensland 4072, Australia.
ect.com).2005; Maroso et al., 2011) but also in selected drug-resistant patients
(Marchi et al., 2011) advocating inflammation as a key pharmacological
target to reduce seizures and modify the disease.
The complement cascade is a major component of the innate
immune system, and produces a potent inflammatory response when
activated (Amara et al., 2010). Recent evidence has linked complement
factor expression and activation with epilepsy and seizure develop-
ment. For example, gene expression studies demonstrated upregulation
of various complement factors in surgically removed tissue from
patients with temporal lobe epilepsy (TLE), and in rodent TLE models
(Becker et al., 2003; Gorter et al., 2006; Jamali et al., 2006; Aronica
et al., 2007). Increased immunoreactivity of multiple complement fac-
tors, such as C1q, C3, C4, and the membrane attack complex (MAC),
consisting of theC5b-9 complex, are documented on activatedmicroglia
and select neurons in brain tissue from TLE patients and rodent TLE
models (Aronica et al., 2007; Kharatishvili et al., 2014). The presence
of MAC strongly suggests complement cascade activation in “epileptic
tissue”, which includes C5a formation. Moreover, in untreated people
88 M.J. Benson et al. / Neurobiology of Disease 76 (2015) 87–97with epilepsy, significantly increased C3 serum levels were found com-
pared to healthy and epileptic control patients, indicating complement
involvement in seizures (Başaran et al., 1994).
There is also functional evidence that complement in the brain may
contribute to seizure generation. The presence of specific genetic poly-
morphisms in the C3 promoter region was significantly greater in mesial
TLE patients and correlated with increased febrile seizure susceptibility
(Jamali et al., 2010). In addition, sequential infusion of individual C5b-
C9 complement proteins into the rat hippocampus resulted in MAC im-
munoreactivity and induced seizures and neurodegeneration (Xiong
et al., 2003). Recently, it was also reported that C5a receptor (C5ar1) ex-
pression on microglia was upregulated following excitotoxic kainate in-
sult and is controlled by FosB, a mediator of transcriptional activator
AP-1 (Nomaru et al., 2014). Deletion of FosB, and hence lack of C5ar1 up-
regulation also reduced pro-inflammatory cytokine expression following
the insult. These studies provide evidence that complement presence
and/or activation in the brain can mediate changes relevant to seizure
generation and epilepsy pathophysiology.
In this study, we aimed to identify the therapeutic potential of
inhibiting complement-mediated inflammation using several epilepsy
models. We focussed on the complement peptide C5a, an inflammatory
mediator. It is produced from proteolytic cleavage of its precursor C5,
typically via C5 convertases formed fromC3 during complement cascade
activation. C5a is extremely potent at stimulating immune cell recruit-
ment and subsequent activation through its receptor C5ar1, and induces
production of pro-inflammatory cytokines and mediators (Woodruff
et al., 2010).
Here, we used the selective cyclic hexapeptide C5ar1 antagonist,
PMX53 (Wong et al., 1998; Finch et al., 1999) to assess the role of
C5ar1 activation in seizures and epilepsy pathophysiology. Binding stud-
ies have demonstrated that PMX53 binds to and inhibits C5ar1with high
affinity (~20 nM). Also, PMX53 did not alter the action of closely related
inflammatory mediators including fMet-Leu-Phe, leukotriene B4,
platelet-activating factor, C3a, or IL-8 (March et al., 2004). Furthermore,
it has been shown that PMX53 does not inhibit the binding of C5a to
the second, alternative C5a receptor, C5ar2 (Scola et al., 2007). Preclini-
cally PMX53 has been neuroprotective in several neurological disease
models, including Huntington's disease, amyotrophic lateral sclerosis,
traumatic brain injury, stroke, and spinal cord injury (Sewell et al.,
2004;Woodruff et al., 2006, 2008, 2010; Kim et al., 2008; Li et al., 2014).
We identified the effects of C5ar1 inhibition and absence in several
models of experimental epilepsy revealing that it may provide new av-
enues for AED discovery, specifically for pharmaco-resistant patients.
Materials & methods
Mice
8–10 week old male Swiss CD1 mice (Animal Resources Centre,
Western Australia) were singly housed with a 12 h light/dark cycle and
access to food and water ad libitum. Male C57BL/6 C5ar1-deficient mice
were bred into the CD1 background at The University of Queensland
(UQ). CD1 mice were obtained from Animal Resource Centre (Perth,
Australia). Initial C5ar1-deficient breeding pairs were obtained from
Trent Woodruff (UQ) and were originally described by Hollmann et al.
(2008). After five generational crosses, male mice were used. C5ar1-
deficiency was verified by standard PCR genotyping methods. All exper-
imentswere approved by theUQAnimal Ethics Committee and conduct-
ed in accordance with their guidelines. All experiments were performed
with experimenters blinded to treatment/genotype.
Drugs
PMX53 (AcF-[OP(D-Cha)WR]) and PMX203 (AcF-[OPGWR]) were
synthesized as described (Finch et al., 1999; Woodruff et al., 2005).
PMX53 was provided by Cephalon (Australia). After dissolving in3.75% ethanol (at 0.75 mg/ml), PMX53 was administered subcutane-
ously 30 min prior to seizure induction unless otherwise stated.
Liquid chromatography tandem mass spectrometry (LC–MS/MS)
Plasma and perfused whole brain samples were extracted as de-
scribed (Strachan et al., 2001). HPLC Grade acetonitrile and formic
acid (AR Grade) was purchased from RCI Labscan (Bangkok, Thailand)
and Labscan (Gliwice, Poland) respectively. Deionisedwater was gener-
ated via an Elga Purelab Classic water purification unit (Veolia Water
Solutions and Technologies, Saint-Maurice Cedex, France).
Liquid chromatography tandem mass spectrometry (LC–MS/MS)
data were acquired on a Dionex UltiMate 3000 liquid chromatography
system (Dionex, Sunnyvale, CA) coupled to an ABSciex 4000 QTRAP
mass spectrometer (ABSciex, Concord, Canada). The liquid chromatog-
raphy system was controlled by Chromeleon software (v6.80, Dionex),
and chromatographic separation was achieved by injecting 10 μl onto
a Gemini-NX C18 150 mm × 2 mm I.D., 3 μm 110 Å particle column
(Phenomenex, Aschaffenburg, Germany) equipped with a pre-column
Security Guard Gemini-NXC18 4mm×2mm I.D. cartridge. The column
oven temperaturewas controlled andmaintained at 60 °C throughout the
acquisition. The mobile phase flow rate was maintained at 300 μl/min
for 5 min and the mobile phase (isocratic) was 50:50 (v/v) purified
water:acetonitrile plus 0.1% (v/v) formic acid.
The mass spectrometer was controlled by Analyst software (v1.5.2,
ABSciex) andwas equippedwith a TurboV electrospray source operated
in positive ion mode. The following optimized parameters were used to
acquire Multiple Reaction Monitoring (MRM) data: ionspray voltage
5300 V, nebulizer (GS1), auxiliary (GS2), curtain (CUR) and collision
(CAD) gases were 40, 80, 15 and high (arbitrary units), respectively,
generated via a N300DR nitrogen generator (Peak Scientific, Massachu-
setts, USA). The auxiliary gas temperature was maintained at 420 °C.
The analyte-dependent parameters for the detection of PMX53 are
given in Table 1. For all analytes the entrance potential (EP) was 10 V.
The sampleswere runwith sample- and analyte-relevant calibration
standards and pooled QC samples (Sangster et al., 2006; Hodson et al.,
2009) to control for reproducibility of data acquisition and to ensure
data integrity. Analyte stock solutions were prepared in purified water
(Veolia). Data were processed and analysed in Analyst 1.5.2 and
MultiQuant 2.1 (ABSciex).
Animal seizure models
6 Hz test
0.5% tetracaine (Sigma Aldrich, Australia) in 0.9% saline was applied
to both corneas of the mice. Corneal electroshocks from a rodent elec-
troshock unit (Ugo Basile, Varese, Italy; 6 Hz, 3 s, 0.2millisecond rectan-
gular pulse width) were given starting at 14 mA (Samala et al., 2008).
Using the up down method we determined the critical current at
which 50% of mice seized (Thomas et al., 2012).
Corneal kindling model
Electroshocks (50 Hz, 0.4 millisecond pulse) to the tetracaine-
anaesthetised corneas were administered twice per day for 20 days
using a rodent electroshockunit (Ugo Basile). A single seizurewas expe-
rienced by each mouse as a result of a single kindling stimulus. Seizures
were scored as previously described (Willis et al., 2010).
Pilocarpine status epilepticus (SE) model
Based on the protocol described by Borges et al. (2003), mice were
injected with methyl-scopolamine (2.5 mg/kg i.p. in 0.9% NaCl) 15 min
prior to 345 mg/kg (s.c.) pilocarpine, which induced SE in N60% of
mice. Ninety minutes post-pilocarpine all mice received 30 mg/kg
(i.p.) pentobarbitone to stop seizures. Post-SE, mice received 1 ml 4%
dextrose twice daily (s.c.) and health was monitored (Smeland et al.,
2013). 3 days later animals were perfused and brains fixed with 4%
Table 1
Analyte-dependent parameters for the transitions used in Multiple Reaction Monitoring data acquisition.
Analyte Q1 mass (daltons) Q3 mass (daltons) Dwell time (milliseconds) DP (volts) CE (volts) CXP (volts)
PMX53 (quantifier) 896.2 69.9 50 151 129 2
PMX53 (qualifier 1) 896.2 158.9 50 151 89 8
PMX53 (qualifier 2) 896.2 223.4 50 151 87 12
Key: Q — quadrupole; DP— declustering potential; CE— collision energy; and CXP — collision cell exit potential.
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N1 week before recording (see i.h. kainate model).
Intrahippocampal (i.h.) kainate model
Based on the protocol described by Gouder et al. (2003), briefly,
micewere deeply anesthetised with 1.8% isofluranemixedwith oxygen
(Troylab, Glendenning, Australia). Eighty nanolitres of 20 mM kainic
acid (~1.7 nmol, Sigma Aldrich) was stereotaxically (Kopf, Tujunga,
California) injected unilaterally into the hippocampal CA1 pyramidal
cell layer (AP−1.94, ML−1.25, DV−1.5 from bregma) using a 0.1 μl
microsyringe (Hamilton, Reno, NV) attached to a 0.28 mm stainless
steel cannula via PE20 tubing (Plastics One, Roanoke, VA). After awak-
ening, mice underwent SE for a continuous period N3 h. Three weeks
later, a unilateral bipolar depth electrode (formed from two twisted
enamel-coated insulated stainless steel 170 μm diameter wires,
0.4 mm tip separation, Plastics One) was implanted stereotaxically
into the same site, along with 3 stainless steel surface screw electrodes
(1.2 mm diameter, Plastics One). Two were placed bilaterally 2.5 mm
posterior to the lambda and one was placed over the contralateral
(3 mm from midline) frontal cortex 1 mm posterior to bregma, to act
as ground and reference (including cortical reference) electrodes. Elec-
trode wires were mounted into a multichannel electrode pedestal
(MS363, Plastics One) and secured with dental cement. Mice recovered
for N1 week prior to EEG recordings.
Video electroencephalographic (EEG) recording of seizures
EEG was recorded with a sampling frequency of 512 Hz (E-Series
EEG system with Profusion 4 software, Compumedics, Melbourne,
Australia) and analysed using Labchart 8 custom seizure detection and
analysis software involving Matlab calculations (AD Instruments, Bella
Vista, Australia). Seizure detection involved six digital filtering steps
from raw EEG output and detected seizure events within the 6–12 Hz
bandwidth. All seizures were confirmed using parallel video recording
by a blinded experimenter. Seizure frequency is reported as the number
of seizure events per minute. Seizure power is defined as the signal in-
tensity of the EEG trace given in unit μV2 over a defined time period (a
seizure or SE). Seizure power was quantified using Labchart to calculate
the sum of the area under the curve based on EEG trace amplitude for
defined time periods (seizures/SE). This value gave power for an indi-
vidual seizure, which was then calculated for all seizures for each
mouse and averaged. Seizure power is reported as an average for each
individual animal normalized to baseline to compare treatment groups.
SE seizure power is reported as an average for each treatment group.
Typically pilocarpine-SE mice experienced severe clonic seizures
often including loss of balance, whilst kainate-SEmice experienced par-
tial forelimb clonuswith head bobbingmost commonly. However some
generalised seizures were also recorded in kainate-SE mice. Exclusion
criteria: seizures b10 s in length; mice with baseline changes of N50%
total seizure time between recording weeks.
Fluoro-Jade B (FJB) staining
Coronal 9 μm paraffin brain sections were stained as described
(Schmued and Hopkins, 2000). Degenerating cells were visualized on
an upright fluorescent microscope (Axio Imager, Zeiss, Jena, Germany)
and images captured for each slide at 20× magnification. For each ani-
mal three 9 μm sections of medial hippocampus were analysed. We av-
eraged FJB-positive cell number for each mouse based on automatedspot detection of all sections (including both hemispheres) using Imaris
software (BitPlane, Belfast, UK). Spots were automatically detected
based upon cell size, shape and fluorescence intensity andwere verified
for each slide by eye to ensure false-positives were not detected. The
total area of each region of the hippocampal formation in the 2D plane
was outlined in the programme and calculated in mm2. From this
count we then determined the total number of FJB-positive cells per
area (mm2) for each region of the hippocampal formation (CA1, CA3,
DG) for each individual mouse. Average values for a total group of
mice (n=14–20 per group) were then reported in Figs. 4i & j. NoSE an-
imals were used at conditional controls for all experiments.
Flow cytometry
Forebrain cells from two PBS-perfused mice were isolated and
pooled. Cells were incubated with a cocktail containing Alexa Fluor
488 — anti-C5ar1 (MCA2456A488, AbD Serotec), PE-Cyanine 7 — anti-
CD45 (25-0451, eBioscience), BD Horizon V450 — anti-Ly-6G (560603,
BD Bioscience) and non-conjugated anti-CD16/32 (16-0161,
eBioscience) for 20 min at 4 °C before fixation. For IL-1β and TNFα,
cells were pre-incubated for 3 h in RPMI medium containing β-
mercaptoethanol and Brefeldin A (1:1000) with 10% Foetal bovine
serum then incubated in antibody cocktail. Cells were fixed and
permeabilised prior to incubation with APC-conjugated — anti-IL-1β
(17-7114, eBioscience) or PE-conjugated — anti-TNFα (554419, BD
Pharmingen) for 45 min at RT. Cells were analysed using a BD LSRII
flowcytometer (BDBiosciences, San Jose, CA) andBD FACSDiva software.
Real-time quantitative polymerase chain reaction (qPCR)
Forebrains (pilocarpine) or hippocampus (kainate model) were dis-
sected from saline-perfused brains. After RNA extraction (RNAeasy
MiniPrep, Qiagen, Hilden, Germany), DNase I treatment (Promega,
Madison, Wisconsin) and determination of concentrations, cDNA was
synthesised (Tetro kit, Bioline, Alexandria, Australia). qPCRs were per-
formed with gene-specific primers spanning across an intron and SYBR
green reagents (Applied Biosystems, Foster City, CA) on a Viia7 machine
(Applied Biosystems) with Tata Box protein and hydroxymethylbilane
synthase as housekeeping genes and glyceraldehyde-3-phosphate dehy-
drogenase as control for DNA contamination.
Microglial cell culture
Briefly, forebrains were isolated from E17 CD1 mouse embryos
and the meninges removed. Tissue was digested with 0.5% trypsin
solution and then incubated with 1% trypsin inhibitor (Sigma Aldrich,
St. Louis, MO). Cells were dissociated via trituration and plated at
3 × 105 cells/ml density in poly-D-lysine (PDL) coated culture flasks
with 1:1 Dulbecco's modified Eagle's medium (DMEM) with Ham's
F12 nutrient containing 10% foetal bovine serum and antibiotics (peni-
cillin, streptomycin, 25 U/ml final). Mixed glial cells were cultured for
approximately 2 weeks until the underlying astrocyte layer was conflu-
ent, during which time frequent media changes occurred. No neurons
were present in this culture. At this time,microglial cells were separated
from astrocytes by shaking and allowed to adhere to PDL-coated glass
coverslipsmaintained inmacrophage serum-freemedium supplement-
ed with 20% astrocyte conditioned medium (DMEM cultured for 3 days
with astrocyte-only cultures and filtered). Isolated microglia were
maintained for 2 days prior to use in patch clamp experiments. All tissue
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Fig. 1. Levels of PMX53 in plasma and brain following PMX53 injection determined using
quantitative LC–MS/MS. (a) Plasma levels of PMX53 peaked 15 min post-injection
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brain tissue 96%. One way ANOVA with Bonferroni post-test was used for both data sets.
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Carlsbad, CA.
Patch clamping
The procedure was modified from Ilschner et al. (1996). Coverslips
were placed on the stage of an inverted microscope (CKX4ISF, Olympus
Ltd., Japan) and superfused with standard extracellular solution (KCl
5.4, NaCl 150, MgCl2 1, CaCl2 2, glucose 10, HEPES 10 at pH 7.3 adjusted
with KOH). Whole cell recordings were made using the patch-clamp
technique in the whole cell voltage clamp configuration using an Axon
Multiclamp 700B (Molecular Devices LLC, Sunnyvale, CA). Patch pi-
pettes were pulled from borosilicate glass (GC150F-7.5, Harvard Appa-
ratus, UK) with a vertical micropipette puller (PC10, Narishige, Japan).
The resistance of pipettes was 4–5 MΩ. The standard recording pipette
solution contained (in mM): KCl 130, CaCl2 1, MgCl2 1, EGTA 10 mM,
HEPES 10mM, ATP 2mMat pH 7.4 adjustedwith KOH. The series resis-
tance was compensated by 40–50% prior to recordings and cells were
held at−70 mV. When measuring potassium currents, voltage steps
with 35 mV increments were applied for 100 ms from a holding
potential of 0 mV in both depolarising and hyperpolarising directions.
Currents were digitized at 10 kHz and filtered at 2 kHz. Mouse recombi-
nant C5a (20 nM, R&D systems,Minneapolis,MN) and PMX53 (100nM)
were applied via a continuous gravity perfusion system.
Statistical analysis
Statistical tests completed using GraphPad Prism 6.0 software (La
Jolla, CA) are detailed for each data set in the results. Post-hoc
Bonferroni multiple comparisons test was used for all ANOVA analysis.
Results
C5ar1 antagonist, PMX53, reached the CNS in levels equivalent to the IC50
LC–MS/MS analysis of plasma and brain tissue after PMX53 injection
(3mg/kg, s.c.) showed that circulating PMX53 levelswere highest at the
measurement timepoint 15min post-injection at 432 ng/ml (~480 nM)
and were rapidly depleted by 90 min (Fig. 1a), with no drug detectable
in the plasma or brain after 4 h (data not shown). 15 ng/g of PMX53was
found in perfused brain tissue at 30 min post-injection, equating to ap-
proximately 20 nM in brain extracellular fluid, the IC50 for the drug at
the C5a receptor (Finch et al., 1999) (Fig. 1b). This pharmacokinetic pro-
file correlates well with the protective effects described below, as
maximal anticonvulsant action in the 6 Hz test was observed 30 min
post-administration, when the IC50 of PMX53 was present, which was
diminished by 20% 60 min post-administration and absent after
90 min (data not shown). For this reason the 30 minute timepoint
was chosen as the optimal pre-treatment timeframe for further
PMX53 anticonvulsant experiments.
PMX53 significantly reduces electroencephalographic spontaneous seizures
in the chronic i.h. kainate epilepsy model
Significant improvements in seizure behaviour were found with
single PMX53 administration (s.c.) to chronically epileptic mice in the
intrahippocampal kainatemodel compared to vehicle. In a paired cross-
over design, each animal was injected with PMX53 and vehicle one
week apart, with half of the group receiving PMX53 first. Seizure behav-
iour during a 90 minute period following injection was evaluated rela-
tive to a 90 minute baseline recorded before treatment (Figs. 2a, b). A
58% reduction in the total time spent in seizure, as well as a 22% reduc-
tion in average seizure power was found with PMX53 treatment, rela-
tive to vehicle injection (Figs. 2c, d). Decreased seizure frequencies
were seen with PMX53 treatment in the majority of mice (Fig. 2e),
but no significant changes to average seizure length were observed be-
tween treatments (Fig. 2f).At both 3 and 21 days post-kainate-induced SE, we observed signif-
icant increases in hippocampal mRNA levels of C5ar1 and C3, central
components of the complement cascade, suggesting a consistent pres-
ence of complement components throughout the epileptogenic period.
Relative to vehicle-injected control mice, mRNA levels of C5ar1were in-
creased by 4 and 1.7 fold and those of C3 by 2.4 and 3.6 fold, respectively
(Fig. 2g). Additionally, C3mRNA, but not C5ar1, was also increased by 4
fold at the chronic 12 month timepoint post-SE compared to vehicle-
injected control mice, inferring upregulation of complement once sei-
zures were established (Fig. 2h).
PMX53 is anticonvulsant in a model predisposed to seizures and shows
C5ar1-dependent anticonvulsant effects in the 6 Hzmodel of acute seizures
In the predisposed seizure model, mice were stimulated through
their anesthetised corneas until 5 consecutive stage 5 seizures were ex-
perienced from 5 independent kindling stimuli, at which time they
were considered to be “fully kindled” (Fig. 3a). Thirty minutes before
the next kindling stimulus mice were injected with PMX53 (3 mg/kg,
s.c.) or vehicle. 50% less of the PMX53-treated mice experienced stage
5 seizures compared to the vehicle-treated mice, showing an anticon-
vulsant effect of PMX53 in this model (Fig. 3b).
In the acute 6 Hz seizure model the effect of PMX53 was maximal
30 min after a single injection (3 mg/kg, s.c.) and lost after 90 min (data
not shown). The current atwhich 50% ofmice seize (CC50)was increased
on average by 6.6 mA± 1.6 relative to vehicle-injected mice (Fig. 3c).
To determine if this anticonvulsant effect in the 6 Hz model (Fig. 3c)
was C5ar1-dependent,we injected inparallel, an inert structural analogue
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91M.J. Benson et al. / Neurobiology of Disease 76 (2015) 87–97of PMX53, where glycine is substituted for D-cyclohexylalanine
(PMX203). In contrast to PMX53, no changes in seizure threshold were
seen with this inert compound (Fig. 3d). Additionally, the effect of
PMX53 was tested in C5ar1-deficient mice. PMX53 again elevated the
seizure threshold in C5ar1 wild type mice by 6.1 mA, but no significant
protective effects were found in C5ar1-deficient and heterozygous mice
(Fig. 3e). Interestingly, lack of C5ar1 expression alone did not alter the sei-
zure threshold in a statistically significant manner (Fig. 3e), suggesting
that other molecules compensate for the lack of C5ar1 in these animals.
Together, these results support that functional C5ar1 is necessary for the
anticonvulsant effect of PMX53 in the 6 Hz model.No effects were seen with PMX53 in either the intravenous pentyl-
enetetrazol (PTZ) or maximal electroshock threshold mouse seizure
tests at the same dosage and timepoint (data not shown). Lack of effect
in the PTZ model may suggest that acute anticonvulsant action of
PMX53 is not through a GABAA receptor related mechanism.
PMX53 is anti-convulsant in the pilocarpine model of SE leading to
subsequently reduced hippocampal neuronal damage
The effect of PMX53 on SEwas determined in the pilocarpinemodel.
Injection of PMX53 30 min after pilocarpine administration halved SE-
ac d e
b
Fig. 3. Anticonvulsant effects of PMX53 in two seizure models; the corneal kindlingmodel and the 6 Hz acute seizure model. (a) Overview of corneal kindling paradigmwith median sei-
zure score shown for total group (n = 30). (b) 30 min pre-treatment with PMX53 reduced the number of mice with stage 5 seizures by 50% compared to vehicle-injected mice
(****P b 0.0001, n= 15, Fisher's exact test). (c) In the 6 Hz acute seizure model PMX53 pre-treatment significantly increased the critical current at which 50% of the mice seize (CC50)
by 6.6 mA (~35%) compared to vehicle (***P= 0.0003, n= 17, student's t-test). (d) Whilst PMX53 increased the CC50 (*P= 0.0063, n= 15, one-way ANOVA with P b 0.05 Bonferroni
post-test), the inert structural analogue PMX203 did not in the 6 Hzmodel. (e) There was a lack of effect of PMX53 in C5ar1-deficient and heterozygotemice in the 6 Hzmodel, whilst the
CC50 was increased by 6.1 mA in C5ar1-wild type mice (*P b 0.05, n= 14, 2-way ANOVA with Bonferroni post-test). Data expressed as mean ± SEM.
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enced SE, defined as a period of continuous seizure activity lasting
N30 min (Fig. 4b), corroborating the anticonvulsant efficacy of PMX53.
When injecting PMX53 15 min prior to pilocarpine (Figs. 4c, d), we
could not detect any significant changes in the time to the first seizure
or SE induction (Figs. 4e, f). However, there was a N70% decrease in
overall SE seizure power evaluated by EEG in PMX53-treated mice
(Fig. 4g). Hippocampal neuronal damage was assessed 3 days post-SE
using Fluoro-Jade B (FJB) as a marker for degenerating neurons
(Fig. 4h). PMX53 treatment prior to SE reduced the number of FJB-
positive cells in both the CA1 and CA3 pyramidal areas, by 50% and
75% respectively, but not in the hilus (Fig. 4i). Comparison of C5ar1-
deficient vs.wild typemice 3 days after pilocarpine-induced SE revealed
a significant 40% reduction in FJB-positive cells in the CA3 region inmice
lacking the C5ar1 gene (Fig. 4j). No significant differences were seen in
the CA1 region or the hilus between the different genotypes, indicating
inflammation-independent cell death mechanisms.
Three days post-SE, we found an 18 fold rise in hippocampal C5ar1
mRNA levels relative to NoSE control mice (Fig. 4k) and a 27 fold in-
crease in C5ar1-immuno-positive microglia, confirming that C5ar1
mRNA is expressed in the post-SE brain at elevated levels indicating a
potential role in epileptogenesis (Fig. 4l).
Absence of C5ar1 in the pilocarpine SE model attenuates TNFα increases in
microglia
Microglial-specific expression of cytokines TNFα and IL-1β was
assessed 3 days post-pilocarpine SE in C5ar1-deficient and wild type
mice. Initial experiments with C5ar1-deficient mice in the pilocarpine
model showed no differences fromwild type in SE-associatedmortality,
proportion ofmice undergoing SE vs. NoSE or seizure score severity dur-
ing SE (scored by a modified Racine scale, data not shown).
Proportions of microglia (CD45-intermediate) and infiltrating im-
mune cells (CD45-high) were consistent between genotypes of both
SE and NoSE mice (Figs. 5a, b). C5ar1-deficient animals showed com-
plete attenuation of TNFα protein increase compared to wild type SEanimals (Fig. 5c). No significant differences of IL-1β expression on mi-
croglia were observed between genotypes (Fig. 5d). Similarly, changes
to IL-6, IL-12 and IL-10 following acute pilocarpine-SE were not differ-
ent between C5ar1-deficient and wild type mice (data not shown).
PMX53 inhibits C5a-induced outward K+ currents in cultured microglial
cells
To activate voltage-gated currents in cultured embryonic-derived
forebrain microglial cells, the membrane potential was stepped from a
potential of 0 mV to membrane potentials from−70 to +140 mV at
35 mV intervals (Figs. 6a, b, c). In the absence of C5a, hyperpolarising
steps activated an inwardly rectifyingK+ current however, after C5a ap-
plication outward currents at depolarising potentials were significantly
increased (Fig. 6d) consistent with the findings of Ilschner et al. (1996).
Pre-application of PMX53 (100 nM) prior to C5a applications selectively
inhibited the outward C5a-induced currents with no significant differ-
ences found between control and PMX53-pre-treated cells (Fig. 6d).
Discussion
In these studies we have shown the therapeutic potential for the in-
hibition of the innate immune complement receptor C5ar1 as a novel
anticonvulsant pathway with possible association to neuroprotective
effects.
The ability of PMX53 to significantly increase seizure thresholds and
reduce spontaneous recurrent seizures in several murine seizure
models suggests that C5ar1 has an important influence on seizures
and that C5ar1 inhibitionmay be a viable strategy to reduce seizure bur-
den in several types of epilepsy. In addition, the increased expression of
this receptor atmRNA and protein levels in two chronic epilepsymodels
is consistent with previous literature (Osaka et al., 1999; Nomaru et al.,
2014) and further supports its involvement in epilepsy.
Given the dual efficacy of PMX53 as an anticonvulsant against both
acute (6 Hz and pilocarpine models) and chronic seizures (i.h. kainate,
kindled mice), it is suggested that there may be several mechanisms
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93M.J. Benson et al. / Neurobiology of Disease 76 (2015) 87–97of action by which PMX53 can exert its anticonvulsant and potential
neuroprotective effects. Primarily, inhibition of inflammationwould ex-
plain actions against both chronic seizures (i.h. kainate and potentially
kindled mice) and acute neuronal death (pilocarpine model). However
acute anticonvulsant actions in healthy mice are difficult to explain as-
suming lack of inflammation in the normal brain. It is currently not pos-
sible to deduce a definitive mechanism of action from the
anticonvulsant profile of a drug, due to the fact that drugs with different
mechanisms of action are effective in specific models, indicating that
numerous anti-epileptic approaches can block seizures in these animal
models. The anticonvulsant profile of PMX53 is similar to that oflevetiracetam (Klitgaard et al., 1998), which binds to the synaptic pro-
tein SV2a, but in addition is postulated to act via other mechanisms.
Lack of effects in the PTZ and MEST models suggest mechanisms of ac-
tion independent from GABAA receptors and sodium channels. The i.h.
kainate model (Wilcox et al., 2013) is resistant to major AEDs, which
all inhibit voltage-gated sodium channels. Efficacy of PMX53 in this
model therefore advocates that C5ar1 inhibitionwith PMX53may be ef-
fective against refractory seizures, independent from sodium channel
inactivation and GABAA receptors. Assessment of the impact of PMX53
against chronic seizures in the pilocarpine model, which are known to
be more refractory to benzodiazepines, would also be of interest should
a b
c d
250K
200K
150K
100K
50K
0
100 101 102 103 104 105
250K
200K
150K
100K
50K
0
100 101 102 103 104 105
250K
200K
150K
100K
50K
0
100 101 102 103 104 105
250K
200K
150K
100K
50K
0
100 101 102 103 104 105
Fig. 5. C5ar1-deficiency leads to reduced TNFα expression onmicroglia 3 days post-pilocarpine SE. (a, b) Representative gating of CD45 positive cells as either CD45-intermediate (microg-
lia) or CD45-high (infiltrating immune cells) by flow cytometry. Both microglial and infiltrating cell populations were consistent in number between genotypes, in both NoSE (a) and SE
(b) mice. Values indicate proportion of cell total within each gate. SEmice show a greater proportion of infiltrating cells due to BBB breakdown. (c)Microglial specific expression of TNFα
was increased in wild type SE animals compared to NoSE controls (****P b 0.0001, n= 6) measured by flow cytometry, however C5ar1-deficient SE mice showed a non-significant TNFα
expression increase compared to NoSE controls (P N 0.05, n= 6). (d) Microglial expression of IL-1βwas increased in SE mice compared to NoSE controls of both wild type (***P b 0.001,
n= 6) and C5ar1-deficient mice (*P b 0.05, n= 6). No significant differences between NoSE or SE groups between each genotype were observed (P N 0.05, n= 6). 2-way ANOVA with
Bonferroni post-tests used for all data sets. Data expressed as mean ± SEM, normalised to naïve control animals of each respective genotype.
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seizures such as this would further support C5ar1 inhibition as a novel
anticonvulsant pathway.
Based on the premise that seizures cause inflammation that potenti-
ate further seizures (Vezzani et al., 2011), we suggest that C5ar1 antag-
onism reduces inflammation leading to fewer seizures in the chronic
phase. C5ar1 inhibition or absence can reduce the generation of pro-
inflammatory cytokines such as TNFα and IL-1β (Lappas et al., 2012),
which are known to be pro-convulsant (Vezzani et al., 1999, 2000;
Riazi et al., 2008), and we propose a similar mechanism in this study.
This effect on inflammation is consistent with our finding that C5ar1 is
expressed on microglial cells and that 1) PMX53 reduces C5a-induced
outward potassium currents and 2) C5ar1 absence leads to attenuation
of SE-induced microglial TNFα upregulation, indicating that C5ar1-
mediated release of microglial TNFα and/or potassium may be a con-
tributor to seizures and subsequent neuronal damage. Furthermore, it
has been shown in several cell types, including macrophages and
dendritic cells, that C5a/C5ar1 activation drives production of pro-
inflammatory cytokines, such as TNFα and IL-1β, through NFκB activa-
tion (O'Barr and Cooper, 2000; Kastl et al., 2006; Lappas et al., 2012).
TNFα is a key pro-inflammatory and pro-convulsant mediator
(Balosso et al., 2013). Microglial specific expression of TNFα induced
by peripheral inflammation caused a significant decrease in seizure
thresholds of rats in the i.v. PTZ seizure test (Riazi et al., 2008). Themechanisms by which TNFα can affect brain excitability have been
well studied and include promotion of increased synaptic AMPA recep-
tor availability (Beattle et al., 2002), endocytosis of GABAA receptors
(Stellwagen et al., 2005) and alterations to glutamate uptake and re-
lease by glia through CXCR4 signalling (Bezzi et al., 2001).
Furthermore, there is extensive evidence that inhibition of IL-1β is
anticonvulsant and neuroprotective in rodent models and that C5ar1
can drive IL-1β expression through the NFκB pathway (Lappas et al.,
2012). Direct effects of IL-1β on neuronal excitation, via activation of
Src kinase, causing NMDA receptor activation were shown leading to
calcium flux into neuronal cells promoting excitotoxicity and seizures
(Viviani et al., 2003; Balosso et al., 2008). Similar to TNFα, IL-1β is also
thought to affect excitability through inhibition of glutamate uptake
by astrocytes (Hu et al., 2000). Even though no changes to IL-1β levels
were observed in C5ar1-deficient compared to wild type post-SE mice,
it is possible that this cytokine is still playing a role in earlier and/or
later stage inflammatory events promoting excitation, which may be
mediated in part by C5ar1.
Reduction of C5ar1-mediatedNFκB signallingmay also contribute to
potential neuroprotection, as seen in the pilocarpine-SE model. In addi-
tion to the decreased SE seizure power foundwith PMX53, reduction of
NFκB signalling would improve neuronal survival as inflammation is
thought to contribute significantly to neuronal death. This is due to pro-
duction of pro-inflammatory cytokines, such as IL-1β and TNFα, which
ac d
b
Fig. 6. C5a application induced outward rectifyingK+ currents inmousemicroglial cells whichwas inhibited by PMX53. (a) Inwardly rectifying K+ currents recorded from amicroglial cell
without stimulation by C5a. During this time, the holding potential was 0 mV and voltage steps of 100 ms duration to potentials from−70 to +140 mV with a 35 mV increment were
applied. The stimulation protocol is presented in the inset. (b) Recording from the same cell after 20 nM C5a application. (c) Current trace from the same cell pre-applied with PMX
(100 nM) followed by C5a application (20 nM). (d) Averaged current–voltage curves. C5a (squares) at 20 nM exhibited a significant increase (*P b 0.05, n=4) in outward rectifying cur-
rents as compared to control (circles). Pre-application of PMX53 (100 nM, diamonds) inhibited the C5a-induced outward current inmicroglia (P N 0.05 as compared to C5a-only and con-
trol stimulations). PMX53 application had no effect on baseline current (triangle). One way ANOVA with Bonferroni post-hoc multiple comparisons test used for analysis. Data shown as
mean ± SEM (n= 4–5 cells per group).
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2006). It must be made clear however, that reduced neuronal death in
PMX53-treated mice following pilocarpine-SE can be attributed to the
anticonvulsant actions of PMX53, however this same statement does
not hold true for C5ar1-deficient mice which showed no difference in
SE or seizure severity compared towild typemice followingpilocarpine.
Lack of altered SE in C5ar1-deficientmice is consistentwith results from
the 6 Hz study showing that vehicle-treated C5ar1-deficient and wild
type mice had consistent seizure thresholds (CC50) therefore C5ar1-
deficiency alone did not alter seizure response. For this reason reduced
neuronal damage in C5ar1-deficient mice following pilocarpine may be
attributed to a neuroprotective role of inhibiting C5ar1 and not due to
anticonvulsant actions. The putative neuroprotective mechanism of
C5ar1 inhibition during SE suggested here is similar to that found in sev-
eral disease models (Woodruff et al., 2010), and may also be related to
improved preservation of the blood brain barrier during prolonged
seizures.
In rodents, SE is known to harm the integrity of the blood brain bar-
rier. Also, the extent of blood brain barrier damage, induced by seizures
or mannitol treatment, correlated positively with increased spontane-
ous and induced seizures (Van Vliet et al., 2007; Fabene et al., 2008).
PMX53 was previously shown to block NFκB translocation to the nucle-
us in mouse brain microvascular endothelial cells treated with mouse
serum containing high levels of endogenous C5a (Jacob et al., 2011).
This prevented transcription of inflammatory mediators, maintained
expression of ZO-1, a key tight junction scaffolding protein of the
blood brain barrier, and reduced caspase-3 activity of endothelial cells
thereby decreasing apoptosis and improving blood brain barrier integri-
ty (Jacob et al., 2011). These findings collectively signal that C5ar1 inhi-
bition may contribute to preserving blood brain barrier integrity during
SE, thus reducing SE severity aswell as neuronal damage and potentiallylessening spontaneous seizure development and/or improving disease
outcomes. The latter outcomes still need to be investigated.
Additionally, the effect of C5ar1 activation on neurons is of interest
in regards to the reduced neuronal loss in CA1 and CA3 seen with
C5ar1 inhibition or absence prior to pilocarpine SE. C5a treatment of cul-
tured murine neurons was shown to induce apoptosis, which was re-
duced with PMX53 pre-treatment and C5ar1-deficiency (Pavlovski
et al., 2012). Despite the difficulty to assess the extent towhich contam-
inating microglia and astrocytes contributed to these effects, these data
confirm that C5ar1 inhibition is beneficial to neuronal survival and
hence may suggest a neuroprotective contribution of inhibiting C5ar1
signalling in the pilocarpine model, which is in addition to reduced sei-
zures via anticonvulsant mechanisms. In order to fully define and con-
firm neuroprotective potential of C5ar1 inhibition, treatment with
PMX53 following termination of pilocarpine-SE would be required.
Such experiments are planned in the future.
The anticonvulsant mechanism of PMX53 in the acute 6 Hz seizure
model may seem difficult to explain due to the expected lack of inflam-
mation in the animals. However, neuro-modulatory actions of IL-1β and
TNFα in normal brain have been previously reviewed (Vitkovic et al.,
2000). Similar to our data with C5ar1 inhibition, blockade of IL-1β
actions either through direct receptor antagonism (anti-IL-1ra) or inhi-
bition of caspase-1 (the interleukin-converting enzyme) was anticon-
vulsant in both the acute bicuculline and kainic acid rodent models of
acute seizures (Vezzani et al., 1999, 2000), aswell as in chronic epilepsy
models (Vezzani et al., 2000;Maroso et al., 2011). This reveals that acute
cytokine inhibition in normal brain can reduce excitability and increase
seizure thresholds (Vitkovic et al., 2000).
An additional potential anticonvulsant mechanism to explain ac-
tions of PMX53 in acute seizure tests is related specifically to C5ar1
expressed by microglia. In microglia, C5a can stimulate outward
Fig. 7. A proposedmechanism of C5ar1 involvement in seizure initiation and neuronal hyper-excitability and damage. Increases in C5a driven by seizures or status epilepticus (SE) lead to
C5ar1 activation which modulates multiple pathways affecting neuronal hyper-excitability and damage. These pathways include NFκB-mediated production of pro-inflammatory cyto-
kines including TNFα, IL-1β and IL-6, which have each been shown to have proconvulsant actions in a variety of seizure models. C5ar1 activation is also known to affect all brain cell
types and causes apoptosis in neurons, changes K+ channel outflow inmicroglia and potentially indirectly impairs glutamate uptake and release in astrocytes through TNFα. Additionally,
deleterious effects of C5ar1 activation in endothelial cells alter BBB integrity potentially leading to increased inflammatory cell infiltration, perpetuating further CNS inflammation. We
propose that inhibition of C5ar1 reduces the extent of inflammation and lessens neuronal hyper-excitability and subsequent excitotoxic damage through some of these mechanistic
pathways.
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which may contribute to neuronal excitation if microglia are in close
proximity to neuronal membranes, that are highly sensitive to
depolarisation. PMX53 was shown to inhibit this outward current
therefore preventing destabilisation of extracellular K+ homeostasis
and potentially providing a possible explanation as to how PMX53 can
increase acute seizure thresholds.
Clinically PMX53 has previously been trialled as a dermal cream for
inflammatory psoriasis and as an oral treatment for chronic rheumatoid
arthritis (Ji et al., 2002; Koehl, 2006). In both trials, PMX53 passed safety
and tolerability barriers, with apparent efficacy in the psoriasis, but not
rheumatoid arthritis study (Koehl, 2006; Vergunst et al., 2007). These
data support that chronic C5ar1 antagonism is not deleterious in itself,
which is key for future drug development. Furthermore, a C5a antibody,
Eculizumab, is currently used in the clinic for a rare immunological con-
dition, paroxysmal nocturnal hemoglobinuria (Hillmen et al., 2006),
further supporting that C5ar1 pathway inhibition is safe. However,
due to the short half-life of PMX53, newer brain-permeable C5ar1 in-
hibitors with an improved pharmacokinetic profile would need to be
developed.Conclusions
In conclusion, this work has demonstrated a pathogenic role of com-
plement C5ar1 signalling in seizure initiation and severity as well as SE-
induced neuronal degeneration. From these studies the definitive
mechanisms of anticonvulsant action for PMX53 are still unclear. How-
ever, this work has outlined that inflammatory cytokine expression and
modulation of microglial potassium channels are affected by C5ar1 ab-
sence or inhibition by PMX53 and may be part of a larger mechanism
of action (Fig. 7). Given the efficacy of PMX53 in refractory seizure
models, ourfindings provide a novel target for future AED development,
which may be effective for pharmaco-resistant seizure types.Acknowledgments
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SUMMARY
Objective: To characterize the changes in microglial proinflammatory M1 and antiin-
flammatory M2 marker expression during epileptogenesis in the chronic pilocarpine
and intrahippocampal kainatemodels.
Methods: M1-activated microglia express proinflammatory cytokines driving infiltra-
tion of cells, whereas M2-activated microglia are more reparative, promoting phago-
cytosis of debris and expression of proteins associated with cellular stability and repair.
Microglial markers were characterized as acute (3 days after status epilepticus [SE]),
early chronic (21 days post-SE), and late chronic epileptic (5–12 months post-SE) time
points. Following pilocarpine-SE, microglial markers were assessed by flow cytometry.
Quantitative real-time polymerase chain reaction (RT-PCR) was used to measure
messenger RNA (mRNA) levels of selected M1 (interleukin [IL] 1b, tumor necrosis
factor a [TNFa] cluster of differentiation [CD],CD16, and CD86), interleukin-6 [IL-6],
interleukin-12 [IL-12], Fc receptors 16, and CD86) and M2 (arginase 1 [Arg1], chiti-
nase-3-like protein [Ym1], found in inflammatory zone [FIZZ-1] [FIZZ-1], mannose
receptor C type-1 [CD206], interleukin-4 [IL-4], and interleukin-10 (IL-10)) markers
in both models. Video–electroencephalography (EEG) recordings were used to quan-
tify late chronic seizure frequency.
Results: Three days post-SE microglia in the pilocarpine model expressed M1 and M2
markers, but only M1 markers were upregulated after kainate-induced SE. After
3 weeks, M1/M2 marker expression was largely ablated in the hippocampal formation
of both models. Small mRNA level increases of CD11b, glial fibrillary acidic protein
(GFAP), and IL-1b were found in the pilocarpine model, consistent with IL-1b contrib-
uting to spontaneous seizures, whereas mRNA levels of TNFa and Ym1 were
decreased. In the late chronic phase, some M1/M2 markers, IL-1b, TNFa, Arg1, Ym1,
and CD206, resurged in the kainate, but not pilocarpinemodel, which may reflect and/
or contribute to highly frequent seizures in kainate-SEmice.
Significance: The common M1 upregulation acutely post-SE may signal a role early in
epileptogenesis, with a more pure “inflamed” central nervous system state after
kainate-SE, potentially contributing to the development of more frequent seizures.
The difference may also be due to the contribution of peripheral inflammation after
pilocarpine injection. In summary, the microglial inflammatory response during epile-
ptogenesis is complex, varies between models, and appears to correlate with chronic
seizure frequency.
KEY WORDS: Inflammation, Cytokine, Seizure, Pilocarpine, Kainate, Status
epilepticus.
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FULL-LENGTHORIGINALRESEARCH
Microglia are the resident immunomodulatory cells
within the central nervous system (CNS), which regulate
processes associated with innate and adaptive immune
response including phagocytosis, cell migration, antigen
presentation, cell proliferation, and cytokine production.1
To perform their diverse functions they can adopt several
activation states, which can be condensed into the classical
M1 or alternative M2 phenotypes as in macrophages.2
M1-polarized cells are more inflammatory in nature,
expressing proinflammatory cytokines such as tumor necro-
sis factor a (TNFa) and interleukin (IL) 1b, as well as key
phagocytic markers including Fc receptor cluster of differ-
entiation (CD)16.3 Conversely, M2-polarized microglia are
suggested to be reparative and neuroprotective in nature,
expressing enzymes associated with cellular integrity and
scaffolding such as chitinase-3-like protein (Ym1) and
arginase 1 (Arg1), as well as anti-inflammatory cytokines
interleukin-4 (IL-4) and interleukin-10 (IL-10).4 Microglia
have been shown to express both M1 and M2 markers
simultaneously, indicating a spectrum of cell polarization.5
M1/M2 marker expression varies in other CNS diseases
such as stroke6 and spinal cord injury,7 but is still unex-
plored during epileptogenesis. Characterization of specific
microglial gene expression will broaden our understanding
of microglial roles in epileptogenesis and seizure
generation.
Microglial activation has been found in brain tissue from
rodent epilepsy models and human patients; however, our
understanding about the role of microglia in epilepsy is still
limited. Activated microglia are present in as little as 8 h
following initial epileptic insult8 and are typically located
within the hippocampal Cornu Ammonis (CA)1 and CA3
areas,9–11 known locations of reorganization leading to
hyperexcitability and seizure generation.12 In addition,
functional changes to microglial cells were shown, such as
upregulation of purinergic receptors, which enhanced puri-
nergic signaling and cell process motility,9 potentially facil-
itating excitation. In resected human epileptic tissue,
activated human leukocyte antigen (HLA)-DR- and CD68-
immunopositive microglia were found.13,14 Patients with
temporal lobe epilepsy (TLE) and hippocampal sclerosis,
many of which do not respond to antiepileptic medications,
commonly show activated microglia with a high prevalence
in the hippocampus.15,16
It has been shown previously that proinflammatory cyto-
kines TNFa, IL-1b, and interleukin-6 (IL-6), which are lar-
gely produced by microglia in the epileptic brain, are
proconvulsant in several seizure models.17–20 In addition,
anti-inflammatory treatments, including specific inhibition
of IL-1b, have been shown to be anti-convulsant in rodent
models21,22 and in some children with drug-resistant epi-
lepsy.23
Here we have utilized two epilepsy models, inducing sta-
tus epilepticus (SE) using injection of subcutaneous pilocar-
pine11 and intrahippocampal (i.h.) kainic acid.24 In both
models, maximal neuronal death is observed acutely post-
SE (~3 days) and spontaneous recurrent seizures present
within the following weeks.25,26 Both models are effective
for the study of TLE, as they replicate key characteristics
present in the human condition, including spontaneous
seizures, depressive behavior; neuronal cell death, especially
in the hippocampus and dentate hilar area; gliosis, mossy
fiber spouting; and granule cell dispersion.26 In addition,
the chronic seizures in the i.h. kainate model are largely
resistant to antiepileptic drugs acting at sodium channels.27
Peripheral inflammation is present after pilocarpine
injection,28 which is similar to many human epileptogenic
insults, such as febrile seizures and viral infections.
This study aims to determine the activation state of
microglia at different stages of the epilepsy disease process
by measurement of classical M1 and alternative M2markers
at both mRNA and protein levels. We found complex altera-
tions in M1 and M2 phenotypes, which differ between the
two models.
Methods
Mice
Male Swiss CD1 outbred mice were purchased from
Animal Resources Centre (Canning Vale, WA, Australia)
and used between 8 and 10 weeks of age. Animals were
singly housed and maintained on a 12 h light/dark cycle and
allowed food and water ad libitum. All experiments were
approved by The University of Queensland Animal Ethics
Committee and conducted in accordance with their
guidelines.
Intrahippocampal (i.h.) kainate model
Mice were deeply anesthetized and similar to a previous
study,26 80 nl of 20 mM kainic acid (~1.7 nmol; Sigma
Aldrich, St. Louis, MO, U.S.A.) was stereotaxically
injected unilaterally into the CA1 pyramidal cell layer of
the hippocampus (anteroposterior [AP] 1.94, mediolater-
al [ML] 1.25, dorsoventral [DV] 1.5 from bregma).
Upon awakening, mice underwent SE for a continuous per-
iod >3 h and were scored intermittently using a modified
Racine scale.11 Mice averaged a score of between 2 and 3
for the majority of SE, with intermittent stage 4 and 5 sei-
zures. Mortality during SE was 10%. Two weeks later, a
unilateral bipolar depth electrode (Plastics One, Roanoke,
VA, U.S.A) was implanted stereotaxically into the same
CA1 site along with three surface screws to act as ground
and reference electrodes (Plastics One). Electrode wires
were mounted into a multichannel electrode pedestal (Plas-
tics One) and secured with dental cement. Mice recovered
for >1 week prior to electroencephalography (EEG)
recordings to determine seizure presence/frequency
(≥3 weeks post-SE). More detail is provided in Data S1.
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Pilocarpine-induced model
As described previously,29 mice were administered
methyl scopolamine (2.5 mg/kg, i.p.) prior to injection of
345 mg/kg (s.c.) pilocarpine. Ninety minutes after pilocar-
pine, mice were given 30 mg/kg (i.p.) pentobarbitone to
stop SE. No-SE animals were used as controls, in addition
to naive control animals. A subset of animals were
implanted with hippocampal (CA1) and surface recording
electrodes 1 week prior to SE (see i.h. kainate). Spontane-
ous recurrent seizures developed in SE animals and were
recorded using EEG by 3 weeks post-SE. More detail is pro-
vided in Data S1.
Electroencephalography (EEG) recordings
Video-EEG recordings were obtained in mice for a
continuous period of 24 h on a 12 h light/dark cycle with free
access to food and water during the recording period. EEG
was recorded using Compumedics E-series EEG system
with Profusion 4 software (Compumedics, Melbourne, Vic.,
Australia) at a 512 Hz sampling frequency and analyzed
using Labchart 8 seizure detection and analysis software
with accompanying video, which detected seizure events
within 6–12 Hz bandwidth (AD Instruments, Bella Vista,
NSW, Australia). We excluded ictal events of <10 s
duration.
Quantitative real-time polymerase chain reaction
(RT-PCR)
Hippocampal formations and cerebral cortices were sepa-
rated in saline-perfused brain samples and immediately fro-
zen on dry ice. RNA extraction was carried out using the
Qiagen RNAeasy MiniPrep kit according to manufacturer’s
instructions (Qiagen, Limburg, The Netherlands). DNase
treatment was carried out using Promega DNase kit (Pro-
mega, Madison, WI, U.S.A.) and mRNA concentrations
were determined using NanoDrop (Thermo Scientific, Wil-
mington, DE, U.S.A.). complementary DNA (cDNA) syn-
thesis was performed using the Tetro kit (Bioline, London,
United Kingdom). All RT-PCR was completed using SYBR
green reagents (Applied Biosciences, Foster City, CA,
U.S.A.) and run on Viia7 machine (Applied Biosystems). A
comparative Ct analysis was completed using Tata Box Pro-
tein (TBP) and hydroxymethylbilane synthase (HMBS) as
housekeeping reference genes, along with glyceraldehyde-
3-phosphate hydrolase (GAPDH) to control for DNA
contamination.
Flow cytometry
Phosphate-buffered saline (PBS)–perfused forebrains
from two mice were pooled and cells isolated as
described.30 Cells were incubated with PE-Cyanine 7 conju-
gated anti-CD45 (25-0451; eBioscience, San Diego, CA,
U.S.A.) and blocked with non-conjugated anti-CD16/32
(16-0161; eBioscience) for 20 min at 4°C. Cells were then
washed before fixation in fixation buffer (eBioscience).
Intracellular Arg1 (Fluorescein, IC5868F; R&D Systems,
Minneapolis, MN, U.S.A.) and Ym1 (nonconjugated,
MAB2446; R&D Systems; secondary – PE conjugated)
were visualized after cell permeabilization. Intracellular
cytokines were detected after 3 h incubation with protein
transport inhibitor Brefeldin A (00-4506; eBioscience)
using conjugated antibodies to IL-1b pro-form, IL-4, IL-6,
IL-10, IL-12, and TNFa (eBioscience; BD, Franklin Lakes,
NJ, U.S.A.).
All samples were read on an LSRII flow cytometer (BD
Biosciences, San Jose, CA, U.S.A.) and were analyzed
using BD FACSDiva software (Becton Dickinson, Franklin
Lakes, NJ, U.S.A.). CD45-intermediate cells were gated as
microglia, whereas CD45-high cells were gated as infiltrat-
ing immune cells for all analysis (Fig. S1). This protocol
has been reported previously.30 Ym1 staining showed clear
positive and negative populations; therefore, percentages of
positive and negative cells were measured. All other cyto-
kines were measured using median fluorescence intensity
(MFI). More detail is available in Data S1.
Statistical methods
All statistical analyses were completed with GraphPad
Prism 7.0 software (GraphPad, La Jolla, CA, U.S.A.). All
figures show Mean  standard error of the mean (SEM)
unless otherwise stated. Statistical significance was consid-
ered when p < 0.05. More detail is provided in Data S1.
Results
Microglia show increases in bothM1 andM2markers in
the acute phase postpilocarpine SE with reversion to
control levels in the early chronic phase
To address the M1/M2 profile specifically in microglia,
flow cytometry of immune cells isolated from whole fore-
brain homogenates was used to distinguish microglia
(CD45 intermediate) from other leukocytes (CD45 high)
and selected expression of M1/M2 markers was quantified.
Results from naive control animals are illustrated by the
dashed line (Fig. 1). No significant differences in expres-
sion of any markers were observed between No-SE and
naive animals at any time point.
Microglia showed significant increases in all M1 and M2
markers in SE animals assessed acutely (3 days, Fig. 1)
post-SE; however, complete ablation of these increases was
observed by the early chronic time point (21 days post-SE,
Fig. 1). At the acute post-SE time point, significant
increases in microglial-specific expression of M1 markers
including IL-1b, TNFa, IL-6, and IL-12 were observed
compared to No-SE and naive controls (Fig. 1A,
p < 0.001). Similarly, increases in M2 phenotypic markers
including Arg1, Ym1, IL-10, and IL-4 were detected on
microglia compared to naive and No-SE controls (Fig. 1B,
p < 0.001). At the early chronic time point, only the M2
marker, Ym1, was still increased on microglia compared to
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controls (Fig. 1B, p < 0.001). This indicates that forebrain
microglia show widespread transient heterogeneous activa-
tion acutely after pilocarpine-induced SE insult and largely
return to their surveying phenotype during epileptogenesis
(Fig. 1).
Similar to the results obtained by flow cytometry, signifi-
cant increases in mRNA expression of M1 and M2 activa-
tion markers were found acutely after pilocarpine SE in
forebrain tissue samples (Fig. 2). Forebrain was chosen at
this time point to match the flow cytometry data and
because SE consists of generalized seizures involving the
whole brain. Inflammatory cytokine mRNA amounts of
TNFa and IL-1b showed 11- and 3-fold increases, respec-
tively, in SE animals compared to No-SE controls (Fig. 2A,
A C
B
Figure 1.
Microglial-specific expression of M1
and M2markers peak at the acute
(3 days post-SE) but not early
chronic (21 days post-SE) time point
in pilocarpine SE forebrains as
determined by flow cytometry. (A)
M1-associated cytokines were
collectively increased at the 3-day
time point in SE compared to No-SE
animals, including TNFa, IL-1b, IL-6,
and IL-12, but returned to control
levels after 21 days. (B) M2-
associated cellular markers, Arg1,
Ym1, IL-4, and IL-10 were all
increased 3 days, but not 21 days,
after SE. Only Ym1 remained
elevated in SE mice at 21 days post-
SE. (C) Representative median
fluorescent intensity (MFI) curves of
M1/M2 marker expression on
microglial cells comparing naive
(dotted line), No-SE (solid line,
open), and SE (shaded fill) animals
determined by flow cytometry at the
3-day post-SE time point. Data shown
are normalized to naive controls
(n = 8 per group for 3 days; n = 12
per group for 21 days after SE).
***p < 0.001, ****p < 0.0001.
Mean fold change  SEM shown.
Two-way analysis of variance
(ANOVA) with Bonferroni posttest
used for statistical analysis of all data
sets.
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p < 0.001). The Fc receptor CD16 mRNA was elevated in
SE mice by 3.6-fold (p = 0.002); however, the increase of
the antigen presentation molecule CD86 mRNA was not
statistically significant (p = 0.11). Finally, transcript
amounts of myeloid CD11b integrin and the astrocyte-spe-
cific marker glial fibrillary acidic protein (GFAP) were also
increased in SE animals at this time point by 4.7- and 9.7-
fold, respectively (p < 0.001), indicating increased pres-
ence of microglia, astrocytes, and/or myeloid cells post-SE.
The increased expression of CD11b is most likely due to
increased expression by microglia and/or infiltration of
myeloid cells. These data support the protein expression
patterns found on microglial cells (Fig. 1).
The quantities of mRNA of M2-associated enzymes Arg1
and Ym1, and the antiinflammatory cytokine IL-4 were also
increased in SE mice in the acute phase by 10.4-, 8.0-, and
6.3-fold, respectively, compared to No-SE controls
(Fig. 2B, p = 0.017, 0.0015, and 0.04). No significant
differences in IL-10 mRNA levels were observed
(p = 0.89). Of interest, significant expression decreases of
>35% and >50% were seen of both the mannose receptor
CD206 and the secreted protein found in inflammatory zone
(FIZZ-1) (Fig. 2B, p = 0.006, <0.001). The data reveal a
specific microglial marker signature acutely post pilocar-
pine-SE with mixed expression of several, but not all M1
andM2markers.
A B
Figure 2.
mRNA expression of M1 and M2 phenotypic markers at different stages throughout the pilocarpine model in forebrain (acute 3 days
post-SE) and the hippocampal formation (early and late chronically epileptic time points) largely peak early after SE. (A) M1-associated
markers TNFa, IL-1b, CD16, and CD11b and the astrocytic marker GFAP were significantly increased in forebrain mRNA of SE animals
compared to No-SE controls at the acute post-SE time point. At the early chronic time point, IL-1b, CD11b, and GFAP remained elevated
above No-SE control levels in the hippocampal formation, despite there being no obvious changes in whole cortical samples (data not
shown). TNFamRNA levels, however, were significantly reduced at the early chronic stage in hippocampus. No significant changes to any
M1 markers were observed in hippocampal mRNA extracts in the late chronic phase (n = 5–9 per group). (B) M2-associated markers
Arg1, Ym1, and IL-4 were significantly increased in SE animals compared to No-SE controls, whereas FIZZ-1 and CD206 showed signifi-
cant reductions in expression in SE animals at the acute time point in forebrain (n = 5–9 per group). Together this indicates a heteroge-
neous M1/M2 microglial activation state acutely after pilocarpine-induced SE. M2-associated Ym1 was the only marker for which mRNA
amounts decreased in the hippocampal formation at the early chronic time point (n = 12 per group). No significant changes to any other
markers were found in either the early or late chronic phases in hippocampal mRNA extracts. Data were expressed relative to house-
keeping gene mRNA expression. Mean  SEM shown for each data set. **p < 0.01, ***p < 0.001, ****p < 0.0001. Independent
unpaired student’s t-tests used for statistical analysis of each data set.
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SelectM1-associated mRNA elevations found in the
hippocampal formation in the early chronic phase
postpilocarpine-SE
Given that the hippocampus is the site of seizure initiation
in the chronic phase of the rodent pilocarpine model,12 we
focused on this brain region. Assessment of mRNA extracts
of the hippocampal formation highlighted significant differ-
ences 21 days post pilocarpine-SE, despite there being no
changes evident in the forebrain (data not shown).
IL-1b mRNA amounts remained significantly elevated
by approximately twofold 21 days post-SE (early chronic
time point, Fig. 2A, p < 0.001). Similarly, CD11b and
GFAP transcript levels also remained elevated by approxi-
mately fivefold in the hippocampal formation of SE ani-
mals (p < 0.001 and 0.008, respectively). However,
hippocampal mRNA concentrations of TNFa were
reduced at this time point by 50% compared to No-SE
controls (p < 0.001). No significant changes to any other
M1 markers including CD16 and CD86 were observed in
the hippocampal formation at this time point (Fig. 2A,
p = 0.21, 0.24). Similarly, the majority of M2 markers
were unchanged from controls at the early chronic time
point in the hippocampal formation (Fig. 2B). These data
illustrate that specific areas of the brain may experience
altered local expression of M1/M2 markers, which is not
detectable when assessing entire forebrain samples by flow
cytometry.
Ym1 mRNA levels were reduced by 30% relative to
No-SE controls (Fig. 2B, p < 0.001), which did not match
the increased protein expression by forebrain microglia
(Fig. 1B), indicating that increases in Ym1 expression are
elsewhere in the brain, and not found in the hippocampal
formation.
Ablation of elevated hippocampal M1/M2mRNA
expression during the late chronic phase in pilocarpine
SEmice
No significant changes from control levels were observed
for any mRNA of M1 or M2 markers in the late chronic
phase (5–12 months post-SE) of pilocarpine-SE mice
(Fig. 2, p > 0.05). Overall expression levels in the hippo-
campal formation of the majority of M1 and M2 markers
were higher than in the early chronic epileptic phase for both
control and SE animals, indicating that these markers are
induced with age, independent of SE-induced neuropathologic
changes and chronic spontaneous seizures (Fig. 4A,C,D).
M1 activation in the acute phase of the i.h. kainate model
is repressed in the early chronic period with late
resurgence of a mixedM1/M2 state in the chronic
epileptic state
Here, we aimed to assess the pattern of microglial activa-
tion markers in a second chronic mouse epilepsy model, in
order to understand which changes may be associated with
SE-induced epileptogenesis in a model-independent fash-
ion. We chose to investigate the expression of mRNA in the
hippocampal formation of the i.h. kainate model of epilepsy,
in which 40% of mice develop spontaneous chronic hippo-
campal (and sometimes cortical) seizures approximately
3 weeks post-SE (Fig. 4B,D).
Microglial marker transcript expression in the i.h. kainate
model was mostly similar to that of the pilocarpine model at
the two earlier time points. Similar significant increases in
hippocampal mRNA amounts of M1markers were observed
acutely 3 day post-SE, with IL-1b, TNFa, CD11b, and
CD16 mRNA quantities increased by >3.5-fold in SE mice
compared to No-SE controls (Fig. 3A, p < 0.001, 0.037,
<0.001, <0.001 respectively). GFAP mRNA levels were
also increased acutely post-SE by approximately eightfold
(Fig. 3A, p = 0.008). In contrast to the pilocarpine model,
no significant changes to any M2 mRNA markers were
observed acutely (Fig. 3B). All M1 and M2 marker tran-
script levels had returned to control levels by the early
chronic phase (21 days post-SE, Fig. 3), similar to the
pilocarpine model (Figs. 1 and 2). Please note that at
21 days after kainate SE, there is a trend of increased IL-1b
mRNA concentrations (p = 0.06) which is similar to the
increase reported in the i.h. rat kainate model previously.20
All mice used for the late chronic post-SE time point
(8–12 months post-SE), were earlier confirmed to experi-
ence hippocampal and sometimes additional cortical chronic
recurrent seizures (examples in Fig. 4B). Resurgence in M1
marker mRNA expression was observed in the SE animals
(Fig. 3). IL-1b, TNFa, and CD11b mRNA levels were all
elevated by more than threefold (Fig. 3A, p = 0.02, <0.001,
and 0.0015, respectively). Similarly, selected M2 mRNA
amounts were increased at this time point, including Arg1
(ninefold, p < 0.001), IL-10 (3.5-fold, p = 0.004), and
CD206 (2.2-fold, p < 0.001; Fig. 3B), showing reversion to
a mixed M1/M2 phenotype in the late chronic phase. This
late increase in M1/M2 expression could be due to the pro-
longed exposure of frequent seizures, conditioning micro-
glia to perpetuate a persistent inflammatory state in the
brain.
Discussion
In this study, we have used the M1/M2 paradigm to
profile the immune status of the “epileptic” brain during the
development of epilepsy in two mouse models. The key out-
comes of this work are threefold. Firstly, we found that the
acute microglial activation phenotype after SE differs in the
two SE models used. Secondly, microglial activation
declines mostly to control levels during the early chronic
phase. Finally, our data showed that resurgence of microgli-
al activation in the late chronic phase is present only in the
i.h. kainate model. The interpretation of the RT-PCR data
needs to be considered with caution, because it does not
reveal the cell types expressing the mRNAs studied, such as
leukocytes32 including bone marrow mononuclear cells33 In
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addition, astrocytes can express some of the markers used
including cytokines IL-1, TNFa, and IL-6,34 antigen presen-
tation markers CD16 and CD86,35 and M2 marker Arg1,36
but not CD11b or CD206.35 Finally, our flow cytometry
results do not allow us to distinguish between parenchymal
and perivascular immune cells; therefore, a generalized
“immune state” of the brain is being assessed for this early
study. The following discussion highlights the relevance
and implications of these findings in terms of understanding
the disease progression of epilepsy.
Acute post-SEM1/M2marker expression
Our data revealed a differential acute response of micro-
glia to SE between the two models. In the pilocarpine
model, a mixed M1/M2 phenotype was present 3 days after
SE, in comparison to a solely M1 phenotype in the i.h. kai-
nate model. These differences may be explained by the
length and/or severity of SE and/or extent of cell death in
each model, with SE scores averaging 2–3 for i.h. kainate
mice and more severe scores of 3–4 for pilocarpine mice
based on a modified Racine scale. The longer SE period
after kainate injection may be driving a more M1-polarized
microglial phenotype. However, after kainate injection, the
SE is less severe in terms of the behavioral seizures
observed; mice recover more easily and neuronal cell death
is restricted to the hippocampal formation, whereas cell
death after pilocarpine-induced SE can be extensive and
includes the thalamus, cortical areas, the amygdala, and pir-
iform cortex.11 Alternatively, the more severe seizures and
widespread cell death in the pilocarpine model could be
responsible for inducing M2 markers acutely. An additional
factor to consider is that pilocarpine induces peripheral
inflammation prior to SE induction, as it is delivered
systemically, which contributes to blood–brain barrier
A B
Figure 3.
Phasic increased hippocampal mRNA expression of M1 and M2 markers in i.h. kainate post-SE mice over disease progression reveal early
and late marker expression. (A) M1-associated TNFa, IL-1b, and CD11b were all increased in SE mice compared to No-SE controls at
the acute and late chronically epileptic time points. No changes in M1 expression were observed at the early chronic time point (n = 6–
12 per group). Antigen presentation M1-associated marker CD16 was increased in SE animals only acutely post-SE. Similarly astrocytic
activation marker GFAP was only significantly increased in SE mice at the acute time point, and did show a trend of increased expression
in the late chronic epileptic period. (B) Selected M2 markers were increased in SE animals in the i.h. kainate model. No significant
increases in any M2-associated marker were measured at either the acute or early chronic time points; however, oxidative stress regula-
tor enzyme Arg1, mannose receptor CD206, and anti-inflammatory cytokine IL-10 were increased in SE mice in the late chronic time
point in this model. No significant changes to Ym1 or IL-4 expression were observed at this same time point. Mean  SEM were shown
for each group. n = 5–12 per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Two-way ANOVA with Bonferroni post-
test used for statistical analysis of all data sets.
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leakage and SE severity.18,28,37 Furthermore, pilocarpine
remains in the peripheral circulation post-SE onset, poten-
tially contributing to further peripheral cell activation over
time. Thus, it is possible that this peripheral inflammation
is linked to the induction of M2 markers in the pilocarpine
model, which is lacking in the i.h. kainate model due to
central administration of the glutamate receptor agonist. It
should be noted that it is difficult to draw conclusions from
data of early time points in the i.h. kainate mouse model,
because only 40% of SE mice later develop chronic sponta-
neous seizures. Therefore, there is the possibility that small
alterations in M1/M2 markers in this minority of mice may
have been missed. Further studies are necessary to test
these possibilities.
At this time, it is not known to which extent the differing
microglial phenotypes in the two models are responsible for
epileptogenesis and/or modulate the frequency and severity
of the chronic seizures. However, there is ample evidence
A C
B
D
Figure 4.
Disparity in M1/M2 mRNA expression in the late chronically epileptic phase may be due to differences in seizure frequency between mod-
els. (A) Example EEG traces from a spontaneous seizure from a pilocarpine SE mouse in the late chronic phase. Typically these seizures
are long in duration (≥120 s), have high amplitude spiking patterns (≥1,000 lV), and are generalized, hence the synchronous hippocampal
(Hip) and cortical (Cortex) traces. (B) Example EEG traces from an i.h. kainate SE mouse in the late chronic phase. Typically, these
seizures are more frequent and shorter in duration (≤60 s) than in pilocarpine-SE animals, and have much lower amplitude (≤500 lV).
Seizures can be both generalized and partial (hippocampal-focused) in this model. Hip1-Cortex1 denotes mixed generalized and partial
seizures. Hip2-Cortex2 shows hippocampal only focal (partial) seizures in the same mouse. Hip, difference between two nodes of a
unilateral bipolar hippocampal depth electrode placed in the pyramidal layer of the CA1; Cortex, surface screw electrode placed in the
contralateral forebrain shows cortical activity with background subtracted from ground and reference electrodes. (C) Correlation of M1
and M2 mRNA expression changes in the two epilepsy models in the late chronic phase, highlighting strong elevations in M1 and M2
marker expression of the i.h. KAmodel in comparison to the pilocarpine model.We postulate that this may be caused by the much higher
seizure frequency/presence in the i.h. kainate model as quantified in (D). Kainate SE animals (n = 8) experience significantly more seizure
events per hour than pilocarpine SE animals (n = 5) in the late chronic phase (unpaired student’s t-test, ****p < 0.0001). Mean  SEM
shown.
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that inhibition of systemic inflammation prior to SE onset or
during kindling usually reduces kindling development, SE
severity, and/or the number of spontaneous seizures.18,38
Thus, it is likely that the M2 response in the pilocarpine
model is protective and limits cell damage and/or decreases
spontaneous seizures frequency.
The different microglial phenotypes in these models
also imply that microglial responses vary in humans after
insults that lead to epileptogenesis. Many data from ani-
mal models indicate that antiinflammatory treatments
before and after insult are beneficial for disease out-
comes.38,39 On the other hand, neuronal cyclooxygenase
(COX)-2–mediated inflammation appears to promote
neurodegeneration early after SE, whereas COX-2–medi-
ated production of prostaglandin E2 protects neurons at a
later stage.40 Therefore, caution is advised for new clinical
trials investigating antiinflammatory strategies in humans.
Low expression ofM1/M2markers during the early
chronic time point
A common feature noted between models was the return
to relatively low levels of M1/M2 marker expression in the
early chronic phase, a time point associated with epilepto-
genesis, circuitry rearrangements, and early spontaneous
seizures. This decline was unexpected, as it has been sug-
gested that epileptogenesis is a critical phase where microg-
lial activation is present and affects epilepsy disease
outcomes.10,20,41 As these studies aforementioned used rat
models, it is possible that the time course of inflammation is
different and/or plays different roles in mouse versus rat epi-
lepsy models. In contrast to the data from rats, our results
and those from Pernot et al.42 show a similar loss of inflam-
matory marker expression in the early phase of the i.h.
kainate mouse model.
Furthermore, similar phasic patterns of microglial activa-
tion have been observed in other neurologic diseases also
known to have an inflammatory component, such as
stroke6,43
In the pilocarpine model, small increases in M1-associ-
ated markers IL-1b and CD11b were revealed in the hippo-
campal formation (Fig. 2A) that were not detected in flow
cytometry experiments using entire forebrain (Fig. 1), sug-
gesting confined local hippocampal expression or expres-
sion in cells other than microglia. The known role of IL-1b
as a proconvulsant mediator of seizures17,22 supports the
possibility that increased IL-1b presence in the hippocampal
formation at this time point is contributing to disease pro-
gression and seizure initiation. The increase in hippocampal
CD11b mRNA levels in the pilocarpine model, which is
absent in the i.h. kainate model, may arise from differences
in SE severity and subsequent neuronal cell death. Increased
neuronal damage in pilocarpine mice may lead to a longer
period of clean up and repair requiring increased presence
of myeloid cells, which is reduced in i.h. kainate mice possi-
bly due to less neuronal injury.
Similar to findings in the i.h. kainate rat model,20 we
found a reduction in hippocampal TNFa mRNA levels at
the early chronic time point in the pilocarpine model. TNFa
can have dual functions in the brain; it was shown to be neu-
roprotective in the systemic kainate model,44 whereas infu-
sion of TNFa was proconvulsant in rats.18 It is therefore
possible that TNFa is playing various roles in epilepsy mod-
els and potentially human disease, which may also depend
on disease stage.
M1/M2markers during the late chronic epileptic time
point
Resurgence of M1/M2 mRNA was found during the late
chronic stage in the i.h. kainate SE mice, which experience
electrographic seizures 50% of the time, namely 33 electro-
graphic seizures of 20–40 s duration per hour as well as
very rare behavioral seizures (not quantified here). Mice in
the late chronic stage of the pilocarpine model experience
approximately one to two generalized seizures of 40–100 s
duration per day, which is 500-fold less frequent than in the
kainate model and showed no obvious microglial activation
(Fig. 4C,D). This reappearance of microglial activation in
the i.h. kainate model is potentially related to the very fre-
quent seizures experienced by kainate-SE mice and may
contribute to further seizure generation (Fig. 4D). The pro-
posed relation could be addressed with an analysis of M1/
M2 marker expression in parallel with individual seizure
frequency at time points between the early and late chronic
stages.
The signature phenotype in late chronic kainate-SE mice
was a mixed expression of selected M1/M2 markers, indi-
cating that microglia may play various roles in this chronic
stage, such as promoting seizures via IL-1b and/or TNFa,
while limiting seizures and/or repairing damage via
increased IL-10, Arg1, and CD206 expression. To confirm
these theories, specific correlative studies such as those sug-
gested earlier are needed. In view of our data, we could
speculate that patients with highly frequent seizures may
benefit more from anti-inflammatory intervention than
those with fewer seizures.
In summary, our data revealed that microglia show a
complex proinflammatory and antiinflammatory response
during epilepsy development. This response appears to be
related to chronic seizure frequency as well as to the contri-
bution of peripheral inflammation to initial SE onset. It is
suggested that attempts to quell inflammation and/or
microglial activation during epileptogenesis may be futile
given that little expression of M1/M2 activation markers
was observed during this time. A treatment paradigm that
specifically addresses the phases of inflammation and mi-
croglial activation after epileptogenic insults, potentially
using imaging techniques monitoring inflammation,45 may
have the greatest disease modifying outcome. Our data
advocate that inhibition of proinflammatory cytokines is
most effective in the chronic epileptic phase and not prior.
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Abstract 
Background: The complement receptor C5ar1 is involved in the initiation and severity of 
seizures and it worsens status epilepticus (SE) outcomes, including in the pilocarpine model.  
Findings: To determine the role C5ar1 plays in mediating immune cell responses acutely 
after pilocarpine SE, we measured key inflammatory cytokines and repair enzymes on 
infiltrating cells and microglia in C5ar1-deficient and wildtype mice using flow cytometry. In 
addition we assessed the mRNA and protein levels of C5ar1 following SE. Acutely after SE 
C5ar1 levels increased specifically in microglia. Also,  approximately 30% of infiltrating 
immune cells expressed C5ar1, but this proportion was similar in the presence and absence 
of SE. Large increases in pro-inflammatory cytokines including IL-1β and TNFα and anti-
inflammatory cytokines such as IL-4 and reparative enzymes Arg1 and Ym1 were found in SE 
mice compared to controls. Notably, C5ar1 absence lowered TNFα expression by microglia 
but not in infiltrating cells, and increased IL-4 expression by infiltrating immune cells but not 
by microglia.  
Conclusions: Increases in the anti-inflammatory cytokine IL-4 in the epileptogenic period 
may lead to an improved disease outcome given that inflammation is a key contributing 
factor to epilepsy pathophysiology. This evidence further supports the role of C5ar1 in 
epilepsy as a key mediator of inflammatory processes following SE. 
Keywords 
Epilepsy; microglia; immunology; cytokine; infiltrate; C5ar1; complement; status epilepticus; 
pilocarpine 
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Findings 
1. Introduction 
Inflammation can play a complex role in epilepsy pathophysiology and seizure initiation [1] 
and is being targeted by new treatments currently in development [2-4]. Pro-inflammatory 
cytokines such as IL-1β and TNFα are highly involved not only in neurodegeneration but also 
CNS hyperexcitability [5, 6]. Recently, we have shown that innate immune activation of the 
complement system, namely through the C5a anaphylatoxin receptor C5ar1, also plays a 
role in epilepsy models. Inhibition of C5ar1, using the receptor antagonist PMX53 was 
anticonvulsant in several seizure models, including the 6 Hz model, corneally kindled mice 
and chronic electroencephalographic seizures in the intrahippocampal kainate model [7]. 
Additionally C5ar1 absence as well as pharmacological inhibition of C5ar1, lead to reduced 
hippocampal neuron death after pilocarpine-induced status epilepticus (SE).  
Here, we investigated the effect of C5ar1 on infiltrating immune cells after pilocarpine-
induced SE. Pilocarpine, a muscarinic agonist, stimulates inflammation in the periphery, e.g. 
via muscarinic receptors expressed by leukocytes, and acts in the central nervous system 
(CNS) inducing epileptic seizures [8]. Increased levels of IL-1β have been measured in serum 
prior to SE onset following pilocarpine injection, illustrating that SE is not the primary source 
driving inflammation in this model [8, 9].   Additionally, C5ar1 can contribute to blood-brain-
barrier (BBB) leakage, specifically by inducing caspase-3 activation and down regulating 
scaffold protein ZO-1 expression in endothelial cells [10]. Here, we show that C5ar1 is 
involved in modulating the response of microglial and infiltrating immune cells after 
pilocarpine-induced SE. 
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2. Materials and Methods 
2.1 Mice 
9 week old male Swiss CD1 mice (Animal Resources Centre (ARC), Western Australia) were 
used for all experiments. Animals were housed individually on a 12 hour light/dark cycle and 
had access to food and water ad libitum. C57/BL6 C5ar1-/- (Australian Institute for 
Bioengineering and Nanotechnology, Brisbane, Australia) mice were bred into the CD1 
background using 5 generation crosses. All genotypes were confirmed with PCR prior to use. 
All experiments were approved by The University of Queensland Animal Ethics Committee 
and conducted in accordance with their guidelines.  
2.2 Pilocarpine model of status epilepticus (SE) 
Mice were administered methyl scopolamine (2.5mg/kg i.p. in saline) 15 minutes prior to 
injection of 345mg/kg (s.c.) pilocarpine which induced SE in >60% of mice with 10% 
mortality. 90 minutes post pilocarpine, all mice were given 30mg/kg (i.p.) pentobarbitone to 
stop SE [11]. 3 weeks following SE spontaneous recurrent seizures have been recorded with 
video and EEG [7, 12, 13].  
2.3 Quantitative Real Time PCR (qPCR) 
All qPCR was completed as described [7] using comparative Ct analysis using Tata Box 
Protein (TBP) and hydroxymethylbilane synthase (HMBS) as housekeeping reference genes.  
2.4 Flow cytometry 
As previously described cells were isolated from saline-perfused forebrains [14], stained and 
analysed by flow cytometry [1, 7] on a BD LSRII flow cytometer (BD Biosciences, San Jose, 
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 5 
California) using BD FACSDiva software.  C5ar1 was visualised using Alexa-488 conjugated 
anti-C5ar1 antibody (10/92, AbD Serotec). Cells which were CD45-high were gated as 
infiltrating cells and CD45-intermediate gated as microglia (Fig. 1b). The neutrophil 
subpopulation of CD45-high cells was labelled with Ly6G antibody, but the results revealed 
no significant quantitative or qualitative differences between neutrophils and the remaining 
CD45-high cells” (data not shown). 
2.5 Data analysis 
All statistical analysis was performed using GraphPad Prism 7.0 software (San Diego, USA). 
Specific tests used for each data set are outlined in the results. P values ≤ 0.05 were 
considered significant (*p<0.05; **p<0.01; ***p<0.001; p<0.0001). 
 
3. Results 
3.1 Increased C5ar1 expression by microglia 3 days post-pilocarpine SE 
A significant 18 fold increase in C5ar1 mRNA was seen in cortex 3 days post pilocarpine SE 
when compared to mice which did not develop SE (no SE mice; Fig. 1a; p<0.0001, unpaired 
student’s t-test). To elucidate if this increase occurs in immune cells, flow cytometry was 
employed. The expression of C5ar1 protein increased specifically in resident microglial cells 
(CD45-intermediate) by approximately 28 fold, from 0.27% of total C5ar1-positive cells in 
NoSE animals to 7.4% in SE mice (Fig. 1c, p<0.0001, unpaired student’s t-test relative to 
NoSE control animals). The proportion of C5ar1-positive infiltrating cells remained 
consistent between NoSE and SE animals (Fig. 1c, p>0.05) In naïve mice C5ar1-positive 
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populations of microglia and infiltrating cells were 0.2% and 22%, respectively (p<0.05, 2 
way ANOVA with Bonferroni post-test, data not shown). This suggests pilocarpine 
administration initiates a peripheral inflammatory response accounting for the increase in 
C5ar1-positive infiltrate between naïve and NoSE mice. C5ar1 expression in neutrophils 
(Ly6G+ subtype of infiltrating cell group) was also unchanged between NoSE and SE groups 
(data not shown). 
3.2 C5ar1-deficiency did not affect immune cell infiltration post-SE 
The proportion of immune infiltrating cells (CD45 high) was significantly increased by > 4.5 
fold in forebrains from SE animals compared to NoSE controls (Fig. 2; p<0.05, 2 way ANOVA 
with Bonferroni post-test). We did not find any changes in infiltrating cell numbers in C5ar1-
deficient vs. wildtype mice in NoSE and SE groups (Fig. 2; p=0.7722, 2 way ANOVA), 
suggesting that C5ar1 is not mediating the infiltration of immune cells in this experimental 
model. Neutrophil invasion numbers were similar between C5ar1 genotypes 3 days post-SE.  
3. 3 Absence of C5ar1 elevated IL-4 on infiltrating immune cells and moderated TNFα 
increases on microglia 
To assess the influence of C5ar1 on phenotypes of immune cells, markers of inflammation 
and repair were quantified in NoSE and SE mice of wild type and C5ar1-deficient genotypes 
3 days post SE (Fig. 3).  
The levels of expression of the inflammatory cytokine IL-1β and the repair protein Ym1 were 
significantly increased in SE mice in both infiltrating and microglial cell populations, with no 
significant differences between C5ar1 genotypes (Fig. 3a & b).  Levels of Arg1, another 
repair protein, were also increased in wildtype SE animals in both infiltrate and microglia. 
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However in C5ar1-deficient SE mice Arg1 expression was only significantly elevated in 
infiltrating, but not microglial cells (Fig. 3c), indicating that C5ar1 expression plays a role in 
microglial upregulation of Arg1.   
TNFα expression was increased in infiltrating cells after SE irrespective of C5ar1 genotype 
(Fig. 3d, p<0.0001). Increases of TNFα content were found on wildtype SE microglia 
(p<0.0001), however this elevation was ablated in C5ar1-deficient microglia.  
The only marker to be differentially expressed between genotypes in infiltrating cells was 
anti-inflammatory cytokine IL-4. C5ar1-deficient SE mice displayed >40% elevated levels of 
IL-4 on infiltrating cells compared to wildtype SE animals (p<0.05, Fig. 3). In microglia, IL-4 
expression was not significantly altered after SE (Fig. 3e, p>0.05), Analysis of IL-4 specific 
expression in neutrophils was also assessed; however no significant differences between 
C5ar1-genotype groups were found (data not shown). 
No significant differences in IL-6, IL-10 or IL-12 were observed in any SE group compared to 
controls in either cell population (data not shown).  When measuring the expression of all 
previous markers specifically on neutrophils infiltrating the brain, we found no significant 
differences between genotypes (data not shown). 
 
4. Discussion 
Based on our previous reporting that complement receptor C5ar1 is involved in seizure 
initiation and worsens status epilepticus (SE) outcome [7], we here investigated the role of 
C5ar1 in mediating immune cell phenotypes after pilocarpine-SE in C5ar1-deficient and 
wildtype mice.   
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Our results indicate that C5ar1 is affecting the cytokine profile of infiltrating immune cells 
and microglia 3 days after pilocarpine-SE. Firstly we found that C5ar1 expression is increased 
in microglia however no changes to the proportion of C5ar1-positive infiltrating cells were 
seen due to pilocarpine-SE at 3 days. Previously, it was shown that protein and mRNA levels 
of the C5a precursor complement factor 3 (C3) are also increased in epilepsy [7, 13] 
suggesting increased presence of circulating C5a and potentially complement system 
activation following acute pilocarpine-induced SE.  
As expected, SE animals in general showed a greater level of peripheral immune cell 
infiltration compared to NoSE, possibly due to BBB breakdown, a hallmark of SE [15]. There 
were no differences between C5ar1 genotypes suggesting that C5ar1 is not critically 
involved in mediating cell infiltration from the periphery. The expression of both pro-
inflammatory and reparative markers in infiltrating cells was similar to that of microglial 
cells.  Interestingly no changes to the proportion of infiltrated neutrophils were measured at 
3 days post-SE. It is possible that neutrophil changes may have occurred earlier (6-24hr post-
SE) however were no longer present at 3 days.  
However, in C5ar1-deficient mice, unlike wildtype mice, we found a significant increase in 
anti-inflammatory IL-4 [16] in infiltrating immune cells, coupled with reduced TNFα 
expression on microglia, revealing an effect of C5ar1 in the inflammatory response to SE. 
Overall presence of C5ar1 in the acute period following SE, resulted in a more inflammatory 
phenotype, potentially contributing to increased neuronal death as previously reported [7]. 
Supporting this finding, inhibition or absence of C5ar1 during pilocarpine SE reduced death 
of hippocampal CA1 and CA3 pyramidal cells. It remains to be investigated to which extent 
pharmacological blockade of C5ar1 affects these immune responses. 
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A potential relevance of IL-4 in epilepsy has been elucidated in human cases, as resected 
epileptic cortical foci from refractory epilepsy patients showed high levels of expression of 
the IL-4 receptor, IL-4Rα on astrocytes [17]. This suggests that pharmacological inhibition of 
C5ar1 may elicit responses to IL-4 specifically in “epileptic” brains that may have potentially 
enhanced benefits to disease progression. IL-4 is also associated with learning and memory 
specifically mediated by T-cell regulation of the cytokine [18]. This was illustrated in IL-4-
deficient mice that showed cognitive deficits dependent on T-cell derived IL-4 production. 
Both learning and memory are tasks controlled by the hippocampus; one of the key 
epileptogenic centres of the brain, highlighting that IL-4 has functional roles in this brain 
region.  
The connections between C5ar1 and suppression of IL-4 level increases after SE had been 
thus far unknown, but have been noted before in an asthma study. After challenge with an 
antigen  mice deficient in C5, the precursor to C5a, had more IL-4 expressing cells in the lung 
compared to wildtype mice [19]. The increase in IL-4 levels in the C5ar1-deficient mice could 
also explain the reduced microglial TNF levels in the current study. This is supported by 
results showing that lipopolysaccharide or aggregated β-amyloid-stimulated rat microglia 
application of IL-4 to lead to down-regulation of TNFα [20].  
Here, we showed that C5ar1 contributes to the inflammatory response elicited by 
infiltrating and microglial cells acutely following pilocarpine-SE. These findings help explain 
the protective effects of C5ar1 pharmacological inhibition or genetic absence we have 
reported previously [7]. Attenuation of increased TNFα expression on microglia, in addition 
to increased IL-4 expression by infiltrating immune cells may synergistically reduce the 
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inflammatory state after SE. This signifies that C5ar1 inhibition has beneficial disease-
modifying outcomes after SE due to the alteration of several immune pathways.   
 
List of Abbreviations 
SE  Status Epilepticus 
C5ar1  Complement C5a receptor 1 
IL-4  Interleukin 4 
IL-1β  Interleukin 1β 
TNFα  Tumour necrosis factor α 
CNS  Central nervous system 
BBB  Blood-brain-barrier 
Ym1  Chitinase-like-3 protein 
Arg1  Arginase 1 
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Figure Legends 
 
Figure 1 C5ar1 expression was increased acutely 3 days post pilocarpine-SE. (a) Expression 
of C5ar1 mRNA in cerebral cortex was increased by approximately 18 fold in SE (blue) mice 
compared to NoSE (white) controls 3 days post pilocarpine-induced SE. Data shown as 
relative expression of mRNA compared to housekeeping genes. Unpaired student’s t-test; 
***p<0.0001, NoSE n=9; SE n=11. (b) Gating of CD45+ cells into microglia and infiltrating cell 
types in both NoSE and SE animals. The proportion of infiltrating cells in SE animals was 
increased compared to NoSE. (c) Increased C5ar1 expression post-SE was microglial specific 
(****p<0.0001, n=8). No change in C5ar1 expression was observed on infiltrating cells (non-
microglial immune cells) after SE (blue bars) compared to no SE mice (white bars, p>0.05, 
n=8). Endogenous expression of C5ar1 was greater in infiltrating cell populations compared 
to microglial populations also; NoSE vs. NoSE; ****p<0.0001. Two-way ANOVA with 
Bonferroni post-test used. Mean ± SEM shown. 
 
Figure 2 The proportion of infiltrating cells (non-microglial immune cells) was increased at 3 
days post-SE in C5ar1-deficient (red) and wildtype (grey) mice (**p<0.05, *p<0.01 
respectively, Two-way ANOVA with Bonferroni post-test). Also, the total proportion of 
infiltrating cells was similar between C5ar1-deficient and wildtype animals in both NoSE and 
SE groups. (Two-way ANOVA with Bonferroni post-test; p>0.05, NoSE n=4; SE n=12). Dotted 
line represents naïve control infiltrate levels for both genotypes. Mean ± SEM shown.  
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Figure 3 Expression of various cytokines and reparative enzymes 3 days after pilocarpine SE 
on both microglia and infiltrating immune cell populations in both C5ar1-deficient (red bars) 
and wildtype (grey bars) mice. (a) Pro-inflammatory cytokine IL-1β was significantly 
increased in all SE animals independent of cell type or C5ar1-genotype compared to both 
NoSE and naïve controls. (b) Reparative enzyme Ym1 was increased similarly in all SE mice. 
Data expressed as proportion of Ym1-positive cells of total cell number analysed within 
respective cell type due to gating of Ym1+ population. (c) Reparative enzyme Arg1 was 
significantly increased in all SE infiltrating cell groups however only wildtype SE microglia 
showed significant elevation. (d) Pro-inflammatory cytokine TNFα was significantly 
increased in all SE groups except microglia from C5ar1-deficient mice. No significant 
difference in microglial TNFα was found between either NoSE group nor the C5ar1-deficient 
SE cells. (e) Anti-inflammatory cytokine IL-4 expression was only significantly changed from 
controls in C5ar1-deficient infiltrating cells, showing an increase in expression by 40% 
compared NoSE and naïve controls. This change was significant between C5ar1-genotype SE 
groups. All data were expressed as a normalized fold change from naïve control levels, 
represented by the dotted line. Median Fluorescence intensity (MFI) used as a measure to 
delineate positive cell populations. Two way ANOVA with Bonferroni post-test; n=6-12 per 
group. Bracketed stars show significant differences between NoSE/SE groups whilst stars 
above individual bars show significant differences between genotypes within the same 
group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Mean ± SEM shown.  
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